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Abstract 
 
There is an urgent need for safe, efficacious, affordable and field-adapted 
drugs for the treatment of cutaneous leishmaniasis, a disease which affects 
around 1.5 million people worldwide every year. Chitosan, a biodegradable 
cationic polysaccharide, has previously been reported to have antimicrobial, 
anti-leishmanial and immunostimulatory activities. The work described here 
found that chitosan and its derivatives were approximately 7-20 times more 
active in vitro against Leishmania promastigotes and amastigotes at pH 6.5 
than at pH 7.5, with high molecular weight chitosan being the most potent. 
Despite the in vitro activation of bone marrow macrophages by chitosan to 
produce nitric oxide and reactive oxygen species, this work showed that the 
anti-leishmanial activity of chitosan was not mediated by these metabolites. It 
was subsequently shown that rhodamine-labelled chitosan is taken up by 
pinocytosis and accumulates in the parasitophorous vacuole of Leishmania-
infected macrophages. The application of chitosan in drug delivery systems 
was then studied by preparing two types of chitosan nanoparticles (positive 
(with tripolyphosphate sodium (TPP)) and negative (with dextran sulphate) 
surface charge with different sizes) and incorporation of amphotericin B within 
these nanoparticles. These amphotericin B-loaded nanoparticles 
demonstrated a good in vitro anti-leishmanial activity, similar to pure 
amphotericin B, and were also significantly less toxic than pure amphotericin 
B. The positive amphotericin B-loaded chitosan-TPP nanoparticles showed 
promising in vivo efficacy against cutaneous leishmaniasis caused by L. major 
in the BALB/c mouse model, via the intravenous route, and they were more 
active than AmBisome®. The impact of an in vitro media perfusion system on 
host cell phagocytosis and macropinocytosis was evaluated as well as the 
anti-leishmanial activity of chitosan solution and blank or amphotericin B-
loaded chitosan-TPP nanoparticles. There was a significant difference 
between in vitro static and flow culture systems in the cell uptake and anti-
leishmanial activity of the studied compounds. 
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1. General introduction 
1.1. Leishmaniasis and Leishmania species  
Leishmaniasis is an infectious disease caused by parasites belonging to the 
genus Leishmania in the family Trypanosomatidae. Leishmania parasites are 
transmitted to mammals through the bite of sandflies that belong to the genus 
Phlebotomus (Old World) or Lutzomyia (New World). Leishmania species 
cause two main clinical forms, cutaneous leishmaniasis (CL) and visceral 
leishmaniasis (VL) (1). CL is the most common type of leishmaniasis and in 
addition to “simple” CL, there are other complex cutaneous leishmaniasis 
manifestations including mucocutaneous leishmaniasis (MCL), diffuse 
cutaneous leishmaniasis (DCL), disseminated cutaneous leishmaniasis 
(DsCL) and leishmaniasis recidivans (LR) (1, 2). CL is caused by Leishmania 
species that are classified into Old World species, for instance Leishmania 
major (L. major), L. tropica, and L. aethiopica and New World species, such 
as L. amazonensis, L. mexicana, L. braziliensis and L. guyanensis (Fig 1.1) 
(3, 4). CL occurs in 88 countries and 90% of the cases are reported in 
Afghanistan, Brazil, Iran, Peru, Saudi Arabia and Syria (Fig 1.2) (1). Recently, 
a recrudescence has been noticed in Syria as a result of the destruction of the 
public health system and the lack of sanitation caused by the current conflict 
(5). Because of the displacement of Syrian people and the millions forced to 
flee the country, with the majority of them residing in Lebanon, Jordan, Egypt 
and Iraq, reporting of CL has increased across the region (6). 
The clinical features of leishmaniasis depend on the parasite, the host and the 
vectors –  Fig 1.2 shows an overview of the taxonomy of Leishmania species 
and the related clinical manifestations (Fig 1.1 and Table 1.1) (7).  
- VL, also known as kala-azar (black fever), a potentially fatal illness 
which is characterised by irregular fever lasting for 14 days, the 
enlargements of spleen and liver, pancytopenia and weight loss. The 
incubation time for VL is between 2 weeks and 8 months and without 
treatment, the disease is typically fatal. One of the big challenges for 
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VL is the co-infection with HIV. VL is caused mainly by L. donovani, L. 
infantum  and rarely by L. tropica (8).   
 
- LCL is associated with an erythemic papule at the bitten site (1 -10 mm 
diameter) and then can lead to rounded ulcers combined with nodal or 
thick edges. These ulcers or lesions can stay from 5 months to 20 
years. Lesions caused by L. mexicana are typically self-healing within 
3-9 months, 6-15 months in the case of L. braziliensis, L. tropica or L. 
panamensis and within 2-6 months for L. major infections (8).   
 
- DCL is uncommon anergic dissemination form of CL caused by L. 
aethiopica, L. amazonensis or L. mexicana. It begins with erythematous 
nodules resembling lepromatous leprosy and infiltrative plaques and 
then might ulcerate. DCL starts firstly on the face and subsequently 
affects other parts of the body and could affect the complete skin 
surfaces in some cases (8).  
 
- MCL is caused by L. braziliensis, L. guyanensis, or L. panamensis. MCL 
is identified by invasive and destructive lesions of the mucosal 
membrane of the face, mouth and throat cavities. MCL is more frequent 
in immunocompromised patients (4).  
 
- DsCL is caused by L. aethiopica, L. guyanensis and L. mexicana, 
spotted in Latin America and characterised by ten or more lesions 
(mixed type) located in two or more parts of the body. 
 
- LR is caused by L. tropica and L. braziliensis and usually identified as 
new lesions around the old scar that has been cured and infiltrated with 
lymphocytes. 
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Figure  1.1. The distribution of cutaneous leishmaniasis WHO (9) 
 
 
Figure  1.2. Leishmania species and related clinical manifestations (7). 
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Table 1.1. Clinical and epidemiological characteristics of the main Leishmania species copied from (4) 
 
 
 Subgenus Clinical Main clinical features Natural progression Risk groups Main High-burden Estimated annual 
  form    reservoir countries or worldwide incidence 
       regions  
         
Leishmania Leishmania VL and Persistent fever, VL is fatal Predominantly adolescents Humans India, Bangladesh, 50 000–90 000 VL cases; 
donovani*  PKDL splenomegaly, weight loss, within 2 years; PKDL and young adults for VL;  Ethiopia, Sudan, unknown number of 
   and anaemia in VL; multiple lesions self-heal in up young children in Sudan  and South Sudan PKDL cases 
   painless macular, papular, to 85% of cases in and no clearly established    
   or nodular lesions in PKDL Africa but rarely in Asia risk factors for PKDL    
Leishmania Leishmania CL, LR, and Ulcerating dry lesions, CL lesions often No well defined risk groups Humans but Eastern 200 000–400 000 CL 
tropica*  rarely VL painless, and frequently self-heal within 1 year  zoonotic foci Mediterranean,  
   multiple   exist the Middle East,  
       and northeastern  
       and southern Africa  
Leishmania Leishmania CL, DCL, Localised cutaneous nodular Self-healing, except for Limited evidence; Hyraxes Ethiopia and Kenya 20 000–40 000 CL 
aethiopica*  DsCL, and lesions; occasionally DCL, within 2–5 years adolescents    
  oronasal CL oronasal; rarely ulcerates      
Leishmania Leishmania CL Rapid necrosis, multiple Self-healing in No well defined risk groups Rodents Iran, Saudi Arabia, 230 000–430 000 CL 
major*   wet sores, and severe >50% of cases within   north Africa,  
   inflammation 2–8 months; multiple   the Middle East,  
    lesions slow to heal,   central Asia, and  
    and severe scarring   west Africa  
Leishmania Leishmania VL and CL Persistent fever and VL is fatal within Children under 5 years and Dogs, hares, China, southern 6200–12 000 cases of 
infantum*   splenomegaly in VL; 2 years; CL lesions immunocompromised and humans Europe, Brazil, and Old World VL and 
   typically single nodules and self-heal within 1 year adults for VL; older children  South America for 4500–6800 cases of 
   minimal inflammation and confers individual and young adults for CL  VL and CL; Central New World VL; unknown 
   in CL immunity   America for CL number of CL cases 
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  Subgenus Clinical form Main clinical features Natural progression Risk group Main 
reservoir 
High-burden 
countries or 
regions 
Estimated annual 
worldwide incidence 
Leishmania 
mexicana† 
Leishmania CL, DCL, and 
DsCL 
Ulcerating lesions, 
single or multiple 
Often self-healing 
within 3-4 months 
No well 
defined risk 
groups 
Rodents 
and   
marsupials 
South America Limited number of 
cases 
Leishmania 
amazonensis† 
Leishmania CL, DCL, and 
DsCL 
Ulcerating lesions, 
single or multiple 
Not well desribed No well 
defined risk 
groups 
Possums 
and 
rodents 
South America Limited number of 
cases 
Leishmania  
braziliensis†  
Viannia CL, MCL, 
DCL, and LR 
Ulcerating lesions can 
progress to 
mucocutaneous 
form; local lymph 
nodes are 
palpable before and 
early on 
in the onset of the 
lesions 
Might self-heal within 
6 months; 2·5% of 
cases progress to 
MCL 
No well 
defined risk 
groups 
Dogs, 
humans, 
rodents, 
and 
horses 
South America Majority of the 
187 200–300 000 total 
cases of New World 
CL‡ 
Leishmania  
guyanensis†  
 
Viannia CL, DsCL, 
and MCL 
Ulcerating lesions, 
single or 
multiple that can 
progress 
to mucocutaneous 
form; 
palpable lymph nodes. 
Might self-heal within 
6 months` 
No well 
defined risk 
groups 
Possums, 
sloths, 
and 
anteaters 
South America Limited number of 
cases, included in the 
187 200–300 000 total 
cases of New World 
CL‡ 
VL=visceral leishmaniasis. PKDL=post-kala-azar dermal leishmaniasis. CL=cutaneous leishmaniasis. LR=leishmaniasis recidivans. DCL=diffuse cutaneous leishmaniasis. 
DsCL=disseminated cutaneous leishmaniasis, MCL=mucocutaneous leishmaniasis. *Old World leishmaniasis. †=New World leishmaniasis. ‡Estimates are of all New World 
leishmaniases, with Leishmania braziliensis comprising the vast majority of these cases. 
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1.2. Life cycle 
Many causative species for CL, have a zoonotic cycle1 (L. major, L. aethiopica, 
and all the New World species), whilst few have an anthroponotic cycle2 (L. 
tropica). Regarding the VL, humans are the main reservoir for L. donovani 
while dogs form the primary reservoir for L. infantum. The Leishmania life cycle 
starts when infected female sandflies (Phlebotomus species in the Old World, 
Lutzomyia species in the New World) bite their hosts and inject parasites (the 
infective metacyclic promastigote form) into the skin of a mammalian host (a 
sand fly injects 100-1000 promastigotes). Sandflies salivary chemoattractants 
enhance the flow of macrophages, dendritic cells (DCs) and neutrophils to the 
biting site. These promastigotes are then phagocytised by resident 
phagocytes. After which, promastigotes transform in these cells into 
amastigotes which replicate by simple division in the parasitophorous vacuole 
and infect other macrophages, either locally or in remote tissues (1, 4).  
Neutrophils play a critical role in leishmaniasis by acting as Trojan horses for 
Leishmania promastigotes before entering their target cells (macrophages). 
Leishmania survive in the neutrophils by inhibiting the phagosome 
acidification. Leishmania promastigotes directly infect DCs and reside within 
parasitophorous vacuoles. In macrophages, promastigotes are interlined into 
phagolysosome like compartment, named the Leishmania parasitophorous 
vacuole. The maturation of parasitophorous vacuole is regulated by 
Leishmania parasites to protect them from destruction by the macrophage 
microbicidal activity and to avoid the host immune defence responses (9, 10, 
11) 
Female sandflies become infected when they feed on an infected host and 
amastigotes transform into promastigotes in the midgut of the sandfly and then 
migrate to salivary glands and transform into infectious metacyclic 
promastigotes (Fig 1.3) (1, 12).  
                                               
1 In zoonotic cycles: animasl are main reservoirs 
2 In anthroponotic cycles: humans are main reservoirs 
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Figure  1.3. The life cycle of Leishmania parasites (13).  
 
1.3. Immune response in CL 
The cellular immune responses play a critical role in the control or progress of 
cutaneous leishmaniasis and have been widely studied in mouse models, 
often using L. major. Progressive lesions have been developed in susceptible 
mice (BALB/c mice) with a dominance of the Th2 response, leading to the 
production of anti-inflammatory cytokines, such as IL-4, IL-5, and IL-13, which 
suggests that Th2 cells are associated with develop progressive lesions. On 
the other hand, resistant mice (C57BL/6 and C3H/HeJ mice), infected by L. 
major, present small lesions with few parasites and a dominance of the Th1 
response, with the production of IFN-γ, TNF-α and IL-12. These cytokines 
activate macrophages to produce reactive oxygen species (ROS) and nitric 
oxide (NO), which are responsible for killing intracellular parasites as seen in 
Fig 1.4 (14, 15, 16). In humans, resolution from cutaneous leishmaniasis is 
recognized by induction of specific IFN-γ releasing CD4+ T cells (17, 18). The 
response in individuals with moderate CL caused by L. major is a mixture of 
Th1 and Th2. There is an absence of a Th1 response in individuals with severe 
CL (17, 18).  
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To conclude, the control of CL is linked with Leishmania-specific T 
lymphocytes producing TNF-α and IFN-γ and this enhances macrophages in 
the skin to produce microbicidal materials (NO and ROS). It is obvious from 
Fig 1.5 that, the balance between pro- and anti-inflammatory factors controls 
the consequence of CL infection (19).  
The functions of B cells are still a matter of debate. Several studies suggest 
that these cells enhance the Leishmania infection while some state that B cells 
have a protective function against L. amazonensis (20).  
 
 
Figure  1.4. Immune response against leishmaniasis. A: neutrophils play an 
important role during the early stage of infections. B: the essential role of 
monocytes in killing Leishmania and promoting the differentiation of Th-1, which 
leads to the elimination of parasites (16)  
 
1.4. Current treatment of cutaneous leishmaniasis 
CL lesions can heal spontaneously in most cases within 2-18 months. Infection 
is not usually fatal but can cause considerable cosmetic morbidity, 
psychological disorders, social stigma leading to changes in individual self-
esteem (4, 8). The important goal of making the decision to treat CL is to 
eradicate the Leishmania parasites and enhance the lesion healing process.  
This will reduce the risk of scarring and help to lower the risk of dissemination 
or progression other forms of more sever CL.  
A B 
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Other criteria to commence treatment includes the presence of many lesions 
(more than 5), large size (>4 cm), location over sensitive body areas such as 
the face, or lasting for more than 6 months and/or in Immunosuppressed 
patients (Table 1.2) (4, 21). The Infectious Diseases Society of America 
recently published comprehensive treatment guidelines for the management 
of CL according to the clinical characteristics, summarised in Table 1.2  (22).  
Table 1.2. Clinical features of New World CL that might modify management 
copied from (23) 
Simple CL Complex CL 
Caused by a Leishmania species 
unlikely to be associated with mucosal 
leishmaniasis 
Caused by a Leishmania species that 
can be associated with increased risk 
for ML, particularly Viannia spp in the 
“mucosal belt” of Bolivia, Peru, and 
Brazil a,b,c 
No mucosal involvement noted Local subcutaneous nodules d 
Absence of characteristics of complex 
CL 
Large regional adenopathy d 
Only a single or a few skin lesions >4 skin lesions of substantial size (eg, 
>1 cm) 
Small lesion size (diameter Large individual skin lesion (diameter 
≥5 cm) 
Location of lesion feasible for local 
treatment 
Size or location of lesion such that local 
treatment is not feasible 
Nonexposed skin (ie, not cosmetically 
important) 
Lesion on face, including ears, eyelids, 
or lips; fingers, toes, or other joints; or 
genitalia 
Immunocompetent host Immunocompromised host (especially 
with respect to cell-mediated immunity) 
Lesion(s) resolving without prior 
therapy 
Clinical failure of local therapy 
 Unusual syndromes: leishmaniasis 
recidivans, diffuse CL, or disseminated 
CL 
Abbreviation: CL, cutaneous leishmaniasis. 
a The highest risk areas for mucosal leishmaniasis (ML) are south of the Amazon 
basin in parts of Bolivia, Peru, and Brazil (defined here as the “mucosal belt”). 
Moderate-risk areas are south of Nicaragua to the Amazon basin. Low-risk areas 
for ML are in New World CL (Viannia)–endemic regions north of Costa Rica. 
Amazonian basin regions up to an altitude of approximately 2000 meters are 
referred to as increased ML-risk regions. 
b Leishmania species with an increased risk of causing ML include L. (V.) 
braziliensis mainly, but also L. (V.) guyanensis and L. (V.) panamensis. There are 
other species that can be associated with ML less frequently. In this document, we 
refer to these 3 species as “increased ML-risk species.” Geographic regions in 
which there is an increased risk for ML are defined above. 
c High therapeutic failure rates after treatment with pentavalent antimonial drugs 
have been observed in CL acquired in Amazonian Bolivia (eg, Madidi National 
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Park) and southeastern Peru (eg, Manu National Park and Puerto Maldonado). 
Poor efficacy after using miltefosine in the treatment of L. (V.) braziliensis was 
reported in Guatemala. 
d It is somewhat controversial whether the presence of small subcutaneous nodules 
is always associated with complex CL, but certainly complex CL applies if bubonic-
like adenopathy is present in regional drainage area of lesions. These findings have 
been linked to complications or treatment failure when only local treatment is 
administered. Some experts would not consider systemic therapy needed for a few, 
small subcutaneous nodules in Old World CL 
 
Treating CL can include (i) chemotherapy (anti-leishmanial drugs that kill the 
parasites directly) (ii) local physical methods (cryo- or thermotherapy), (iii) 
immunotherapy (by immune modulators for stimulating effective immune 
response against Leishmania parasites) (Fig 1.5) (24).   
 
 
Figure  1.5. Strategies for treatment of CL and the related limitations. 
Syst=systemic. Tx= treatment. ACL=asymptomatic CL (25). 
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1.4.1. Systemic therapies  
1.4.1.1. Pentavalent Antimony  
Pentavalent antimony (SbV) compounds like sodium stibogluconate (SSG, 
Pentostam ®, GSK, contains 100 mg/ml of SbV) and meglumine antimoniate 
(Fig 1.6) (MA, Glucantime®, Sanofi, contains 85 mg/ml) have been the 
standard therapy for CL since they were developed in the 1940s (26, 27). The 
severity of CL can determine the routes of administration (locally or 
systemically). In local treatment, SbV (1-5 ml) is administrated by injection (1- 
5 times every 3-7 days for up to 5 sessions) in lesions edges with or without 
cryotherapy (application of liquid nitrogen after the injection) (28, 29). The 
parenteral route includes intravenous or intramuscular administration of 20 
mg/kg/day of SbV, typically in the case of complex CL (28). Intralesional 
administration benefits include making a high enough concentration of the 
drug at the site of infection, reduced costs, limiting the systemic side effects 
and faster healing time (30). However, the problems with this route includes 
the difficulty of administration, pain of these injections, sensations of burning, 
itching and sometimes the appearance of inflammation in the location of the 
injections (31). On the other hand, parenteral injections can lead to adverse 
side effects (hepatoxicity and cardiotoxicity) (32). There is a lack of placebo-
controlled randomized clinical trials to compare the activity of SbV therapy 
against specific species of CL (31). Variability of the sensitivity of Leishmania 
(promastigotes and intracellular amastigotes) species to SbV has been 
confirmed in vitro (33, 34).  
There is still no clear definition of the mechanism of the action of SbV, in spite 
of these drugs being used for several decades. One of the suggested 
mechanisms is that SbV is converted after administration to the trivalent form 
(SbIII) which is the active but more toxic form. This trivalent antimony (SbIII) 
intervenes with the trypanothione reductase system that protects the 
Leishmania amastigotes from the harm caused by the oxidation and toxicity of 
heavy metals (35, 36). Others suggested that SbIII can cause Leishmania 
apoptosis by fragmenting DNA of amastigotes (37, 38). A third mechanism has 
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suggested that SbV interacts with adenine ribonucleoside and produces a 
complex that causes a depletion of intracellular ATP and the prevention of 
macromolecule synthesis in amastigotes by inhibiting type I DNA 
topoisomerase (32, 39).  
 
 
Figure  1.6. Proposed structural formula for 364 Da and 365 Da ions identified by 
ESI(-)-MS in aqueous solutions of meglumine antimoniate and stibogluconate, 
respectively, copied from (40) 
1.4.1.2. Miltefosine 
Miltefosine (MF), an alkylphospholipid, was developed as an antineoplastic 
agent (for cutaneous cancers). Croft et al in 1987 showed the anti-leishmanial 
activity of miltefosine and other phospholipid compounds (1). MF is 
recommended for VL and complex cases of CL and considered as the only 
effective drug that can be given orally for leishmaniasis treatment. The 
effective dose for CL is a daily oral dose 2.5 mg/kg for 28 days (1, 41).  
However, different Leishmania species show significantly different sensitivity 
to MF (42). Randomized clinical trials have been conducted in different regions 
against different species with various clinical responses. For instance, in 
Colombia the cure rates against L. panamensis were 91% in comparison to 
38% for placebo group (43). While the cure rates were just 53% in Guatemala 
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against L. mexicana and L. braziliensis compared to 32% in placebo treatment 
(43). In vitro studies confirmed the species variation in MF sensitivity (44). The 
two major concerns about this drug is that, (i) MF is a teratogenic agent and 
so cannot be given to women who are pregnant and (ii) the presence of 
resistance development in vitro (42). Some common side effects of MF 
treatment are gastrointestinal discomfort, renal disorders, headache and 
raised liver enzymes (45).  
The mechanism of action of MF remains unclear. Different mechanisms have 
been suggested such as the inhibition of synthesis of phospholipids, 
interaction with the parasite membrane, dysfunction of mitochondria or 
stimulation of apoptosis-like cell death (46, 47, 48, 49). 
 
Figure  1.7. Chemical structure of miltefosine (50) 
1.4.1.3. Amphotericin B (AmB) 
The second most common treatment for leishmaniasis is amphotericin B, 
which is a polyene antibiotic (Fig 1.8), mainly used for VL and MCL (51). The 
therapeutic dose of AmB deoxycholate (Fungizone) is 0.7 mg/kg/day by slow 
intravenous infusion for 25-30 days or 2-3 mg/kg/day of liposomal formulations 
for 10-15 days (28). In 1950s, AmB was firstly noted and derived from 
Streptomyces nodosus. Sodium deoxycholate solution of AmB (DAmB, 
Fungizone) was brought to the market in 1959. Fungizone has been used 
intravenously as a standard treatment for invasive fungal infections for several 
decades. Fungizone has serious side effects such as nephrotoxicity and fever, 
anaemia, malaise and abdominal pain (52).  
Several lipid formulations, including liposomal amphotericin B (AmBisome®), 
amphotericin B lipid complex (AbelcetR), and amphotericin B colloidal 
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dispersion (AmphocilTM) have been developed and used in treatment of VL to 
reduce the previous toxicities since 1990s (53). AmBisome® (liposomal 
amphotericin B, LAmB; Gilead Sciences, Dimas, CA, USA) has been approved 
by the Food and Drug Administration (FDA) for treatment of VL in 1997 with 7 
intravenously doses of 3 mg/kg/day over 21 days (54). Yardley and Croft 
(2000) found that AmBisome® (liposomal amphotericin B) was also successful 
in reducing the size of lesions in CL caused by L. major in BALB/c mouse 
model (55). The high cost of these formulations (up to 250 USD$ per vial) 
prevents more widespread use (56, 57). Recently there is an agreement 
between WHO and Gilead Sciences for the donation through WHO of 
AmBisome® vials for VL treatment (58). Other problems related to AmBisome® 
were reported in s study with a low positive outcome of 63% among travellers 
infected with CL and MCL coming back from both Old- and New-World 
countries and 53% of these treated patients showed renal toxicity and infusion-
related reactions (59) and higher rates of relapse were noticed in 
immunocompetent patients with VL treated with AmBisome® (60, 61). 
Amphotericin B acts by forming a complex between its hydrophobic polyene 
region and the ergosterol in the plasma membrane of Leishmania or fungi 
which causes transmembrane channels, after which a death of the microbe is 
induced by the collapsing of ion gradient (62, 63). Recently, an alternative 
mode of action has been suggested, that AmB primarily exists as large, extra-
membranous aggregates that results in the removal of ergosterol from the lipid 
bilayer leading to microbe death (64). Additionally, reports claim that AmB has 
immunomodulatory effects and stimulates oxidative stress in immune cells 
(52, 65, 66).  
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Figure  1.8. Chemical structure of amphotericin B (A), Fungizone (B) and 
AmBisome® (C) (67) 
 
1.4.1.4. Pentamidine  
Pentamidine is, an aromatic diamidine, as effective as antimonial drugs for 
healing CL caused by L. panamensis or L. guyanensis (30, 57). The cure rates 
of parenteral pentamidine with 7 doses of 2 mg/kg for 14 days vary from 35% 
to 95% (1). This drug offered significant advantages such as shorter duration 
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of the therapy and lower costs in comparison with other drugs for CL (68) but 
is rarely used due to low cure rates and significant side effects of diabetes, 
myocarditis and nephrotoxicity (69). 
The mode of action is not completely clear but interference with Leishmania 
DNA and disruption of mitochondrial membrane have been suggested (70). 
 
  
 
Figure  1.9. Chemical structure of pentamidine (71)  
 
1.4.1.5. Azoles 
Azoles are antifungal agents, which also have an anti-leishmanial activity 
because they inhibit the 14 a-demethylation of lanosterol and this inhibition 
leads to an accumulation of 14 a-methyl sterols and blocks ergosterol 
synthesis of Leishmania parasites (72). The most important azoles that are 
active against Leishmania parasites are fluconazole, ketoconazole and 
itraconazole which have been used orally with different results against CL. The 
effectivity of ketoconazole, with the oral dose 8 mg/kg/day for 4 to 6 weeks, 
was 76–90% in CL caused by L. panamensis and L. mexicana in Guatemala 
and Panama (28). However, in a clinical trial in Colombia, itraconazole (oral 
dose 200 mg twice daily for 28 days) was ineffective against CL caused by L. 
panamensis (73).  
Fluconazole has important properties including a longer half-life and increased 
concentrations in cutaneous tissues. In L. major infections, there was a good 
evidence of the benefit for the use of 200 mg oral fluconazole for 6 weeks (31). 
A study in Saudi Arabia showed cure rates 79% in CL caused by L. major after 
6-weeks of 200 mg daily of oral fluconazole (74). An important advantage of 
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azoles is the ease of administration via the oral route. However, these drugs 
have many side effects such as the low cure rates, hepatotoxicity and 
gastrointestinal symptoms (72). 
 
 
 
 
Figure  1.10. Chemical structure of some azoles(75)  
1.4.2. Local therapy  
1.4.2.1. Paromomycin  
Paromomycin (PM) is an aminoglycoside antibiotic (Fig 1.11) and was 
identified as an anti-leishmanial drug in the 1960s. The sulphate salt of PM is 
given parenterally to treat VL, e.g. 11 mg/kg/day intramuscularly for 21 days. 
A topical formulation of paromomycin sulphate 15% plus 12% methyl-
benzethonium chloride (MBCL) ointment has been used for LCL by applying 
twice daily for 20 days (28, 76). Topical 15% PM + 12% MBCL was active in 
BALB/c mice infected with New World species (L. mexicana) but did not show 
activity against L. panamensis and L. amazonensis (77).  
Different formulations with a lower skin irritancy including one containing 15% 
paromomycin with 0.5% gentamicin gave cure rates of 81-82% for CL caused 
by L. major and 80% in Panama for CL caused by L. braziliensis and L. 
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panamensis in phase 3 studies. However, these results compared with a 
placebo cure rate of 58%, and almost no difference between formulations 
combining paromomycin and gentamicin or paromomycin alone (4). 
Paromomycin has low cure rates against certain Leishmania species and in 
many cases, relapse can be found during the first year (30, 46).  
The exact mechanism of PM against Leishmania parasites is not fully known, 
studies suggest PM inhibits protein synthesis by blocking the dissociation of 
ribosomal subunits (78) , others suggest that PM alters leishmanial lipid 
metabolism leading to the arresting of growth (79).  
 
 
 
 
Figure  1.11. Chemical structure of paromomycin(71)   
 
1.4.2.2. Physical treatments 
Physical methods such as, localised heat or cryotherapy have been used in 
the treatment of CL. Localized heat is performed by using a device (e.g. 
Thermomed®) which provides a focused heat on the lesion (50°C for 30 
seconds once per week for one month) and this method demonstrates about 
69% overall efficacy against CL (1, 80). Cryotherapy is the use of liquid 
nitrogen to freeze lesions, repeated on three separate days. The efficacy of 
this procedure is about 57% against L. major. The benefits of localised heat or 
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cryotherapy methods are the ease of use and the safety. The problems with 
these methods include the low cure rates, the need for expensive equipment, 
and availability of electricity in rural areas (1). A comparison of the effects of 
three different therapies for CL was done in Iran: intralesional meglumine 
antimoniate or cryotherapy (liquid nitrogen (−195 °C)) or a combination of 
these two methods. They found that combining both MA and cryotherapy gave 
a significant higher activity than the two monotherapies (81, 82).  
1.4.3. Immunomodulatory treatment 
The immune response plays an important role in the control of CL - cure 
depends upon the activation of macrophages to produce toxic nitrogen and 
oxygen metabolites to kill the intracellular amastigotes (83). Consequently, 
immunomodulators for CL and VL have been studied widely for many years 
either alone or in combination with other drugs (84). For example, 11532 
Venezuelan patients with American cutaneous leishmaniasis were treated 
with a combination of an immunomodulator (heat 
killed Leishmania promastigotes and bacille Calmette-Guérin (BCG)) and 
chemotherapy (meglumine antimoniate). Cure rates of 91.2 to 98.7% were 
achieved (85).  
 
 Examples of other clinically used immunomodulators include: 
-Imiquimod: an antiviral compound [1-(2- methylropyl)-1H-imidazo (4, 5-c) 
quinolin-4-amine] used topically for the treatment of genital warts, caused by 
the human papillomavirus, via the stimulation of localised immune response.  
Macrophages are activated to produce cytokines and nitric oxide at the site of 
application (76). Many studies have shown that imiquimod has anti-
leishmanial activity. A randomized, double-blind clinical trial in Peru showed 
that patients with CL treated with 5% Imiquimod cream in combination with 
meglumine antimonate therapy showed faster lesion cure in comparison with 
those received meglumine antimonate with placebo vehicle cream therapy  
- Pentoxifylline: Pentoxifylline is s a methylxanthine derivative that inhibits 
TNF-α and decreases tissue inflammation. A clinical study showed that 
patients with CL caused by L. braziliensis who received a combination of 
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pentoxifylline plus SbV had higher cure rates than in those receiving antimony 
plus placebo (86, 87). 
- A topical immunomodulator which is cytokine granulocyte-macrophage 
colony stimulating factor (GM-CSF) was found to accelerate the lesion healing 
in CL patients (88).   
1.5. Challenges for CL treatment  
CL is classified as a neglected tropical disease (NTD). NTDs have been 
described by the WHO as a varied group of diseases that have an impact on 
more than one billion people and dominate in 149 countries in tropical and 
subtropical conditions. These diseases are commonly associated with poverty 
and cause a huge economic and health burden in low- and middle-income 
countries (89, 90).  
Many factors form a challenge for CL treatments. CL happens in tropical areas 
with high temperatures, humidity and without cold chains and these conditions 
affect the stability of drug formulations for CL and even for other diseases (91). 
For example, AmBisome® requires a cold chain to protect its activity and a 
consistent supply of electricity is often difficult in rural regions. Moreover, some 
patients live in remote areas and are unable to access treatment easily. 
Availability of medicine(s) is also a challenge (92). Besides that, WHO 
estimated the cost of CL treatment to be between 12-40 USD$ per patient (28) 
, this cost is prohibitive for many as the monthly income in many CL-endemic 
areas is only 7-17 USD$ /per person (28). Additionally, a delay between 
recognition of CL and starting the treatment increases the possibly of lesion 
progression to an ulcer with subsequent treatment complications and scarring 
(93, 94).  
1.6. Assays to test the anti-leishmanial activity of drugs 
The existing predictive models to study the anti-leishmanial activity of 
compounds are classified into in vitro and in vivo assays.  
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1.6.1. In vitro assays  
These models are classified as either promastigote, axenic (extracellular) 
amastigote or intracellular amastigote assays.  
The advantages of using promastigote and axenic (extracellular) amastigotes 
are higher-throughput, cheaper, quicker and more straightforward screening. 
However, the drawbacks encompass that promastigotes are significantly 
different from intracellular amastigotes (target form in mammalians resides 
within the macrophages of the dermal skin layer) in terms of metabolism and 
ecology. Moreover, these promastigotes grow at 26°C and this could affect the 
anti-leishmanial action of drugs while in vivo temperature of 37 °C ( 34 °C skin 
temperature) (95, 96). The axenic amastigotes test is semi – predictive as it 
does not examine the penetration of the compound into the host cell and does 
not reflect the activity of the compound in the host environment and 
accordingly, is prone to false positive and negative results (95, 97). 
 
On the other hand, the intracellular amastigote test (infected macrophages) is 
the gold standard model. In this model, macrophages can be derived from a 
range of sources, for example murine peritoneal macrophages (PEMs) or 
murine bone-marrow macrophages (BMMs), or chemically differentiated from 
human cancer cell lines (THP-1) (71). 
The activity of tested drugs is evaluated by exposing infected macrophages to 
particular concentrations of the drug for a specific period (such as 2, 3 or 5 
days), and then stained with Giemsa after fixation with methanol. Activity is 
measured by either microscopical counting of number of amastigotes per 
macrophage or the percentage of infected macrophages (containing at least 
one parasite) (% infection). The selections of new compounds as anti-
leishmanial depend on the 50 % and 90 % effective concentrations (EC50, 
EC90) after comparison with an untreated control and a positive control drug 
(95, 97). 
In addition, there are more in vitro methods used to test the anti-leishmanial 
activity of drugs are summarised in Table 1.3 with positive and negative points 
for each assay. 
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Table 1.3. In vitro screening models with positive and negative drawbacks copied 
from (97).  
 
In vitro models Merits Demerits 
Promastigote 
Rapid method and very little 
amount of test compounds are 
required for screening. 
Not relevant life cycle stage 
for mammalian leishmanial 
infection. 
Data correlation with 
amastigote screening is 
unreliable. 
Axenic 
amastigotes 
Test is direct on relevant stage 
of the parasite. 
 
The assay is semi – 
predictive. 
 
 
This stage is as easy to 
manipulate as the 
promastigotes. 
It neither tests for 
penetration of compound 
into host cell nor for activity 
in peculiar environment of 
the macrophage 
phagolysosome 
Quantification of drug activity is 
simple and often inexpensive. 
Different metabolic 
processes than intracellular 
amastigotes. Screening of 
axenic amastigotes from 
clinical isolates is not 
possible as they require time 
to get adapted in the 
cultures. 
Intracellular 
amastigotes 
Effective screening method. Labour intensive and 
subjective. 
Mimic the environment 
encountered by the target cell. 
Provide an approximation of 
the macrophages that are 
counted. Rendered difficult 
the screening of several 
drugs at a time and 
incompatible with HTS. 
Shows the effect of drug 
mediated toxicity on host cell. 
 
Reporter gene 
assays: 
(GFP) Green 
fluorescent 
protein 
Simple Fluorescence intensity in 
parasites decreased with 
time in the absence of 
geneticin sulphate (antibiotic 
G 418), thereby 
necessitating its regular 
addition. 
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Easier kinetic monitoring. Application for drug-drug 
screening is limited to 
promastigotes. 
Low cost and enhanced 
biosafety. 
 
β -galactosidase 
Colorimetric detection can be 
performed 
Large size (the monomer is 
116 kDa). 
Low sensibility. 
Endogenous expression of 
β-galactosidase by some 
mammalian cell types 
including macrophages. 
β–lactamase 
Simple colorimetric β-
lactamase assay for quantifying 
Leishmania amastigotes grown 
in micotiter plates. 
High-level stable expression of 
the enzyme 
Not very sensitive. 
Luciferase 
The method is rapid. 
Very sensitive. 
Highly reproducible. 
Does not require any very 
specialized instrument or 
training. 
Detection of only live, 
metabolically active cells by 
biphotonic imaging. 
Absence of background activity 
in the host cell. 
Compatible with HTS. 
Luminescent read out 
transient. Mixing of the 
samples and reagents 
needs to be timed with 
entering samples into the 
luminometer. 
HTS, high throughput screening 
 
These in vitro screening models have a major drawback related to their lack 
of biological relevance - they involve traditional cell culture methods (static and 
two-dimensional culture systems). Static cell culture systems that use the 
micro well plates are widely used. However, cells in human and animal tissues 
are sensitive to their microenvironment and face different mechanical 
stimulants due to interstitial flow and nutrient diffusion. Static cell culture 
systems are unable to provide these mechanical and physical factors arguably 
significantly limiting the cellular response in vitro l (98, 99). Dynamic culture 
systems have the potential to overcome these limitations and better mimic the 
in vivo situation for drug discovery process (100) . 
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1.6.2. In vivo assays 
Different animal models (summarized in Table 1.4) are used to evaluate the 
effectiveness of drugs against leishmaniasis. These models imitate some of 
the pathological features and immunological responses shown in humans 
when exposed to Leishmania infections. In vivo assays allow the 
determination of drug activity in association with drug administration, 
excretion, and distribution. They can identify adverse events (toxic side 
effects) resulting from a particular treatment (101, 102). Murine models are 
widely used to evaluate the effectiveness of new drugs against leishmaniasis 
and to study the pathogenesis of this disease. L. major-BALB/c is the most 
used, with high reproducibility, and relatively fast progress of skin lesions 
(within 3 weeks). In this model, only potent drugs show anti-leishmanial 
efficacy as self-healing of CL is rare due to the immunological incapability of 
BALB/c mice (97, 101, 102).   
The anti-leishmanial activity of compounds in the animal model is typically 
determined by a reduction of lesion size compared to untreated controls. 
However, inflammation plays a key role in lesion size. Therefore, size alone 
does not accurately reflect the anti-leishmanial activity. An additional indicator 
of therapeutic effect, e.g. determination of parasite burden should be 
considered. This can be achieved by different assays such as quantitative 
polymerase chain reaction (qPCR) or in vivo imaging (semi-quantitative) of 
bioluminescent parasites (97, 101, 102). A Therapeutic Index (TI) is often used 
to express the window between the required effective dose and the toxic/lethal 
doses of the drug (ED50/LD50) (95, 97). 
 
Table 1.4. In vivo models for leishmaniasis copied from (97) 
Animal Species Examples Main strength 
Mice 
BALB/c 
Immunology, Vaccines, 
Chemotherapy 
C57BL/6 
Negative model-Immunology, 
Vaccines, Chemotherapy 
Transgenic mice Immunology 
Hamster Syrian golden hamster Pathology, Chemotherapy 
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Dogs Different breeds 
Pathology, Vaccines, 
Chemotherapy 
Non-human 
primates 
Langurs, Monkeys - 
vervet, rhesus, owl, 
mandrills, baboon, 
marmoset, squirrel 
Vaccine, Pathogenesis, 
Chemotherapy, Pathology 
 
1.7. Drug development for CL: from pipeline to patients  
The currently available drugs for CL have some drawbacks such as, low cure 
rates, toxicity, and high costs. These limitations clearly highlight the need for 
short, safe, efficacious, affordable and field-adapted treatments against 
Leishmania parasites (84). The process of developing and discovering new 
drugs is long, slow, expensive and challenging (Fig 1.12). For example, 
screening 100,000 compounds can lead to just one compound from a research 
and development (R&D) pipeline to a marketed drug and may take more than 
10 years with an estimated expenditure around 2.6 billion USD$ (87). NTDs 
are generally considered commercially unattractive for Pharma research and 
development (R&D) (103) (81). In the last 40 years, only few new drugs have 
been developed for NTDs despite the great knowledge in the field of NTDs 
(88). NTDs usually involve populations with low purchasing power in low 
income countries - not a monetary incentive for the private sector to develop 
new therapies. Publication is typically the end of the line for NTD R&D or at 
other stages in the drug development pipeline (Fig 1.13) (88).   
Nonetheless, there has been a considerable moving forward in VL treatment 
and in the developing of new drugs of this disease. In contrast, no great 
attentions have been paid for CL drugs development (more details later) (90).  
 
One of the strategies to overcome the high cost and long time lines of 
developing a new drug or chemical entity is “drug repurposing” (90). In this 
strategy, a known drug for a specific target is tested against different diseases. 
The drug has already been tested for toxicity, and other pharmacokinetic and 
pharmacodynamic studies have already been carried out, all in relation to its 
original indication. This can save time and money. As a result, getting a drug 
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to market can take less time. For instance, three drugs have been repurposed 
and used clinically for leishmaniasis; AmB was originally developed for fungal 
infections, paromomycin was primarily used for amoeba infections as an oral 
drug, and miltefosine was developed as an anti-cancer treatment (104, 105).  
Many researchers, worldwide, have identified a large number of compounds 
that show anti-leishmanial activity, either via re-purposing (tamoxifen, 
nelfinavir, imipramine, delamanid, fexinidazole) or isolating new chemical 
entities (NCEs) from natural sources (quinones, pyrimidines) (90). Another 
strategy is optimising the drug by reformulation of the active ingredient in the 
current drug or by using drug delivery systems for currently active drugs (more 
details later) (104, 105, 106).  
 
 
Figure  1.12. The process of drug discovery and drug development. 
a) drug discovery stages b) drug development (107)  
A 
B 
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Figure  1.13. The Drug Development Pipeline - potential drugs for NTDs are 
frequently stuck in the early stage of development as a result of pipeline gaps (108) 
1.8. New CL drugs 
Despite limited resources, there have been recent developments in the NTD 
drug development arena. Some non-profit organisations such as TDR3, have 
been involved in the development of 12 new drugs for NTDs. Another 
collaborative, patients’ needs-driven, non-profit drug R&D organisation 
developing new treatments for neglected diseases, is the Drugs for Neglected 
Diseases initiative (DNDi). The partners and collaborators, which include 
academic institutions, Pharma and other non-governmental organizations 
(NGOs) work together, using their knowledge of NTDs, clinical trials and the 
capability of manufacturing drugs. DNDi facilitate these complex partnerships 
to enable rapid development and deployment to patients (80, 108, 109).  
Drug discovery for CL is especially complex as CL is not a single disease with 
a single etiological agent, by contrast it is caused by more than 15 different 
Leishmania species with known variability in susceptibility to drugs. Identifying 
                                               
3 the Special Programme for Research and Training in Tropical Diseases, supported by the 
WHO, the United Nations Children’s Fund (UNICEF) and the United Nations Development 
Programme (UNDP). 
28 
 
a drug that shows activity against all forms and species of CL is a tall order 
(109, 110).  
Some potential new treatment candidates in the DNDi pipeline for NTDs are 
shown in Fig 1.14. Those for CL are: 
 
- CPG-D35 oligonucleotides - synthetic DNA molecules working as an 
immunomodulator (by activating skin immune cells) for use as a 
monotherapy or in combination (111).   
- DNDi-6148 and DNDi-0690 from oxaborole and nitroimidazole classes 
respectively, are undergoing Phase I clinical studies after completing 
the pre-clinical development as drugs for VL and CL.  
- A combination of miltefosine (orally for three weeks) with thermotherapy 
(50°C for 30 seconds once during the treatment course) is in Phase II 
clinical trial (111).  
 
Figure  1.14. New treatment candidates for leishmaniasis (111) 
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1.9. Drug delivery systems for leishmaniasis  
Great attention has been paid in the field of drug development to drug delivery 
systems (DDs). These systems are used to increase efficacy and decrease 
toxicity of already active drugs by controlling their pharmacokinetic properties, 
such as absorption, distribution, metabolism, and excretion and also by 
enabling drug targeting to infected tissues/cells (112, 113).  
The accomplishment of CL treatment depends on the physical accessibility of 
the drug delivery systems to the infected macrophages in the dermis. The DDs 
should be able to penetrate the infected macrophages and by the time, the 
drug reaching the infection site of CL; the drug must cross the infected 
macrophage membrane, then permeate through the membrane of the PV and 
at the end crossing the plasma membrane of the Leishmania parasite, 
releasing the drug inside the PVs, leading to a local high concentration of the 
drug (Fig 1.15) (67, 113).  
 
 
Figure  1.15. Route a drug must take to access intracellular Leishmania 
amastigotes within macrophages (A) (114) and DDs to intracellular Leishmania 
amastigotes(B) (115). A drug-loaded lipid or polymeric nanoparticle (yellow) is 
reaching the infected macrophage (1). This DDs is successfully phagocytosed by 
this infected macrophage (2). The DDs-including endolysosome (or 
phagolysosome) fuses with the amastigote-including parasitophorous vacuole (3). 
Drug is released from phagocytized DDs to kill Leishmania amastigotes (4).  
 
B 
A 
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Another promising approach for leishmaniasis treatment is related to the use 
of anti-leishmanial drugs with nanocarriers (DDs). There are different classes 
of nanocarriers e.g. particles, liposomes, emulsions etc, and many drug 
delivery systems have been evaluated in CL treatment (summarised in Table 
1.5), some with promising results. Liposomal nanocarriers are the most 
studied over the past 30 years (67, 112, 113).  
Using these nanocarriers DDs for CL therapies may facilitate drug solubility, 
reduce the toxicity, improve efficacy, modulate drug pharmacokinetics, permit 
sustainable drug release at the site of infection and protect the drug from 
degradation (113). An additional potential benefit is reducing the number of 
doses and the total dose, which would be significant for a drug like 
amphotericin B.  The physicochemical properties (size, charge, morphology) 
and the rate of drug release from these DDs will significantly affect drug 
release into surrounding tissues, both before and after reaching cells at the 
uptake site (114). Generally, the efficacy of these DDs against CL depends on 
the administration route (Fig 1.16), for example in 1997,  the intravenous 
administration once a day on six alternate days of AmBisome® (liposomal 
AmB) in a BALB/c L. major model of CL produced a dose-response effect, 
while the treatment was ineffective by the subcutaneous route (51). Liposomal 
SbV by the intravenous route is effective (116).  
 
Table 1.5. Experimental studies using nanosystems for CL treatment copied from 
(115). 
Routes Drug Nanosystem Parasite Efficacy 
Parenteral 
Amphotericin 
B 
Chitosan and 
chondroitin 
sulphate 
nanoparticles 
L. amazonensis Yes 
Amphotericin 
B 
Poloxamer 407-
micelles 
L. amazonensis Yes 
Amphotericin 
B 
PLGA-DMSA 
nanoparticles 
L. amazonensis Yes 
Amphotericin 
B 
Liposome L. tropica No 
Amphotericin 
B 
Liposome 
(AmBisome® ) 
L. major Yes 
Amphotericin 
B 
DSHemsPC-
liposome 
L. major Yes 
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Amphotericin 
B 
Nanodisks L. major Yes 
Amphotericin 
B 
PADRE-
derivatizeddendrimer 
complexed with 
liposome 
L. major Yes 
Chalcone 
DMC 
PLA Nanoparticles L. amazonensis Yes 
Nanoselenium 
Inorganic 
nanoparticle 
L. major Yes 
Paromomycin 
Solid lipid 
nanoparticle 
L. major Yes 
Paromomycin 
Solid lipid 
nanoparticle 
L. tropica Yes 
Pentamidine 
Methacrylate 
nanoparticles 
L. major Yes 
Pentavalent 
antimonial 
Nanohybrid 
hydrosols 
L. amazonensis Yes 
Sodium 
stibogluconate 
Liposome 
L. mexicana /L. 
major 
Yes 
Oral 
Quercetin 
Lipid-core 
nanocapsules 
L. amazonensis Yes 
Meglumine 
antimoniate 
Beta-cyclodextrin L. amazonensis Yes 
Meglumine 
antimoniate 
Polarity-sensitive 
nanocarrier 
L. amazonensis Yes 
Topical 
Amphotericin 
B 
Liposome L. mexicana NO 
Amphotericin 
B 
Gamma-cyclodextrin L. amazonensis Yes 
Chalcone CH8 Liposome L. amazonensis Yes 
Paromomycin Liposome L. major Yes 
Paromomycin Liposome L. major Yes 
Meglumine 
antimoniate 
Liposome L. major Yes 
Nano silver 
Inorganic 
nanoparticles 
L. major No 
Nano silver 
Inorganic 
nanoparticles 
L. major No 
Intralesional 
Amphotericin 
B 
Liposome 
(AmBisome®) 
L. major No 
Chalcone CH8 PLGA microparticles L. amazonensis Yes 
Nano silver 
Inorganic 
nanoparticles 
L. amazonensis Yes 
Meglumine 
antimoniate 
Liposome L. major No 
Miltefosine Liposome L. major Yes 
Paromomycin Liposome L. major No 
Paromomycin 
Solid lipid 
nanoparticle 
L. tropica Yes 
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Sodium 
stibogluconate 
Liposome 
L. mexicana/   
L. major 
Yes 
Note: Chalcone DMC – 2’,6’-dihydroxy-4’-methoxychalcone; Chalcone CH8 – 3-
nitro-2’-hydro-4’,6’-dimethoxychalcone; DMSA – dimercaptosuccinic acid; 
DSHemsPC – 1,2-distigmasterylhemi-succinoyl-sn-glycero-3-phosphocholine; 
PADRE – pan DR-binding epitope; PLA – poly(D,L-lactide); PLGA – poly(lactic-
co-glycolic acid); UVB – ultraviolet B radiation. 
 
 
Figure  1.16. Administration routes of DDs and anatomical barriers. A. Intravenous 
route. B. Subcutaneous, intramuscular and intraperitoneal route. C. Oral route. D. 
Topical route. E. CL causes regional inflammation is associated with leaky 
vasculature. In this situation, particles in blood circulation can permeate barrier to 
become close to the infected cells. F. Particles in blood circulation (67). 
 
Despite the promising effectivity against leishmaniasis and the safety profile 
of liposomal formulations, their high cost decreases their use in the 
leishmaniasis field. Subsequently, more attention has been paid recently to 
polymeric nanoparticles, Carvalho et al found that a nanoparticle delivery 
system (consisting of free deoxycholate AmB encapsulated in polylactic-co-
glycolic acid (PLGA)) was more active in the treatment of experimental 
cutaneous leishmaniasis (L. amazonensis) in C57BL/6 mice than free drug 
(117). Kumar et al demonstrated that PLGA-PEG (poly(D,L-lactide–co–
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glycolide)–block–poly(ethylene glycol)) encapsulated amphotericin B 
nanoparticles were significantly more effective than free amphotericin B 
against L. donovani strain MHOM/IN/83/AG83 in both in vitro and in vivo 
(Female hamsters) studies (117). Similarly, Ahmed et al found that a 
noncovalent complex of amphotericin B (AmB) and poly (α-glutamic acid) 
(PGA) with a size of ~100 nm, to be significantly less toxic against KB-cells in 
comparison with free amphotericin B and amphotericin B deoxycholate 
(Fungizone™) whilst keeping the same anti-leishmanial activity against L. 
major (MHOM/SA/85/JISH118) or L. donovani (MHOM/ET/67/HU3) 
intracellular amastigotes (118). Unfortunately, most of these delivery systems 
required organic solvents or heat for preparation - using these solvents or 
temperatures is not ideal as they can influence the integrity of the polyenic 
substances used and besides increase the toxicity of the DDs (119). In 
contrast, ionotropic gelation is a widely used method for preparing polymer 
nanoparticles and this method does not require the use of organic solvents or 
heat (120). In this method, nanoparticles are prepared by the interaction 
between two oppositely charged groups (120). Some benefits of this method 
are the ease of preparation, aqueous environment, low toxicity and protection 
of the chemical structure of the encapsulated drug (120).  
Recently, a nanoparticle delivery system for AmB has been developed using 
the ionotropic gelation method with chitosan as a positive molecule and 
chondroitin sulphate (glycosaminoglycans in the extracellular matrix of 
cartilage) as a negative one. These loaded nanoparticles were 10 times less 
toxic than unincorporated AmB against murine macrophages and showed in 
vitro anti-leishmanial activity against L. infantum and L. amazonensis 
promastigotes and amastigotes. The efficacy of these AmB-loaded 
nanoparticles against L. amazonensis-infected BALB/c mice have been 
evaluated and showed a significant reduction in parasite load at 1 
mg/kg/day/intravenously for 10 days. These nanoparticles induced 
significantly higher levels of IFN-γ and IL-12 in the mice (121, 122). 
Chitosan is a widely used compound in drug delivery systems because of its 
interesting structure - chitosan has a cationic feature , is soluble in acidic 
media and has mucoadhesive properties (123). Chitosan is reported to have 
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immune-stimulatory effects which include inducing NO and ROS production 
(124, 125, 126) and antimicrobial and anti-leishmanial activity (127, 128, 129). 
Chitosan can be used in various formulations in the drug delivery systems and 
these forms are summarised in Table 1.6 with some example of associated 
loaded drugs (130, 131, 132) and molecules (133, 134). Chitosan 
nanoparticles are biocompatible and biodegradable, important properties for 
drug safety and controlled release, and are increasingly being considered for 
a variety of biomedical applications, e.g. would healing (130, 135). Chitosan 
nanoparticles can be prepared in different sizes and different charges, and are 
suitable for different routes of administrations (123) (more details later).   
 
Table 1.6. Chitosan-based drug delivery systems.   
DDs Method of preparation Drug References  
Tablets Matrix 
theophylline, 
mesalamine, glipizide 
and diclofenac 
sodium 
(120, 136, 
137, 138, 
139) 
Capsules Capsule shell insulin (140) 
Microspheres/ 
Microparticles 
Emulsion cross-linking, 
Coacervation/precipitation, 
Spray-drying 
clarithromycin, 
propranolol HCl, 
gentamicin sulphate, 
famotidine and 
cimetidine 
(141, 142, 
143, 144, 
145) 
Nanoparticles 
Emulsion-droplet 
coalescence, Ionotropic 
gelation, Reverse micellar 
method, Coacervation/ 
precipitation 
doxorubicin, 
cyclosporin A, 
gadopentetic acid, 
levofloxacin, 
amphotericin B and 
miltefosine 
(120, 146, 
147, 148, 
149, 150) 
Beads Coacervation/ precipitation insulin (151) 
Films Solution casting 
ofloxacin and 
paclitaxel 
(152, 153) 
Gel Cross-linking 5-Fluorouracil (154) 
 
1.10. Nanoparticles and their interaction with skin lesions 
The ease of administration and reduced systemic side effects of topical 
formulations prioritise them over systemic therapy for uncomplicated CL (30). 
Topical formulations for CL encounter different barriers in the skin and some 
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are shown in Fig 1.17. Nanoparticle carriers have been widely used in topical 
formulations to treat skin disease such as fungal infections, psoriasis and, for 
cosmetic purposes (155). The penetration of nanoparticles through the skin 
can occur by one of these three routes: intercellularly in between corneocytes, 
intracellularly through corneocytes or via dermal structures like the hair follicles 
(Fig 1.18) (155).  
 
Figure  1.17. Factors to be considered in topical delivery (30). 
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Figure  1.18. Pathways of skin nanoparticles penetration. 1) via hair follicles, 2) 
intracellularly through corneocytes and 3) intercellularly around corneocytes 
(155) . 
The biological effects (toxicity, immune interactions), depth and mechanism of 
skin penetration of the nanoparticles are based on their structure and 
properties such as size, zeta potential, aggregation, solubility in the skin, skin 
lipid composition and drug release from these nanoparticles. The condition of 
the skin, healthy or otherwise, influences nanoparticle permeation. Current 
dogma avers that biodegradable polymeric nanoparticles accumulate in the 
hair follicle and on the surface (stratum corneum) of healthy skin (156). In CL, 
drug permeation may be influenced by the morphology of ulcers, such as 
necrotic centres and high borders to the lesion. CL causes an inflammation 
response involving higher permeability and vasodilatation of blood vessels of 
the dermis at the infection site, and moreover several types of immune cells, 
including macrophages, are infiltrated to the infection site and this could 
promote the permeation of the topical drug through the damaged epidermis 
(157), see Fig 1.19. 
Despite this ease of drug permeation caused by the local inflammation in CL, 
the location of Leishmania parasites in the dermis, instead of the superficial 
portions of the epidermis where most fungi typically reside, forms a major 
impediment to the permeation of topical drugs (157). 
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The most favourable drug formulation for topical treatment of CL is the one in 
which the drug has a high anti-leishmanial activity and can permeate through 
the skin to reach Leishmania parasites located in the dermis, in high enough 
concentrations to act (115).  
Chitosan nanoparticles have been reported to (i) improve the drug permeation 
into skin in comparison to other vehicles and, (ii) provide a sustain drug release 
from these nanoparticles. Moreover, chitosan has wound healing effects, 
mucosal adhesion properties and antimicrobial activity (158). Many clinical 
studies demonstrated the positive effects of using chitosan as wound dressing 
in accelerating the rapid wound re-epithelialisation and the regeneration of the 
granular layer, haemostasis in patients undergoing plastic surgery (159), skin 
grafting (160, 161) and endoscopic sinus surgery (162). Chitosan 
nanoparticles have been repeatedly administered for topical skin delivery; 
retinol encapsulated in chitosan-TPP nanoparticles showed less toxicity than 
unloaded retinol and potential activity for acne and anti-wrinkle treatment 
(163). Acyclovir (an antiviral medication) loaded chitosan-TPP nanoparticles 
caused an increase in the drug stability and stimulated drug penetration 
through porcine skin (164). Chitosan–dextran sulphate nanoparticles also 
showed mucoadhesive properties and potent activity in the treatment of ocular 
surface infections (165). Therefore, these encouraging properties make 
chitosan a suitable candidate for further studies in terms of topical treatment 
of CL.   
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Figure  1.19. Interaction of nanoparticles with lesions of CL (156). A high parasitic 
load, low lymphocytes infiltrate and small tissue necrosis is observed in nodular 
lesions. On the contrast, the parasite load is low with higher lymphocytes infiltrate 
and tissue injury. While in the necrotic tissue the neutrophils are gathered, infected 
macrophages and lymphocytes are situated in the border of the ulcers. In nodular 
lesions, nanoparticles are applied to the epidermis. Based on their physiochemical 
properties they either (i) stay on the surface, (ii) penetrate the epidermis (small, 
deformable NPs), and/or(iii) fuse with the epidermis. After which a drug release will 
occur and diffuse to the dermis to meet the infected macrophage and then this drug 
being eliminated by lymphatic and blood clearance. The time of retention in the 
dermis is crucial for the treatment efficacy.  However, these drug carriers encounter 
fibrotic and necrotic dermal tissue with infiltration of neutrophils in the centre of the 
ulcer. The chance to reach infected macrophages is higher in ulcerative lesions. 
Nanoparticles can promote stress and proinflammatory signalling that enable the 
elimination of parasites and accelerate the wound healing and according to the 
nanoparticles physicochemical properties this can be happened by either direct 
influence on macrophages or indirectly by their effects in keratinocytes and 
neutrophils. The design of these nanoparticles should take into consideration the 
maximal eradication of parasites and lowering the tissue injury.  
1.10.1. Mathematical models of skin permeability 
Small uncharged drug molecules mainly permeate through skin by passive 
diffusion in which, move from an area of higher concentration to an area of 
lower concentration (Fig 1.20 ) (166).  
Infinite dose permeation experiment is usually used to examine the 
permeation behaviour of a compound or to determine the influences of 
penetration enhancer on percutaneous permeation. Infinite dose is applied to 
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keep a steady rate of absorption of the compound through the skin, that is 
called the steady state flux and will produce a cumulative permeation amount 
of compound permeated through a unit area of membrane over time (166, 
167).   
 
  
Figure  1.20. The passive diffusion of drug through a membrane (168) 
 
Fick’s first law can give the main equation (Equation 1) to identify the skin 
permeation after exposing the skin membrane to the diffusing molecules on 
one side of the skin when steady state conditions have been reached. This 
equation states the amount of molecule (Q) permeating the skin membrane of 
area (A) over a period of time (T) with the steady concentration gradient across 
the skin membrane, ΔCs (in mol/cm3) and it relates the diffusion coefficient in 
the skin membrane, D (diffusion coefficient) (in cm2/s), and the path length, h(in 
cm) (166, 169). 
Equation (1) 𝑄 =
DAT ΔCs
h
  , ΔCs= C0 - Ci (C0 represents the concentration of 
compound applied to the skin surface and Ci stands for the concentration of 
compound inside the skin) 
This equation assumes that the skin barrier (stratum corneum (SC)) is acting 
as a pseudo homogenous membrane and no changes happen in SC 
properties with time and position.  
Fick’s first law, applied when steady state conditions have been reached, 
states that the rate of transfer of the diffusing molecules per unit area is 
proportional to the concentration gradient measured across the membrane 
(Equation 2). Therefore, equation 2 is indicated as the flux of the permeant per 
unit area (in mol/(cm2·s)) (166, 169), 
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Equation (2) 𝐽 =
Q
AT
=
K.D.ΔCs
h
   , J is the flux of the permeant per unit area (in 
mol/(cm2·s))             
As in most practical situations C0 >>>Ci therefore equation 2 becomes: 
Equation (3) 𝐽 =
Q
AT
=
K.D.C0
h
 
Additionally, the permeability coefficient (kp) is described as the flux of the 
permeant per unit area normalised by the concentration gradient and by 
characterising the skin as a single pseudo-homogenous membrane therefore 
kp (in cm/s) is identified as 
Equation (4) 𝑘𝑝 =
K.D
h
  , K is the stratum corneum-formulation partition 
coefficient 
Accordingly, from both equations 3 and 4, the flux of the permeant per unit 
area (in mol/(cm2·s)) is: 
Equation (5) J = Kp.C0 (166, 169) 
 
Several assumptions should be taken into consideration before applying these 
equations to skin permeation into the experimental design including: 
1- The stratum corneum forms the rate-limiting barrier 
2- The stratum corneum is considered isotropic and its natures is not 
altered by the application of the vehicle of the drug formulation  
3- The drug diffusion is not based on time, concentration or distance 
4- The diffusing compound dissolves in the stratum corneum 
However, in the clinical situations, patients mostly apply finite dose of the 
formulation. The amount of permeated compound through stratum corneum 
will accomplish a peak and stay constant (equation 6) and the diffusion is 
determined as bellow: 
Equation (6) 
𝜕𝐶
∂T
= D
𝜕2𝐶
𝜕𝑥2
   , c is the concentration of the permeating molecule at 
time t at depth x within the skin. This equation is applied just by presuming a 
unidirectional diffusion through an isotropic membrane (166, 167, 169). 
1.11. Pharmacokinetics of ant-leishmanial drugs  
Pharmacodynamic (PD) refers to the link between drug concentration and the 
influences on the biological system and illustrates how the drug influences the 
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parasite and can be determined in regards with effectivity (EC50, EC90), 
potency (maximal effect) and the kill rate (time-dependence of the effect) (70, 
71). While pharmacokinetic (PK) refers to the study of time course of the drug 
absorption, distribution, metabolism and excretion (ADME). The basic PK 
parameters are summarised in Table 1.7. Some concepts that affect 
importantly PK of CL drugs encompass: i) the target site of CL drug as 
Leishmania parasites survive and multiply in the macrophages of the dermis 
of the skin lesion and ii) the route of drug administration, for example, a topical 
drug should have the ability to penetrate through the stratum corneum of the 
epidermis and to retain in the dermis of the lesion. Moreover, iii) the 
metabolism of the parasite or the host (in macrophages, skin and liver) can 
activate or inactivate the drug. Drugs are divided into three groups according 
to PK/PD profile: 1- concentration-dependent antimicrobial effect -, 2- time-
dependent antimicrobial effect or 3- dependent on both time and concentration 
(70, 71). 
  
Table 1.7. Basic PK parameters copied from (71) 
Parameter Symbol Description 
Unit 
(example) 
Formula 
Dose D the dose of drug 
administered 
Mg Design 
parameter 
Dose 
interval 
Τ once per day (QD)                  
twice per day (BD)                            
trice per day (TID) 
Per hour, 
per day 
Design 
parameter 
Cmax Cmax the maximal concentration in 
a specific matrix (usually in 
plasma, but can be in any 
part of the body) after drug 
administration 
µg/ml Direct 
measurem
ent 
tmax tmax the time corresponding to 
Cmax 
Hours Direct 
measurem
ent 
Volume of 
distribution 
Vd the apparent volume in which 
a drug is distributed. Relates 
drug concentration to the 
amount of drug in the body 
and can give information 
about tissue distribution 
Litre =D/C0 
Elimination 
rate 
constant 
Ke the rate at which a drug is 
removed from the system 
Per hour = Cl/VD 
= ln 
(2)/T1/2 
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Clearance CLr the volume of body fluid 
cleared per time unit 
quantifies drug elimination 
from the system by kidney, 
liver and other organs 
litre/hour = Vd.Ke 
=D/AUC 
Half-life t1/2 the time needed for the 
concentration to fall to half of 
its 
previous value 
Hours = ln (2)/Ke 
AUC AUC the area under the curve, an 
expression of total exposure 
mg/liter.ho
ur 
= [∫∞0 C. 
𝑑𝑡] 
Bioavailabili
ty 
F oral bioavailability, the 
fraction of the administered 
dose that reaches the 
systemic circulation. 
N/A 
(fraction) 
=AUC (po)/ 
AUC(i.v.) 
x 
Dose(i.v.)/Dos
e(po) 
 
Regarding the pharmacokinetic of leishmaniasis drugs, pentavalent antimony 
has a long terminal half-life because of the intracellular conversion of SbV to 
SBIII which forms with the quick renal excretion the main characterisations of 
this drug pharmacokinetics. Miltefosine pharmacokinetics are characterised 
mainly by the accumulation in peripheral blood mononuclear cells (PBMCs) 
and long terminal half-life (70). However, paromomycin is characterised by the 
fastest excretion by the kidneys from the body in comparison with other 
leishmaniasis drugs. On the other hand, AmB pharmacokinetics have not been 
evaluated widely in leishmaniasis. It has been reported that the renal and 
faecal excretion of liposomal AmB (AmBisome®) is much slower than AmB 
deoxycholate (Fungizone) excretion which leads to higher exposure (70, 71). 
Wijnant et al reported that liposomal AmB (AmBisome®) caused a higher 
plasma peak and systemic exposure compared with AmB deoxycholate 
(Fungizone, after a single dose of 1 mg/Kg/ i.v. in L. major-infected mice) (170) 
and Table 1.8 summarizes the PK of leishmaniasis drugs including 
pentavalent antimonial, paromomycin, miltefosine, Fungizone and 
AmBisome® in clinical and mouse model studies. The application of PK and 
PD comprehension and understanding the relation between PK and PD 
produce a fundamental base for detecting the optimal dosage and effective 
therapeutic management of drugs for CL treatment and will be helpful in 
antileishmanial drugs combination to increase in an attempt to improve drug 
efficacy and decrease the duration of treatment (70, 170)
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Table 1.8. Pharmacokinetic profile of leishmaniasis drugs (70, 170) 
Patients 
Weight 
(kg) 
Daily dose 
Sampling 
day 
Cmax ( 
µg / 
ml) 
Ctrough ( 
µg / 
ml) 
tmax 
(h) 
ka (h-1) Vd/F (L) 
CLr/F 
(L/h) 
AUC 
(mg.h/L) 
t1/2 (h) 
S
b
V
 
(CL) 
Humans 
Adults: 
 
62 (56–
120) 
20 
mg/kg/days, 
20 days 
(IM) 
Day 19 
38.8 ± 
2.1 
0.198 ± 
0.023 
1.0 
(1.0–
2.0) 
NA 
0.30 ± 
0.01b,c 
0.106 ± 
0.006b 
AUC24: 
190 ± 10 
t1/2,β: 1.99 
± 0.08 
t1/2,24–48 h: 
20.6 ± 1.8 
(CL) 
Humans 
Children: 
 
15 (13–
18) 
20 
mg/kg/day, 
20 days 
(IM) 
Day 19 
32.7 ± 
0.9 
0.113 ± 
0.015 
0.875 
(0.5–
1.5) 
NA 
0.39 ± 
0.03b,c 
0.185 ± 
0.013b 
AUC24:                                 
111 ± 7 
t1/2,β: 1.48
± 0.02 
P
a
ro
m
o
m
y
c
in
 
(VL) 
Humans 
35.5±11
.8a 
15 mg/kg 
(11 mg/kg 
base), 21 
days (IM) 
Day 1 
20.5 ± 
7.01 
4.53 ± 
6.71 
NA 
2.11 
(7.68%)e 
15.3 
(2.27%)e 
4.06 
(3.05%)e 
NA 2.62 
Day 21 
18.3 ± 
8.86 
1.31 ± 
4.16 
      
Data given as either mean ± standard deviation or median (range), unless indicated otherwise AUC area under the concentration–time curve, AUC24 
AUC from time zero to 24 h, , CLr clearance, Cmax peak plasma concentration, Ctrough trough plasma concentration 24 h after dose, F bioavailability, 
ka absorption rate constant, NA not available, t1/2 plasma elimination half-life,  t1/2, β elimination half-life,  t1/2,24–48 h apparent half-life between 24 and 48 
h (an approximation of the c-elimination half-life), tmax time to Cmax, Vd volume of distribution.  b Per kg, c Vβ apparent volume of distribution during the 
b-elimination phase and  e Mean (% standard error) 
 
Patients 
Weight 
(kg) 
Daily dose 
Cssa 
(µg/ml) 
ka 
(day-1) 
tmax 
(h) 
Vcentral/ 
F (L 
CLr/ 
F 
(L/day) 
Vperipheral/ 
F (L) 
Q 
(L/day) 
AUCb 
(µg.day/ml) 
t1/2 (days) 
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M
ilte
fo
s
in
e
 
(CL) 
Humans 
Adults: 
70.84 ± 
11.73 
2.11 ± 0.16 
mg/ 
kg/day, 28 
days 
(Orally) 
31.9 
(17.2–
42.4) 
NA NA NA NA NA NA 
628 
(213–861) 
34.4 
(9.5–
46.15) 
(CL) 
Humans 
Children: 
 
26.22 ± 
7.62 
2.27 ± 0.16 
mg/ 
kg/day, 28 
days 
(Orally) 
22.7 
(17.0–
29.3) 
NA NA NA NA NA NA 
448 
(304–583) 
37.1                      
(7.4–
47.0) 
Patients 
Weight 
(g) 
Daily dose 
Cmax 
(µg/ml) 
AUC 
(h · 
µg/ml) 
Clearance 
(ml/h/kg) 
t1/2 (h) 
V 
(ml/kg) 
    
F
u
n
g
iz
o
n
e
 
L. major-
infected 
mice 
20 
a single i.v. 
1-mg/kg 
dose 
1 30.2 18.9 39.7 1075     
A
m
B
is
o
m
e
®
 
L. major-
infected 
mice 
20 
a single i.v. 
1-mg/kg 
dose 
8.2 71 13.5 8.5 143     
AUC area under the concentration–time curve, CLr clearance, Css steady-state concentration, F bioavailability, ka absorption rate constant, NA not 
available, Q intercompartmental clearance, tmax time to Cmax within one dosing interval, V volume of distribution, t plasma elimination half-life, V central 
volume of distribution of the central compartment, Vperipheral volume of distribution of the peripheral compartment.  a Miltefosine accumulates during 
treatment and reaches Css during the last week of treatment 
b AUCD28 (AUC from start to end of treatment) unless indicated otherwise 
c Unclear whether this is the mean Css or the maximum Css 
d AUC from start of treatment to infinity (AUC∞) 
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1.12. Treatment challenges 
As described in this chapter, currents treatments for CL have drawbacks , for instance 
high toxicity (nephrotoxicity, cardiotoxicity, hepatoxicity etc), the high cost (such 
liposomal amphotericin B), instability, or sometimes low cure rates etc and this draws 
the attention to the need for new safe, effective, economically feasible new treatments 
for CL. Drug discovering and developing is a long, slow and very expensive process 
(71).  
Drug delivery system is considered one of the effective strategies to overcome the 
cost and long process of developing new drugs in which DDs of already know active 
drugs and can be used to increase the activity of loaded drugs and to reduce their 
toxicity.  
Chitosan has shown promising features in therapeutic delivery systems because of 
its biocompatibility, biodegradability, cationic structure, mucoadhesive properties, 
wound healing effects and the antimicrobial activity (130, 135). Therefore, chitosan 
has been chosen in this study as a carrier for AmB and the potential to treat CL, AmB 
is a high active drug against CL but its use has been decreased because of the toxicity 
and we aimed to improve the therapeutic window of AmB by using chitosan as a 
nanocarrier (171).  
There are different methods for chitosan nanoparticles preparation and the ionotropic 
gelation method was chosen in this study as this method is a simple and quick method 
and can be used to synthesize spherical nanoparticles with different sizes and 
charges. Moreover, this method has been reported to produce very stable chitosan 
nanoparticles with sustainable drug release (171). 
In literatures, chitosan nanoparticles showed encouraging properties as DDs for the 
treatment of leishmaniasis. However, there is just a study used the ionotropic gelation 
method and used chitosan nanoparticles with positive surface charge and with size 
of size= 136±11 nm and these studies need more detailed and controlled studies (83, 
122).  
Topical treatments have many advantages over systemic treatment for instance, (i) 
increasing the compliance with patients, (ii) affording a high local concentration of the 
drug at the lesion site and (iii) reduce the toxic effects of systemic drugs (158). 
Therefore, the possibility of use AmB loaded chitosan nanoparticles in this route could 
be of interest to benefit from the small size of the nanoparticles, mucoadhesive and 
wound healing effects of chitosan.   
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1.13. Aims and objectives  
The overall aim of this project was to optimise an effective, safe and 
economically feasible nanoparticle delivery system of amphotericin B with the 
potential to treat cutaneous leishmaniasis.  
- Hence, the aim of the first experimental chapter (chapter 2) was to: 
I. Determine the in vitro anti-leishmanial activity of chitosan and its 
derivatives against L. major and L. mexicana promastigotes and 
intracellular amastigotes at two different pH values of the culture 
medium (the medium pH 7.5 and at lower pH 6.5) 
II. To evaluate the in vitro role of chitosan in the activation of macrophage 
and M1 proinflammatory phenotype, via the measurement of NO, ROS 
and TNF-α production by host cells and by measuring parasite survival 
III. Investigate chitosan uptake by macrophages to explain activity against 
intracellular amastigotes.  
 
- The purpose of the second experimental chapter (chapter 3) was to: 
I.  Prepare two types of chitosan nanoparticles by using the inotropic 
gelation method; one with a positive surface charge using 
tripolyphosphate sodium (TPP) and the other with a negative surface 
charge, using dextran sulphate.  
II. Evaluate the characterisations of blank and amphotericin B loaded 
chitosan TPP or dextran sulphate nanoparticles by studying their 
physicochemical properties (size, morphology, zeta-potential and 
stability). The optimal conditions for nanoparticle preparation were 
chosen with regard to the smallest sizes and different charges. 
III. Determine amphotericin B loading and drug release from the 
amphotericin B loaded chitosan TPP or dextran sulphate nanoparticle 
 
- The third experimental chapter aimed to (chapter 4): 
I. Evaluate the in vitro effectiveness of blank and amphotericin B loaded 
chitosan TPP or dextran sulphate nanoparticles against L. major and L. 
mexicana promastigotes and amastigotes after evaluating their 
haemolytic activity and cytotoxicity against KB-cells.  
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II. Evaluate the intravenous activities of blank and amphotericin B loaded 
chitosan TPP or dextran sulphate nanoparticle in vivo in BALB/c mice 
infected with L. major. 
III. Measure the permeation of blank and amphotericin B loaded chitosan 
TPP or dextran sulphate nanoparticle through uninfected and L. major 
infected mouse BALB/c skin by In vitro Franz diffusion cell permeation 
studies. 
 
-  The fourth experimental chapter (chapter 5) aimed to:  
I. Study the effects of media perfusion on the in vitro host cell 
phagocytosis and macropinocytosis. 
II. Study the effects of the flow on the in vitro anti-leishmanial activity of 
chitosan solution and blank and amphotericin B loaded chitosan TPP 
or dextran sulphate nanoparticles 
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2. Activity of chitosan and its derivatives against Leishmania 
major and mexicana in vitro. 
2.1. What is chitosan? 
Chitosan is produced by the deacetylation of chitin (Fig 2.1). Chitin is the 
second most abundant natural polysaccharide and originates from the shells 
of crustaceans and the cell walls of fungi (172). Chitosan is a biodegradable, 
biocompatible and positively charged nontoxic mucoadhesive biopolymer 
(172, 173). 
  
Figure  2.1. Structure of chitin and chitosan and method of preparation chitosan 
from raw materials (172, 174).  
2.2. Chitosan solubility 
Chitosan is insoluble at alkaline pH but is soluble in dilute acidic solvents like 
glacial acetic acid and acid solvents to form a cationic polymer (–NH3+ groups) 
(Fig 2.2). Chitosan in acidic media has a positive charge and the ability to form 
gels at low pH values because it is hydrophilic and can retain water in its 
structure (175). Chitosan pKa is approximately 6.3 and therefore, the 
approximate ionisation degree of chitosan is a 61% and 6% at pH 6.5 and 7.5 
respectively. 
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Figure  2.2. Schematic illustration of chitosan’s versatility (135).  
2.3. Chitosan toxicity 
Chitosan is widely considered as a non-toxic, biological polymer and has been 
approved by the FDA for use in wound dressings. Chitosan has been 
recognized by FDA as GRAS (Generally Recognized As Safe, GRAS Notice 
No. GRN 000073, EU 2011) (176) and approved for use in dietary applications 
in Italy and France (173). The lethal dose, 50% (LD50 ) of chitosan for mice 
and rats are orally 16000 and 1500 mg/kg respectively (177).  
2.4. Chitosan in wound healing 
Chitosan has a similar chemical structure to hyaluronic acid and additionally 
enhances the functions of inflammatory cells such as polymorphonuclear 
leukocytes (PMN) (phagocytosis, production of osteopontin and leukotriene 
B4), macrophages (phagocytosis, production of interleukin (IL-1), transforming 
growth factor and platelet-derived growth factor) and fibroblasts (production of 
IL-8) (135, 175). Because of these properties, chitosan promotes skin wounds 
granulation with improving collagen production, angiogenesis and re-
epithelialization of skin tissue. As a result, chitosan induces wound healing 
and produces less scarring. Also using chitosan hydrogel will provide a 
painless, antimicrobial and ideal dressing for wounds (135, 175).  
2.5. Chitosan derivatives 
The poor solubility of chitosan and the loss of the cationic nature charge at 
neutral and alkaline pH are two of the major obstacles to the usefulness 
consideration of chitosan as a useful antimicrobial material. Recently, the 
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chemical modification of chitosan to produce various derivatives to improve its 
solubility and widen its application, has gained a great attention. The presence 
of certain functional –NH2 and –OH groups on chitosan structure provides the 
basis for many methods of structural modification. The most used method is 
graft copolymerization (an attractive technique to conjugate bioactive 
molecules on the surface). Derivation of chitosan can be used to improve its 
antimicrobial activity, solubility and the mucoadhesive properties (178, 179). 
2.6. Antimicrobial activity of chitosan 
Many reports mention that chitosan has a potential activity against microbes 
(detailed in Table 2.1) but the actual mechanism has not yet been fully 
elucidated [35]. Three mechanisms have been suggested to explain this 
activity. The first one is the interaction between the protonated NH3+ groups of 
chitosan and the negative cell membrane of microbes. This interaction leads 
to change the permeability of the microbes’ membrane wall, causes osmotic 
imbalances, and as a result prevents the growth of the microbes (174, 180). 
Another mechanism is that chitosan binds to microbial DNA and inhibits DNA 
transcription and mRNA synthesis (180, 181). The third mechanism is the 
chelation of metals and binding the basic nutrients for microbes. These three 
mechanisms lead to killing of the microbes (124). A fourth indirect mechanism 
of action may be related to the known pro-inflammatory activity effect of 
chitosan on macrophages. This involves stimulation of tumour necrosis factor 
(TNF-α), interleukin 6 (IL-6), nitric oxide (NO), reactive oxygen species (ROS) 
and interferon gamma (IFN-γ) which play critical roles in the proinflammatory 
response against intracellular microbes (by enhancing the production of 
microbicidal reactive nitrogen species)  (125, 126, 182, 183, 184).  
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Table 2.1. The antimicrobial activities of chitosan and its derivatives (173, 185, 186, 
187) 
Microbe MIC of chitosan or derivative 
Escherichia coli Chitosan 8 μg/ml; chitosan nanoparticles 0.0625 
μg/ml; Cu loaded chitosan nanoparticles 0.0313 
μg/ml 
Pseudomonas aeruginosa Chitosan 0.0125%(w/v); chitosan-Zn complex 
0.00625%(w/v); N, N-diethyl-N-methyl-chitosan 
32 μg/ml 
Proteus mirabilis Chitosan 0.025%(w/v); chitosan-Zn complex 
0.00625%(w/v) 
Salmonella enteritidis Chitosan 0.05%(w/v); chitosan-Zn complex 
0.00625%(w/v) 
Enterococcus faecalis Chitosan 8 μg/ml; chitosan-Zn complex 0.125; 
N, N-diethyl-N-methyl-chitosan 16 μg/ml 
Staphylococcus aureus Chitosan 0.025%(w/v); chitosan-Zn complex 
0.0125%(w/v); N-methyl-chitosan 16 μg/ml 
Candida albicans Chitosan 5 μg/ml; chitosan-Zn complex 
0.1%(w/v) 
2.7. Anti-leishmanial activity of chitosan 
A few researchers have evaluated the activity of chitosan against Leishmania 
parasites under different conditions and the results are summarised in Table 
2.2. It was observed that chitosan presented an anti-leishmanial activity with 
EC50 (50% effective concentration) values ranging from around 50 to 240 
μg/ml against different strains of Leishmania promastigotes and amastigotes. 
In these studies, there are inconsistent values of the activity of chitosan 
against Leishmania parasites. Accordingly, a lot of clarification and detailed 
controlled studies are needed to determine whether chitosan is a suitable 
candidate to find new chemotherapeutic alternatives for the treatment of 
leishmaniasis. The aim of this chapter was to:  (i) determine the in vitro anti-
leishmanial activity of chitosan and its derivatives against L. major and L. 
mexicana promastigotes and intracellular amastigotes at two different pH 
values (the culture medium pH of 7.5 and a lower pH of 6.5, which are both 
suitable for macrophage and parasite growth (188, 189, 190), (ii) to evaluate 
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the in vitro role of chitosan in the activation of macrophage and M1 
proinflammatory phenotype, via the measurement of NO ,ROS and TNF-α 
production by host cells and by measuring parasite survival and (iii) investigate 
chitosan uptake by macrophages to explain its activity against intracellular 
amastigotes. 
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Table 2.2. The anti-leishmanial activity of chitosan 
Strain Drug Type of study Results 
L. infantum Chitosan solution in 
acetic acid 
In vitro, against promastigotes and 
amastigotes 
- EC50=112.64-μg/ml promastigotes 
- EC50= 100.81 μg/ml amastigotes (127) 
L. amazonensis Chitosan solution in 
acetic acid 
In vitro, against promastigotes and 
amastigotes 
- EC50= 73.00 μg/ml promastigotes. 
-100 μg/ml: Percentage of infected 
macrophages after treatment 66% (122) 
L. amazonensis Chitosan nanoparticles In vitro, against promastigotes and 
amastigotes 
- EC50= 52 μg/ml promastigotes. 
-100 μg/ml: Percentage of infected 
macrophages after treatment 39% (122) 
L. chagasi Chitosan solution in 
acetic acid 
In vitro, against promastigotes EC50= 67 μg/ml promastigotes (122). 
L. chagasi Chitosan nanoparticles In vitro, against promastigotes EC50= 46 μg/ml promastigotes (122). 
L. infantum Chitosan solution In vitro, against promastigotes EC50= 240 μg/ml (128) 
L. major nanochitosan film In vivo study, female BALB/c mice were 
treated with nano-chitosan film four times/day 
There was no significant difference between 
nanochitosan and Glucantime in reduction 
of lesion size of L. major infected mice (191) 
L. major Chitosan microparticles In vivo, (100 μg/100 μl) were subcutaneously 
injected in the infected BALB/c mice) with 
two-day intervals until two weeks 
Lesions of L. major infected mice were 
significantly smaller in chitosan treated 
groups (1.2 ± 0.8 mm) than in the control 
group (6.2 ± 1.7 mm) (129) 
L. major Chitosan solution in 
acetic acid 
In vivo (BALB/c mice), chitosan 200 and 400 
μg/ml were applied topically for 28 
continuous days 
Lesion size L. major infected mice was 8.47 
mm for untreated group and 2.07 and 1.05 
mm in groups treated with the 200 and 400 
μg/ml of chitosan, respectively (192). 
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A pilot clinical 
study for 10 
patients with CL 
(patients did not 
respond to 
traditional 
treatment) 
poly (vinyl alcohol)/ 
chitosan/clay 
nanocomposite film 
Chitosan films were applied on the lesion for 
7 days. This dressing was repeated every 
week until the complete healing. 
Lesions were completely cured after 16 
weeks with no side effects or recurrences 
(193). 
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2.8. Materials and methods 
2.8.1. Drugs and chemicals 
Stocks of amphotericin B deoxycholate (5.2 mM [aq]) (Fungizone; Gibco, UK) 
were prepared, aliquoted, and kept at -20°C until use. Chitosan with three 
different molecular weights and its derivatives were used and are summarised 
in Table 1. Solutions of chitosan and derivatives were prepared by dissolving 
1 g in 100 ml of 1% (v/v) acetic acid solution at room temperature with 
continuous stirring for 24 hours until a clear solution was obtained. The pH of 
the solution was adjusted to approximately 6 by adding sodium hydroxide 2N 
(NaOH, Sigma, UK) solution with a pH meter (Orion Model 420A). The 
chitosan solutions were autoclaved (121 °C; 15 mins). Phosphorylcholine 
substituted chitosan was kindly provided by Prof F Winnik (Montreal 
University, Canada) generated through reductive amination of PC-
glyceraldehyde with primary amines of deacetylated chitosan (57 KDa). 
Percentage of substitution was controlled and determined by NMR (194). In 
our study, two pH values have been used: 7.5 is the medium culture pH and a 
lower pH 6.5. pH 6.5 is a suitable and safe pH for both macrophages and 
parasites, while pH<6.5 affects the growth of both macrophages and 
intracellular amastigotes.  
Chitosan pKa is approximately 6.3 and therefore, the approximate ionisation 
degree of chitosan is a 61% and 6% at pH 6.5 and 7.5 respectively.  
Table 2.3. Details of chitosan and its derivatives used in the study 
Compounds Properties Supplier 
HMW (source: crustacean 
shells) 
MW=310-375 KDa Sigma, UK 
MMW (source: crustacean 
shells) 
MW=190-310 KDa Sigma, UK 
LMW (source: crustacean 
shells) 
MW=50-190 KDa Sigma, UK 
Fungal chitosan (white 
mushroom) 
MW=110-150 KDa Dr Somavarapu 
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Chitosan 
oligosaccharide(synthetic) 
MW=≤ 5KDa Dr Somavarapu 
Chitosan oligosaccharide 
lactate (synthetic) 
MW=average Mn 5, 
oligosaccharide 60% 
Dr Somavarapu 
Chitosan- HCl (synthetic) MW= 47 - 65 KDa Dr Somavarapu 
Carboxymethyl chitosan 
(synthetic) 
MW=543.519 Da, level of 
substitution is 95% 
Dr Somavarapu 
PC1-CH (Phosphorylcholine 
substituted chitosan) 
(synthetic) 
MW=33 KDa, PC(mol%)= 
30 
Prof Winnik 
(194) 
PC2-CH (synthetic) MW=108 KDa, PC(mol%)= 
20 
Prof Winnik 
(194) 
PC3-CH (synthetic) MW=109 KDa, PC(mol%)= 
30 
Prof Winnik 
(194) 
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Figure  2.3. The structure of chitosan and its derivatives (194, 195, 
196, 197) 
 
2.8.2. Ethics statement.  
All animal work is carried out under a UK Home Office project licence 
according to the Animal (Scientific Procedures) Act 1986 and the new 
European Directive 2010/63/EU. The Project Licence (70/8427) has been 
reviewed by LSHTM Animal Welfare & Ethical Review Board prior to 
submission and consequent approval by the UK Home Office.  
2.8.3. Cell lines  
Preparation of macrophages 
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- Peritoneal mouse macrophages (PEMs) were obtained from 8-12-
week-old female CD1-mice (Charles River Ltd, UK). Two ml of a 2% 
(w/v) starch solution in phosphate-buffered saline (PBS, Sigma, UK) 
was injected intraperitoneally (i.p.). After 24 h, the animal was sacrificed 
and the PEMs were harvested by peritoneal lavage with cold RPMI 
1640 medium (Sigma, UK) containing 200 units penicillin and 0.2 mg 
streptomycin/ml (PenStrep; Sigma, UK). Subsequently, PEMs were 
centrifuged at 450 g at 4°C for 15 min and then the pellet was 
resuspended in RPMI 1640 with 10% (v/v) heat-inactivated fetal calf 
serum (HiFCS; Gibco, UK).  
- Bone marrow-derived macrophages (BMMs) were obtained from 
femurs of 8-12-week-old female BALB/c mice (Charles River Ltd). 
Briefly, the bone marrow cells were carefully flushed from the bone with 
Dulbecco’s Modified Eagle’s Medium (DMEM; Thermofisher, UK) with 
10% (v/v) HiFCS, 100 U/ml penicillin and 100 mg/ml streptomycin 
(Sigma, UK). Cells were pelleted by centrifugation (450 g, 10 min) and 
re-suspended in 10ml DMEM with 10% (v/v) HiFCS and human 
macrophage colony stimulating factor 50ng/ml (HM-CSF; 
Thermofisher, UK). After plating out in T175 flasks (Greiner Bio-One, 
Stonehouse, UK), BMMs were kept at 37°C, 5% CO2 for 7-10 days after 
which they were harvested, counted and used. 
- THP-1 cell is a human leukemic monocyte-like derived cell line. THP-1 
cells were cultured in RPMI 1640 medium supplemented with L-
glutamine and 10% HiFCS. THP-1 cells were incubated in RPMI 1640 
plus 10% (v/v) HiFCS and 20 ng/ml phorbol 12-myristate 13-acetate 
(PMA; Sigma, UK) at 37°C and 5% CO2 for 72 h to induce maturation 
transformation of these monocytes into adherent macrophages (198). 
Human squamous carcinoma (KB) cells are adherent cells derived from 
epidermal carcinoma from the mouth. KB cells were cultured in RPMI 1640 
medium 10% HiFCS (199). 
The number of cells and macrophages was estimated by counting with a 
Neubauer haemocytometer by light microscopy (x 400 total magnification). 
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2.8.4. Parasites 
Four Leishmania species; two GFP labelled species (L. major 
(MHOM/SU/73/5ASKH) and L. mexicana (MNYC/BZ/62/M379), kindly 
donated by Dr G Getti (University of Greenwich, UK) were used for the 
fluorescence microscope study. They were cultured in Schneider’s insect 
medium (Sigma, UK) with 23% (v/v) HiFCS, 1× penicillin-streptomycin-
glutamine (Gibco-Invitrogen) and supplemented with 700 μg/ml G418 (an 
aminoglycoside antibiotic, Sigma, UK).  L. major (MHOM/SA/85/JISH118) and 
L. mexicana (MNYC/BZ/62/M379) were used for other experiments as 
described, minus the G418. Promastigotes were incubated at 26°C, maximum 
passage number used = 7.  
2.8.5. In vitro cytotoxicity assays 
Re-suspended KB cells (4 x 104 /100 µl) were allowed to adhere to the bottom 
of 96-well plate overnight and then exposed to specific concentrations of the 
compounds for 72 h at 37°C and 5% CO2 incubator. Podophyllotoxin (Sigma, 
UK) was included as a positive control at a starting concentration of 0.05 μM. 
Cytotoxicity was evaluated by a cell viability assay using the resazurin sodium 
salt solution (AlamarBlue, Sigma, UK) which was prepared according to the 
manufacturer’s instructions. 20μL of the resazurin solution was added to each 
well of the plates and fluorescence (cell viability(200)) was measured over a 
period of 1 to 24 h using a Spectramax M3 plate reader (EX/EM 530 / 580 nm 
and 550 nm cut off). Results were expressed as percentage inhibition = (100 
– x)% viability (means ± standard deviation ). Cytotoxicity was evaluated in 
RPMI 1640 at two pH values (at normal pH of RPMI 7.5 and at a lower pH 
6.5). The pH of RPMI 1640 was reduced from 7.5 to 6.5 by adding 0.05M acidic 
buffer, 2-N-morpholino ethanesulfonic acid (MES, Sigma, UK). RPMI 1640 
plus MES (0.05M) at pH=6.5 did not show any toxicity to KB-cells. 
2.8.6. In vitro 72-hour activity of chitosan and its derivatives against 
extracellular L. major and L. mexicana promastigotes 
Promastigotes in RPMI 1640 medium were tested while in the exponential 
growth phase. The promastigotes were diluted to a density of 5x106 
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promastigotes/ml and then exposed to different concentrations of (HMW, 
MMW, and LMW) chitosan, chitosan derivatives and Fungizone (positive 
control) in 96 well plates for 72 h at 26°C. The activity of the compounds 
against promastigotes was evaluated using the Alamar Blue assay as 
previously described.  pH plays a critical role in the solubility and protonation 
of chitosan, so the activity against promastigotes was evaluated at two 
different pH values (pH=7.5 and a lower pH of 6.5 by adding MES). In addition 
to the colorimetric method of measuring parasite viability, promastigotes were 
manually counted microscopically in a Neubauer haemocytometer. Results 
were expressed as percentage inhibition= 100% - x% viability (means ± SD).  
2.8.7. In vitro 72- hour activity of chitosan and its derivatives against 
intracellular amastigotes of L. major and L. mexicana 
One hundred microliters of PEMs culture at 4 ₓ 105 cells/ml, dispensed into 
each well of a16-well LabTek tissue culture slide (Thermo Fisher, UK) at pH 
7.5 or pH 6.5 and incubated for 24 h at 37 °C in 5 % CO2. After 24 h, the wells 
were washed with fresh culture medium to remove non-adherent cells. 
Stationary phase, low-passage-number Leishmania promastigotes were then 
added at a ratio of 5 :1 PEM. This infection ratio was previously found to give 
sufficiently high and reproducible infection levels. Slides were incubated for 
another 24h at 34 °C to mimic dermal temperatures in 5 % CO2 (201). Any 
free, extracellular parasites were removed by washing the wells with cold 
culture medium. One slide was fixed with 100 % methanol for >30sec and 
stained with 10 % Giemsa for 5 minutes. The number of PEMs infected with 
Leishmania amastigotes per 100 macrophages was microscopically counted.  
All the experiments were conducted at macrophages infection levels above 
80% prior to addition of chitosan.  Chitosan, its derivatives and Fungizone ( 
a micellar suspension) at a range of concentrations (in quadruplicate) were 
added to the wells (100µl) and the slides were incubated for 72 h at 34 °C in 5 
% CO2. After 72 hours, the slides were fixed with 100% methanol for >30sec 
and stained with 10% Giemsa for 5 min. The slides were examined and the % 
of macrophages which were infected was counted. The anti-leishmanial 
activity of compounds was expressed as percentage reduction in infected 
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macrophages compared to untreated control wells (202). RPMI 1640 plus 
MES (0.05M) with pH=6.5 had no activity against Leishmania amastigotes 
2.8.8. Influence of the origin of the host cell on the in vitro activity of 
HMW chitosan against L. major amastigotes  
A further two host cell types, THP-1 and BMMs were infected with L. major 
and the activity of HMW chitosan was assessed. THP-1 cells (were cultured in 
RPMI 1640with 10% HiFCS) and BMMs (were cultured in DMEM with 10% 
HiFCS) were used to assess the host cell dependence of the anti-leishmanial 
activity of HMW chitosan (198). The experiment was conducted as described 
in section (vii) at pH 6.5.  
2.8.9. Influence of incubation duration on chitosan activity against L. 
major amastigotes  
The experiment was conducted using L. major amastigotes in BMMs host cell 
at pH 6.5 as described in section 2.8.7 after 4, 24, 48 and 72h of incubation 
with HMW chitosan and Fungizone as a positive control. 
2.8.10. The role of HMW chitosan on BMMs activation  
One hundred microliters of BMMs, PEMs and THP-1 macrophages (4 x 
105/ml) in DMEM (BMMs) or RPMI (PEMs and THP-1) at pH=6.5 were plated 
in each well of 96 well plates (standard clear plates for nitric oxide assay and 
black wall/clear bottom plates for ROS and TNF-α assay) and incubated for 
24 hours at 37 °C in 5 % CO2. Plates were washed with DMEM (BMMs) or 
RPMI (PEMs and THP-1) to remove non-adherent macrophages. L. major at 
1:5 ratio (5 parasites per host cell) was then added to the wells and the plates 
were incubated for 24h at 34 °C in 5 % CO2 to allow infection of the adherent 
macrophages. After 24h incubation with macrophages infection rate more than 
80%, the immune stimulatory effects of HMW chitosan was determined by 
quantifying the release of TNF-α, ROS and NO by the macrophages, as 
described below at pH 6.5. Then We have chosen BMMs to evaluate if the 
immunostimulatory effects of HMW chitosan have any important role in its anti 
-amastigotes activity as these macrophages are more homogenous than 
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PEMs and THP-1 cells (203). Both PEMs and BMMs have been reported to 
have a similar acidic pH ≈ 5.5 of parasitophorous vacuoles of L. amazonensis 
infected PEMs and BMMs (204, 205, 206).    
2.8.10.1. Measurement of TNF-α                                                           
HMW chitosan at a range of concentrations (1.64, 4.9,14.8, 44.4, 133.3 and 
400 µg/ml ) was added to infected and uninfected macrophages and the plates 
were incubated for 4 and 24 h at 34°C in 5% CO2 . Lipopolysaccharides from 
Escherichia coli O26:B6 (LPS, 100ng/ml; Sigma, UK) was used as a positive 
control and inducer. TNF-α release by the macrophages was measured using 
a mouse TNF-α ELISA kit (ab208348, abcam, UK) according to the 
manufacturer's instructions using a Spectramax M3 microplate reader 
(wavelength 450 nm) to determine if HMW chitosan stimulates T helper 1 or T 
helper 2 cells.  
2.8.10.2. Measurement of ROS  
ROS was measured using a 2′,7′–dichlorofluorescein diacetate (DCFDA, 
cellular reactive oxygen species detection assay kit, abcam, UK). Uninfected 
and infected macrophages were treated with 25 µM DCFDA in in phosphate-
buffered saline (PBS) buffer for 45 min at 37°C and then washed once in 
buffer. The cells were cultured at 34°C in 5% CO2 for 0.5, 1, 2, 4,8 and 24 h, 
with a range of concentrations (1.64, 4.9,14.8, 44.4, 133.3 and 400 µg/ml) of 
HMW chitosan or in the presence of H2O2 (25mM) (Thermofisher, UK) as a 
positive control in DMEM (BMMs) or RPMI (PEMs and THP-1) + 10% HiFCS 
(pH=6.5) in quadruplicate wells. In some experiments, cells were pre-treated 
with a selective inhibitor of ROS, N-acetyl-L-cysteine (NAC, 5mM; Sigma, UK), 
for 2 hours before the addition of the inducer or chitosan.  At 0.5, 1, 2, 4, 8 and 
24 h the plates were read, using a Spectramax M3 microplate reader 
(Ex=485nm, Em=535nm).  
2.8.10.3. Measurement of NO  
NO was measured by the Griess reagent (Thermofisher, UK). HMW chitosan 
at a range of concentrations (1.64, 4.9,14.8, 44.4, 133.3 and 400 µg/ml) was 
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added to infected and uninfected macrophages and the plates were incubated 
at 4 and 24 h at 34°C in 5% CO2. LPS (100ng/ml) was used as a positive 
control. In some experiments, cells were pre-treated with a selective inhibitor 
of nitric oxide with NG-methyl-L-arginine acetate salt (0.4 mM, L-NMMA; 
Sigma, UK) for 2 hours before the addition of LPS. NO was quantified 
according to the kit protocol, Briefly, 150 μl of the cell culture supernatants 
(particulates were removed by centrifugation) was mixed gently with 150μl of 
the Griess reagent in a 96 well plates and the mixture was incubated for 30 
mins at room temperature. The absorbance was measured using a 
Spectramax M3 plate reader (wavelength 548 nm). Sodium nitrite (Sigma, UK) 
at different concentrations was used to create a standard curve(207).  
2.8.11. Uptake of chitosan by macrophages 
The uptake of HMW chitosan was evaluated using two methods. The first 
method used two endocytosis inhibitors: cytochalasin D (1µg/ml , Sigma, UK) 
which is a phagocytosis inhibitor and dynasore (30 µg/ml, Sigma, UK) which 
inhibits pinocytosis (clathrin-mediated endocytosis (CME) by blocking GTPase 
activity of dynamin) (208, 209, 210) . The second method used dynasore and 
rhodamine-labelled chitosan (MW 200 kDa, Creative PEGWorks, USA) to 
track cellular uptake of chitosan over time by fluorescence microscopy. We 
chose BMMs to evaluate the uptake of chitosan by macrophages as these 
macrophages are more homogenous than PEMs (203). 
2.8.11.1. Activity of chitosan after inhibition of the endocytic pathway of 
BMMs 
One hundred microliters of BMMs culture (4 x 105/ml) in DMEM at pH 6.5 or 
pH=7.5 were dispensed into each well of 16-well LabTek culture slides and 
were infected with stationary phase L. major promastigotes. Some of the 
infected BMMs were pretreated with dynasore (30 µg/ml) or cytochalasin D 
(1µg/ml) for two hours. Subsequently, HMW chitosan was added to each well 
at concentrations of 1.64, 4.9,14.8, 44.4, 133.3 or 400 µg/ml and macrophages 
were incubated for 4 or 24 h at 34 °C in 5 % CO2.  After each point, the slides 
were examined as described in section (vii).The inhibition activity of the uptake 
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(phagocytosis or pinocytosis) of the two inhibitor was evaluated by using a 
fluorescence plate reader, by using fluorescent latex beads and pHrodo™ Red 
dextran  (211). We showed that cytochalasin caused 94% and 84% 
phagocytosis inhibition of fluorescent latex beads (Sigma-Aldrich, UK) after 4 
h and 24 h respectively and dynasore caused 95% and 90% pinocytosis 
inhibition of pHrodo™ Red dextran (Mw= 10,000 MW, Thermo Fisher, UK) 
after 4h and 24h respectively. 
2.8.11.2. Microscopic imaging of the cellular uptake of rhodamine-
labelled chitosan 
The qualitative characterisation of chitosan uptake of cells was carried out by 
wide-field microscopy (Nikon Ti-E inverted microscope). Briefly, after deriving 
BMMs, 500μl of the BMMs (in DMEM plus 10% HiFCS at pH 6.5, 4 x 104 
macrophages per ml) was seeded on each well of a 4-well LabTek tissue 
culture slide (Thermo Fisher, UK) and incubated for 24h at 37°C in 5% CO2. 
Subsequently, 5 µg/ml of Hoechst 33342 stain (Ex/Em = 350⁄461 nm, 
Thermofisher, UK) as a nuclear dye was added and the slides were incubated 
for 30 min at 37°C in 5% CO2. The macrophages were washed with PBS, L. 
major-GFP of L. mexicana-GFP was then added, at a ratio of 10:1 and further 
incubated for 24h at 34°C in 5% CO2 (We used 10:1 ratio not 5:1 as previously 
as at this experiment different species of L. major-GFP and L. mexicana-GFP 
were used and the ratio 10:1 was sufficient to obtain a high infection rate). 
Macrophages were then washed with PBS and 500 µl of LysoTracker® far 
Red (50 nM, Ex/Em;647/668nm; Thermo Fisher, UK) was added to each well. 
The labelled, infected macrophages were then exposed to 30 µg/ml 
rhodamine-labelled chitosan (MW 200kDa, Creative PEGWorks, USA) in 500 
µl of fresh DMEM plus 10% HiFCS pH 6.5 and incubated for 4 h and 24h at 
37°C with live imaging at each time point.  In some experiments, infected 
BMMs were pre-incubated with dynasore 30 µg/ml for 2 h before adding 
rhodamine-labelled chitosan. All the images were collected using a Nikon Ti-
E inverted microscope equipped with (63x objective) using Nikon Elements 
software. Three images for each experiment were then analysed using ImageJ 
software (v 1.52, National Institutes of Health, USA). The degree of correlation 
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between pixels in the red and green channels was assessed by the 
Colocalization Colormap plugin in the ImageJ software. This plugin enables 
quantitative visualisation of colocalization by calculating the normalized mean 
deviation product (nMDP) in a colour nMDP scale (from -1 to 1): negative 
refers (cold colours) to no co-localization while indexes more than 0 display 
co-localization and the higher number refers to more colocalization (212, 213).  
2.8.12. Statistical analysis.  
Dose-response curves and EC50 values were calculated by using GraphPad 
Prism version 7.02 software and the corresponding sigmoidal dose-response 
curves were established by using a nonlinear fit with variable slope models. 
Results represent means ± SD. EC50 values were compared by using extra-
sum-of-squares F tests. ANOVA and t-test were used to compare differences 
between two groups means or more. p values of 0.05 were considered 
statistically significant.  
 
 
 
 
 
2.9. Results 
2.9.1. Cytotoxicity of chitosan and its derivatives against KB cells in 
RPMI (pH 7.5 and pH 6.5) 
The cytotoxicity of chitosan and its derivatives against KB cells was clearly 
observed in a dose-dependent manner at two pH values (6.5 and 7.5) as 
shown in Fig 2.4. Chitosan and its derivatives had a low toxicity toward KB 
cells at both pH values and there was no significant difference in the 
cytotoxicity at these two pH values (p<0.05 by an extra sum-of-squares F test) 
(Table 2.4). No significant difference in the cytotoxicity was observed between 
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the chitosans and the derivatives with LD50 ≈ 800 μg/ml, except carboxymethyl 
chitosan with LD50 ≈ 1100 μg/ml was significantly lower toxic (p<0.05 by an 
extra sum-of-squares F test).  
Table 2.4. In vitro cytotoxicity of chitosan and its derivatives against KB cells at 
two pH values after 72h of incubation 
Compound 
pH=7.5*,** pH=6.5*,** 
LD50 µg/ml LD90 µg/ml LD50 µg/ml LD90 µg/ml 
Podophyllotoxin 0.8 ± 0.03 2 ± 0.3 0.8 ± 0.04 2 ± 0.4 
Fungizone 61 ± 8 228 ± 9 58 ± 8 190 ± 9 
HMW chitosan 751 ± 88 3146 ± 377 752 ± 90 3022 ± 366 
MMW chitosan 752 ± 87 3033 ± 410 758 ± 89 3019 ± 400 
LMW chitosan 811 ± 93 3095 ± 425 803 ± 90 3088 ± 420 
Fungal chitosan 734 ± 95 3046 ± 377 759 ± 91 3134 ± 380 
Chitosan Oligosaccharide 727 ± 97 3115 ± 402 765 ± 93 3232 ± 400 
Chitosan Oligosaccharide- 
lactate 
777 ± 98 3134 ± 388 754 ± 92 3058 ± 390 
Chitosan HCL 748 ± 90 3340 ± 409 781 ± 92 3589 ± 405 
PC1-CH 757 ± 91 3398 ± 388 756 ± 93 3364 ± 398 
PC2-CH 794 ± 90 3613 ± 400 800 ± 92 3709 ± 410 
PC3-CH 777 ± 90 3484 ± 357 786 ± 93 3719 ± 378 
Carboxymethyl chitosan 1183 ± 89 3800 ± 488 1184 ± 99 3999 ± 500 
Experiments were conducted in triplicate cultures, data expressed as mean +/- 
SD (experiment was reproduced further two times with confirmed similar data and 
data not shown). Chitosan and its derivatives had a low toxicity at both pH values 
(6.5 and 7.5) toward KB-cells and there was no significant difference in the 
cytotoxicity at these two pH values (p <0.05 by t-test).  ** No statistically significant 
difference was found in LD50 (50% lethal dose) values between three types of 
chitosan and other derivatives against KB-cells (except carboxymethyl chitosan 
which is the least toxic) (p>0.05 by an extra sum-of-squares F test).   
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Figure  2.4. Dose-response curves of the cytotoxicity of chitosan and its derivatives against KB cells at pH=7.5 (A) and 6.5 (B). KB cells were 
cultured in the presence of different concentrations of chitosan and its derivatives. The toxicity of drugs was measured after 72 hours by 
measuring the inhibition of metabolic activity. Values are expressed as % inhibition of KB cells relative to untreated controls. No statistically 
significant difference was observed in LD50 values of chitosan and its derivatives against KB cells between pH=6.5 and pH=7.5 (p>0.05 by an 
extra sum-of-squares F test). 
 
 
 
 
 
 
 
 
 
 
A B 
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2.9.2. Analysis of anti-promastigotes activity 
Anti-leishmanial activity (against promastigotes) of high, medium and low 
molecular weight (HMW, MMW and LMW respectively) chitosan and its 
derivatives (a total of 11) was tested. Dose-dependent activity (Fig 2.5) against 
Leishmania promastigotes was observed for chitosan and its’ derivatives 
except for carboxymethyl chitosan which showed no activity against parasites 
within the experimental parameters tested (pH 7.5 or 6.5 and concentrations 
up to 400 µg/ml). Chitosan and its derivatives showed a higher anti-leishmanial 
activity (with around 7-20 times) at low pH compared with higher pH. 
Furthermore, (HMW, MMW and LMW) chitosan from crustacean source and 
fungal chitosan at pH= 6.5 showed a remarkable activity against L. major and 
L. mexicana promastigotes and were more active than other derivatives 
(p<0.05 by an extra sum-of-squares F test) as shown in Table 2.5. 
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Table 2.5. In vitro activity of chitosan and its derivatives against promastigotes at two pH values after 72h of incubation 
Compound 
pH=7.5 * 
L. major 
pH=7.5* 
L. mexicana 
pH=6.5*,** 
L. major 
pH=6.5*,** 
L. mexicana 
EC50 µg/ml EC90 µg/ml EC50 µg/ml EC90 µg/ml EC50 µg/ml EC90 µg/ml EC50 µg/ml EC90 µg/ml 
Fungizone 0.05 ± 0.01 0.2 ± 0.02 0.14 ± 0.01 0.3 ± 0.03 0.07 ± 0.02 0.3 ± 0.1 0.13 ± 0.07 0.3 ± 0.02 
HMW chitosan 105 ± 12 1549 ± 525 140 ± 12 2187 ± 928 5.9 ± 0.5 37 ± 9 10.4 ± 1.6 98 ± 33 
MMW chitosan 113 ± 9 1277 ± 580 150 ± 12 2223 ± 681 6.2 ± 0.3 43 ± 8 10.9 ± 1.4 96 ± 27 
LMW chitosan 118 ± 11 1238 ± 582 157 ± 13 2225 ± 723 6.7 ± 0.3 40 ± 8 10.2 ± 1.5 84 ± 28 
Fungal chitosan 118 ± 11 1228 ± 560 150 ± 13 1991 ± 580 6.2 ± 0.3 42 ± 6 10.5 ± 1.3 61 ± 17 
Chitosan Oligosaccharide 153 ± 15 1680 ± 506 190 ± 20 2366 ± 461 62.5 ± 4 446 ± 92 77 ± 2.7 452 ± 36 
Chitosan Oligosaccharide- 
lactate 
98 ± 9 1226 ± 130 125 ± 14 765 ± 83 14 ± 0.1 135 ± 2 23 ± 1.4 311 ± 25 
Chitosan HCL 96 ± 7 1189 ± 211 110 ± 24 746 ± 169 13.2 ± 1 118 ± 34 20.8 ± 2.4 264 ± 61 
PC1-CH 111 ± 20 1875 ± 230 176 ± 14 2832 ± 412 19.9 ± 2.8 187 ± 90 32 ± 2.2 328 ± 48 
PC2-CH 104 ± 6 1485 ± 259 170 ± 8 2744 ± 377 16.5 ± 2.7 138 ± 49 28 ± 2.4 296 ± 53 
PC3-CH 119 ± 19 1860 ± 365 187 ± 16 3175 ± 580 23.3 ± 2.5 218 ± 44 37 ± 2.5 442 ± 65 
Carboxymethyl chitosan 
 
 
 
No activity up to 400 µg/ml 
Experiments were conducted in triplicate cultures, data expressed as mean +/- SD (experiment was reproduced further two times with 
confirmed similar data and data not shown). *Statistically significant differences were found for the EC50 values of chitosan and its 
derivatives at pH=6.5 and pH=7.5 (p<0.05 by using t-test). ** L. major promastigotes were significantly more susceptible to chitosan and 
derivatives than L. mexicana ((p<0.05 by an extra sum-of-squares F test)). Amphotericin B deoxycholate (Fungizone) was used as a 
positive control. Both pH of 6.5 and chitosan solvent did not show any activity against promastigotes. Both RPMI alone pH 6.5 and 
chitosan solvent did not show any activity against promastigotes.    
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Figure  2.5. Dose-response curves of the activity of chitosan and its derivatives 
against Leishmania promastigotes at two pH values. A: L. major at pH=7.5; B: L. 
mexicana at pH = 7.5; C: L. major at pH = 6.5; D: L. mexicana at pH = 6.5. 
Promastigotes were cultured in the presence of different concentrations of chitosan 
and its derivatives. The activity of drugs was measured after 72h by measuring the 
inhibition of metabolic activity. Values are expressed as % inhibition of 
promastigotes relative to untreated controls. Statistically significant difference was 
observed in EC50 values of chitosan and its derivatives against L. mexicana and L. 
major promastigotes between pH=6.5 and pH=7.5 (p<0.05 by t-test). Both RPMI 
alone pH 6.5 and chitosan solvent did not show any activity against promastigotes.   
 
2.9.3. Analysis of anti-amastigotes activity in PEMs  
Anti-leishmanial activity (against amastigotes) of high, medium and low 
molecular weight (HMW, MMW and LMW respectively) chitosan and its 
derivatives (a total of 11) was tested. Dose-dependent activity (Fig 2.6) against 
Leishmania amastigotes was observed for chitosan and its’ derivatives except 
for carboxymethyl chitosan which showed no activity against amastigotes 
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within the experimental parameters tested (pH 7.5 or 6.5 and concentrations 
up to 400 µg/ml). In the 72 hour assays, chitosan and its derivatives were 
significantly more active (with around 7-20 times) against intracellular L. major 
and L. mexicana amastigotes at pH 6.5 than pH 7.5 (p<0.05 by a paired t-test) 
as shown in Fig 2.6. (HMW, MMW and LMW) chitosan from crustacean source 
and fungal chitosan exhibited a significantly higher activity against L. major 
and L. mexicana intracellular amastigotes (EC50 ≈ 12 µg/ml against L. major 
and 16 µg/ml against L. mexicana) than other derivatives at pH= 6.5 (p<0.05 
by an extra sum-of-squares F test) as shown in Table 2.6.  
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Table 2.6. In vitro activity of chitosan and its derivatives against amastigotes infecting PEMs after 72h of incubation 
Compound 
pH 7.5* pH 7.5* pH 6.5* pH 6.5* 
L. major L. mexicana L. major L. mexicana 
EC50 µg/ml EC90 µg/ml EC50 µg/ml EC90 µg/ml EC50 µg/ml EC90 µg/ml EC50 µg/ml EC90 µg/ml 
Fungizone 0.07 ± 0.01 0.13 ± 0.05 0.19 ± 0.05 1.5 ± 0.2 0.06 ± 0.01 0.11 ± 0.06 0.18 ± 0.06 1.7 ± 0.3 
HMW chitosan 98 ± 6 1635 ± 245 119 ± 9 1804 ± 304 11.4 ± 1 69 ± 18 15.4 ± 2 103 ± 28 
MMW chitosan 103 ± 8 1652 ± 287 125 ± 10 1793 ± 323 12.9 ± 1 81 ± 18 16.3 ± 2 122 ± 34 
LMW chitosan 102 ± 7 1651 ± 282 125 ± 10 1795 ± 320 12.1 ± 1 74 ± 14 16.1 ± 2 116.6 ± 33 
Fungal chitosan 102 ± 7 1650± 276 124 ± 9 1796 ± 316 12.6 ± 3 92 ± 27 16.9 ± 2 144 ± 44 
Chitosan Oligosaccharide 145 ± 12 2473 ± 500 175 ± 14 2543 ± 505 73 ± 4 260 ± 32 86.2 ± 6 288 ± 39 
Chitosan 
Oligosaccharide- lactate 
93 ± 7 1957 ± 174 120 ± 9 2365 ± 239 39 ± 1 201 ± 16 47 ± 2 245 ± 23 
chitosan HCl 97 ± 11 2080 ± 516 121 ± 15 2402 ± 667 40 ± 2 210 ± 23 47.9 ± 3 243 ± 33 
PC1-CH 144 ± 10 1292 ± 217 169 ± 12 1365 ± 212 68 ± 3 246 ± 26 81.7 ± 6 274 ± 38 
PC2-CH 133 ± 6 1005 ± 194 159 ± 6 1705 ± 170 60 ± 3 202 ± 22 71.9 ± 5 237 ± 36 
PC3-CH 163 ± 11 1052 ± 144 187 ± 10 1107 ± 142 71 ± 4 251 ± 30 83.5 ± 6 286 ± 41 
Carboxymethyl chitosan 
 
No activity up to 400  µg/ml 
Experiments were conducted in quadruplicate cultures, data expressed as mean +/- SD (experiment was reproduced further two times 
with confirmed similar data and data not shown). *Statistically significant differences were found between the EC50 values of chitosan 
and its derivatives at pH=6.5 and pH=7.5 (p<0.05 by using t-test). Both pH of 6.5 and chitosan solvent did not show any activity against 
amastigotes.  Both RPMI alone pH 6.5 and chitosan solvent did not show any activity against amastigotes.     
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Figure  2.6. Dose-response curves of the activity of chitosan and its derivatives against 
Leishmania amastigotes at two pH values. A: L. major at pH=7.5; B: L. mexicana at pH 
= 7.5; C: L. major at pH = 6.5; D: L. mexicana at pH = 6.5. PEMs were infected with 
stationary-phase promastigotes and exposed to various concentrations of chitosan and 
its derivatives, followed by microscopic counting of the number of infected 
macrophages*. Values are expressed as % inhibition of infection relative to untreated 
controls. Chitosan and its derivatives are significantly more active in pH 6.5 than in pH 
7.5 (p<0.05 by t-test). * Macrophage infection rate was >80% after 24h. Both RPMI 
alone pH 6.5 and chitosan solvent did not show any activity against amastigotes.   
To allow like-for-like comparison, EC50 values were recalculated in terms of 
molarity using estimated molecular weights (HMW: MW= 342.5 KDa, MMW: 
MW=250 KDa, LMW: MW= 120 KDa and fungal chitosan MW=130 KDa) at pH = 
6.5. Based on molarity (Table 2.7 and 2.8 ), HMW chitosan was significantly more 
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active against L. major and L. mexicana promastigotes and amastigotes and 
hence used in all subsequent studies. Fig 2.7 observes the morphology of infected 
macrophages before and after treatment with HMW chitosan is taken by a 
microscope provided with a digital camera. 
Table 2.7. In vitro activity of chitosans against promastigotes based on molarity 
Compound 
pH=6.5*,** 
L. major 
pH=6.5*,** 
L. mexicana 
EC50 µM EC90 µg/ml EC50 µM EC90 µM 
HMW chitosan 0.017 ± 0.001 0.10 ± 0.02 0.03 ± 0.005 0.28 ± 0.1 
MMW chitosan 0.024 ± 0.001 0.172 ± 0.03 0.04 ± 0.005 0.38 ± 0.1 
LMW chitosan 0.05 ± 0.001 0.33 ± 0.06 0.08 ± 0.005 0.7 ± 0.2 
Fungal chitosan 0.05 ± 0.003 0.31 ± 0.005 0.08 ± 0.01 0.5 ± 0.1 
Data expressed as mean +/- SD HMW chitosan is significantly more active against 
Leishmania promastigotes than other types (p <0.05 by one-way ANOVA) 
A 
 
B 
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Figure  2.7. Morphology of infected (PEMs) with L. major and L. mexicana after 
treatment with HMW chitosan. Slides were fixed with 100% methanol for 5 minutes 
and stained with 10 % Giemsa for 5 minutes. These figures have been taken by a 
microscope attached to a digital camera. A: L. major infected macrophages before 
treatment (L. major amastigotes with tight vacuoles). B: L. mexicana infected 
macrophages before treatment (L. mexicana amastigotes with large vacuoles). C: L. 
major infected macrophages after treatment with HMW chitosan.  
 
Table 2.8. In vitro activity of chitosans against amastigotes based on molarity  
Compound 
pH 6.5* 
L. major 
pH 6.5* 
L. mexicana 
EC50 µM EC90 µM EC50 µM EC90 µM 
HMW chitosan 0.03 ± 0.01 0.2 ± 0.05 0.04 ± 0.005 0.3 ± 0.08 
MMW chitosan 0.05 ± 0.04 0.32 ± 0.07 0.06 ± 0.008 0.5 ± 0.1 
LMW chitosan 0. 1 ± 0.008 0.6 ± 0.1 0.13 ± 0.01 0.97 ± 0.3 
Fungal chitosan 0.09 ± 0.002 0.7 ± 0.2 0.13 ± 0.01 1.1 ± 0.3 
Data expressed as mean +/- SD HMW chitosan is significantly more active against 
Leishmania promastigotes than other types (p <0.05 by one-way ANOVA) 
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2.9.4. Host cell dependence of antileishmanial activity of HMW chitosan and 
time to kill assay on amastigotes at pH 6.5 
We aimed to assess the host cell dependence of anti-leishmanial activity of HMW 
chitosan and Fungizone by evaluating the in vitro activity against L. major 
amastigotes in three different host cells (PEMs, BMMs and THP-1). EC50 and 
EC90 values of HMW chitosan and Fungizone against amastigotes infecting three 
different macrophage populations are summarized in Table 2.9. As can be seen, 
there was a significant difference in the activity of HMW chitosan and Fungizone 
depending on the type of the host cells (p < 0.05 by one-way ANOVA) and both 
HMW chitosan and Fungizone displayed higher activity in PEMs and BMMs than 
in differentiated THP-1 cells. The results in Fig 2.8 clearly show that both HMW 
chitosan and Fungizone had time-dependent effects against intracellular 
amastigotes in RPMI with pH=6.5.  
Table 2.9. HMW chitosan activity against L. major amastigotes in three different 
macrophage cultures after 72 h 
Host cell/infection 
rate % at 24h 
HMW chitosan Fungizone 
 EC50 µg/ml EC90 µg/ml EC50 µM EC90 µM 
PEMs / > 80% 10.31 ± 1.22* 89.07 ± 20.46 0.02 ± 0.004** 0.27 ± 0.07 
BMMs / > 80% 14.60 ± 1.79* 145.7 ± 36.2 0.04 ± 0.005** 0.43 ± 0.1 
THP-1/ > 80% 24.28 ± 2.87* 200.1 ± 48.8 0.08 ± 0.006** 1.15 ± 0.37 
Experiments were conducted in quadruplicate cultures, data expressed as mean +/- 
SD (experiment was reproduced further two times with confirmed similar data and data 
not shown).,*,**  statistically significant difference in EC50 values between the three 
types of cells (Fungizone and were significantly more active in PEMs and BMMs 
compared with THP-1 cells) (p<0.05 by an extra sum-of-squares F test) taking into 
consideration that infection levels were higher in PEMs and THP-1 than BMMs. % 
infection rate gives the percentage of infected macrophages.. Both pH of 6.5 and 
chitosan solvent did not show any activity against amastigotes.   
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Figure  2.8. Influence of incubation duration on the chitosan and Fungizone activity 
against L. major intracellular amastigotes in BMMs. BMMs were infected with 
stationary-phase promastigotes and exposed to fixed concentrations of chitosan HMW 
and Fungizone for 4, 24, 48 and 72 h, followed by microscopic counting of the number 
of infected macrophages. (A) In vitro time-to-kill for Fungizone (B) In vitro time-to-kill 
for chitosan HMW. Results shown are the means ± SD of quadruplicates and represent 
one experiment of three performed 
2.9.5. Effects of HMW chitosan on the production of TNF-α by uninfected or 
L. major infected macrophages at pH = 6.5 
The activation of M1 macrophages by Th1 lymphocyte plays an important role in 
the control of CL (14, 15, 16) therefore, we measured TNF-α production by 
macrophages stimulated by HMW chitosan. Following the stimulation by HMW 
chitosan, the TNF-α production by macrophages (BMMs, PEMs and THP-1) was 
found to be in a dose-dependent manner in both infected and uninfected cells as 
shown in Fig 2.9. After 24 h, the levels of TNF-α in the culture fluid of 
macrophages (both infected and uninfected BMMs, PEMs and THP-1) containing 
concentrations of HMW chitosan (14.8, 44.4 and 133.3 µg/ml) was significantly 
higher than untreated macrophages, with TNF- α being highest at 44.4 µg/ml 
chitosan. While at other concentrations (1.64, 4.9 and 400 µg/ml), HMW chitosan 
did not stimulate macrophages to produce TNF-α (p < 0.05 by t-test). HMW 
chitosan at concentrations 14.8, 44.4 and 133.3 μg/ml stimulated uninfected 
BMMs to produce TNF-α with 87± 4.5 - 712± 9 - 48±3 pg/ml, uninfected PEMs 
with 67± 5 - 570± 8 - 33±3 pg/ml and uninfected THP-1 with 47± 3.5 - 412± 10 - 
A Fungizone B Chitosan 
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22±3 pg/ml respectively and 56± 3.5 - 464± 10 - 32±4 pg/ml, 46± 5 - 400± 7 - 
22±4 pg/ml and 36± 2 - 310± 10 - 15±4 pg/ml in L. major infected BMMs, PEMs 
and THP-1 respectively. In other words, HMW chitosan stimulated less amount of 
TNF-α in L. major infected than uninfected macrophages (p < 0.05 by t-test) and 
BMMs produced higher levels of TNF-α after the stimulation in comparison with 
PEMs and THP-1(p < 0.05 by one-way-ANOVA). Less TNF-α was generated 
when the chitosan concentration was increased to 133.3 µg/ml and above.  
Lipopolysaccharides from Escherichia coli O26:B6 (LPS; positive control) 
stimulated TNF-α production in both uninfected and infected BMMs, PEMs and 
THP-1 after a 24 h incubation period and at a significantly higher level than 
chitosan (p < 0.05 by t-test).  Our results indicated that HMW chitosan activated 
M1 macrophages.   
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Figure  2.9. TNF-α production in uninfected and L. major infected BMMs, PEMs and 
THP-1 macrophages* after 24 h of exposure to 1.64, 4.9,14.8, 44.4, 133.3 and 400 
µg/ml of chitosan at pH = 6.5. The dose-response in both uninfected and L. major 
infected macrophages was bell-shaped. TNF- α production was significantly decreased 
(p < 0.05 by t-test) by infecting the cells with L. major. TNF-α stimulation was higher 
with the rank BMMs, PEMs and THP-1.  Experiments were conducted in quadruplicate, 
data are expressed as mean +/- SD (experiment was reproduced further two times with 
confirmed similar data and data not shown). Positive control= macrophages treated 
with LPS 10 µg/ml. Negative control = macrophages not exposed to chitosan. *Initial 
macrophage infection rate was >80% after 24 h. Chitosan solvent did not cause any 
TNF-α production. 
2.9.6. Effects of HMW chitosan on the production of ROS by macrophages 
at pH = 6.5  
ROS plays an important role in the killing of intracellular amastigotes (14, 15, 16) 
therefore, we measured ROS production by macrophages stimulated by HMW 
chitosan. HMW chitosan (at concentrations 14.8, 44.4 and 133.3 µg/ml) increased 
the production of ROS (indicated by H2DCFDA fluorescence) after 4 h of 
incubation but did not stimulate ROS after 8 h of incubation (Table 2.10). Other 
concentrations of HMW chitosan (1.64, 4.9 and 400 µg/ml) did not stimulate 
BMMs, PEMs or THP-1 to produce ROS after 4 h or 8 h of incubation. 
The ROS response in both uninfected and infected BMMs, PEMs and THP-1 was 
in bell shaped – similar to that seen with TNF-. Increasing chitosan concentration 
(more than 14.8 μg/ml) increased ROS production until concentration 44.4 μg/ml 
(the maximum production of ROS), after which increasing concentration reduced 
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ROS production. In addition, we showed that ROS production by macrophages 
was significantly decreased (p < 0.05 by t-test) by infecting the cells with L. major 
as shown in Fig 2.10. BMMs produced higher levels of ROS after the stimulation 
in comparison with PEMs and THP-1(p < 0.05 by one-way-ANOVA).   
Table 2.10. ROS production in uninfected and L. major infected BMMs after 8 h 
of exposure to different concentrations of HMW chitosan at pH=6.5 
 ROS (Relative Fluorescence Intensity) in: 
Chitosan µg/ml Uninfected BMMs Infected BMMs 
1.64 4000 ± 100 2650 ± 100 
4.9 3999 ± 200 2550 ± 150 
14.81 4020 ± 150 2650 ± 100 
44.4 4050 ± 100 2750 ± 200 
133.3 4000 ± 200 2564 ± 150 
400 3959 ± 100 2400 ± 100 
Negative control = 
BMMs not exposed 
to chitosan 
4750 ± 100 2850 ± 100 
Experiments were conducted in quadruplicate, data is expressed as mean +/- 
SD (experiment was reproduced a further two times with confirmed similar data 
(not shown). Chitosan solvent alone did not cause any ROS production. 
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Figure  2.10. ROS production in uninfected and L. major infected BMMs, PEMs and THP-1 
macrophages * after 4 h of exposure to 1.64, 4.9,14.8, 44.4, 133.3 and 400 µg/ml of HMW 
chitosan at pH=6.5. High levels of ROS were induced by both uninfected and L. major 
infected macrophages exposed to HMW chitosan compared to those that were not (P <0.05 
by t-test). Maximum production of ROS occurred at 44.4 μg/ml of chitosan. ROS production 
by L. major infected macrophages was significantly lower compared to uninfected cells (p < 
0.05 by t-test). ROS stimulation was higher with the rank BMMs, PEMs and THP-1.  
Experiments were conducted in quadruplicate, data is expressed as mean +/- SD 
(experiment was reproduced a further two times with confirmed similar data (not shown). 
Positive control = macrophages treated with H2O2 25 mM (a known ROS inducer). Negative 
control = macrophages not exposed to chitosan. *Initial macrophage infection rate was >80% 
after 24 h. Chitosan solvent did not cause any ROS production. 
 
We found that HMW chitosan had an in vitro stimulatory effect on BMMs ROS 
production after 4h of incubation. We therefore investigated whether this ROS 
plays any role in the activity of HMW chitosan against intracellular amastigotes. 
For these experiments, the 4 h post treatment time point was taken because ROS 
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peaked at this point in BMMs in response to chitosan treatment at a time when 
chitosan does not induce NO in BMMs (ibid).  Scavenging of ROS by the ROS 
scavenger, 5mM N-acetyl-L-cysteine (NAC), had no significant impact on the 
activity of chitosan against intracellular amastigotes (p > 0.05 by t-test) – see Fig 
2.11. ROS scavenger (N-acetyl-L-cysteine (NAC), 5mM) caused a complete 
scavenging of ROS after 4 h (Table 2.11). and had no cytotoxicity against KB cells 
or leishmanicidal against L. major amastigotes. Even though chitosan stimulated 
ROS production but this did not play a role in the anti-leishmanial activity of 
chitosan. 
 
 
 
Figure  2.11. Activity of HMW chitosan against L. major amastigotes in BMMs* after 4 
h, with and without ROS scavenger at pH = 6.5. Infected macrophages were pre-
incubated with 5 mM NAC for 2 h, after which HMW chitosan at concentrations 1.64, 
4.9,14.8, 44.4, 133.3 and 400 µg/ml was added and the cells were incubated for a 
further 4 h. Chitosan activity against intracellular amastigotes was evaluated as 
described in section (vii). Values are expressed as % inhibition of infection relative to 
untreated controls. After 4h, there was no significant difference in the anti-leishmanial 
activity of chitosan after scavenging of ROS (p >0.05 by t-test). Experiments were 
conducted in quadruplicate, data is expressed as mean +/- SD. Experiment was 
reproduced further two times with confirmed similar data (not shown). *Initial 
macrophage infection rate was >80% after 24 h. 
 
 
 
 
82 
 
Table 2.11. ROS production in uninfected and L. major infected BMMs after 
exposure to chitosan in the presence of ROS scavenger  
 
ROS (Relative Fluorescence Intensity) 
after 4 h in: 
Chitosan µg/ml 
Uninfected BMMs pre-
treated with ROS 
scavenger 
Infected BMMs 
pre-treated with 
ROS scavenger 
1.64 4700 ± 200 2850 ± 150 
4.9 4800 ± 250 2750 ± 200 
14.81 4750 ± 100 2950 ± 150 
44.4 4800 ± 100 2750 ± 100 
133.3 4900 ± 150 2864 ± 100 
400 4950 ± 100 2600 ± 100 
Positive control (ROS) = 
BMMs treated with 25 mM 
H2O2 
4800 ± 250 2750 ± 100 
Negative control =  BMMs not 
exposed to chitosan or to 
H2O2 
4800 ± 100 2900 ± 100 
Experiments were conducted in quadruplicate, data is expressed as mean +/- 
SD (experiment was reproduced a further two times with confirmed similar data 
(not shown). ROS was measured after 4 h of exposure to HMW chitosan. 
2.9.7. Effects of HMW chitosan on the production of NO by macrophages at 
pH = 6.5 
NO plays an important role in the killing of intracellular amastigotes (14, 15, 16) 
therefore, we measured NO production by macrophages stimulated by HMW 
chitosan. We showed that chitosan did not have a stimulatory effect on BMMs, 
PEMs and THP-1 NO production after 4 h of incubation (Table 2.12). However, 
after a 24 h incubation, HMW chitosan at pH=6.5 had a stimulatory effect on 
BMMs, PEMs and THP-1 NO production in a clear bell-shaped dose-dependent 
manner. HMW chitosan at concentrations 14.8, 44.4 and 133.3 μg/ml induced 
uninfected BMMs to produce NO with 14.9± 0.3 - 34±1.2 - 11±1 μM, uninfected 
PEMs with 10.9± 0.4 - 26±1.2 - 8.5±1 μM and uninfected THP-1 with 8.9± 0.2 - 
20±1- 6.1±0.5 μM respectively and 11 ±1- 26 ± 2.5 - 8 ± 1.2 μM, 8 ±1 - 20 ± 2 - 6 
± 1.2 μM and 6± 0.1 - 14±1 - 4.1±0.5 μM  in L. major infected BMMs, PEMs and 
THP-1 respectively, NO being highest at 44.4 μg/ml. While other concentrations 
of HMW chitosan (1.64, 4.9 and 400 µg/ml) did not stimulate macrophages to 
produce NO after 24 h of incubation. In other words, HMW chitosan stimulated a 
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lower quantity of NO in infected than uninfected macrophages (p < 0.05 by t-test) 
and BMMs produced higher levels of NO after the stimulation in comparison with 
PEMs and THP-1(p < 0.05 by one-way-ANOVA) (Fig 2.12). 
LPS caused significantly higher NO production compared to HMW chitosan (p < 
0.05 by t-test) in both uninfected and infected BMMs, PEMs and THP-1. The 
levels of NO produced by L. major infected BMMs exposed to LPS (positive 
control) or HMW chitosan were significantly lower than levels produced by 
uninfected macrophages (p < 0.05 by t-test) (Fig 2.12). 
Table 2.12. NO production in uninfected and L. major-infected BMMs after 4h of 
exposure to different concentrations of HMW chitosan at pH=6.5 
 NO production (uM) in: 
Chitosan µg/ml Uninfected BMMs Infected BMMs 
1.64 0 0 
4.9 0 0 
14.81 0 0 
44.4 0.05 ± 0.01 0 
133.3 0.06 ± 0.01 0.05 ± 0.01 
400 0.05 ± 0.01 0.04 ± 0.01 
Negative control =  
BMMs not exposed 
to chitosan 
0.07 ± 0.01 0.05 ± 0.01 
Experiments were conducted in quadruplicate, data is expressed as mean +/- SD 
(experiment was reproduced a further two times with confirmed similar data (not 
shown). Chitosan solvent alone did not cause any NO production. 
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Figure  2.12. NO production in uninfected and L. major infected BMMs, PEMs and THP-
1 macrophages * after 24 h of exposure to 1.64, 4.9,14.8, 44.4, 133.3 and 400 µg/ml of 
chitosan at pH = 6.5. The response in both uninfected and infected macrophages was 
bell-shaped in relation to chitosan concentration. Maximal production of NO was 
stimulated by 44.4 μg/ml of chitosan. NO production was significantly decreased (p < 
0.05 by t-test) when the cells had been infected with L. major. NO stimulation was higher 
with the rank BMMs, PEMs and THP-1.  Experiment was conducted in quadruplicate 
cultures, data expressed as mean +/- SD (experiment was reproduced a further two 
times with confirmed similar data and data not shown). Positive control = macrophages 
treated with LPS 10 µg/ml. Negative control = macrophages not exposed to chitosan.  
*Initial macrophage infection rate was >80% after 24 h. Chitosan solvent did not cause 
any NO production.  
 
As HMW chitosan had an in vitro stimulatory effect on BMMs NO production after 
24h of incubation we investigated further whether NO has any role in the activity 
of HMW chitosan against intracellular amastigotes. Inhibition of NO production by 
the NO inhibitor NG-methyl-L-arginine acetate salt (L-NMMA) at 0.4mM, had no 
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significant influence on the activity of chitosan against intracellular amastigotes (p 
> 0.05 by t-test) (Fig 2.13). The NO inhibitor (L-NMMA, 0.4 mM) caused 90% 
reduction in NO production (Table 2.13) after 24 h and had no cytotoxicity effects 
against KB cells and no leishmanicidal against intracellular L. major amastigotes. 
Even though chitosan stimulated NO production but this did not play a role in the 
anti-leishmanial activity of chitosan. 
 
Figure  2.13. Activity of HMW chitosan against L. major -infected BMMs* after 24 h in 
the presence or absence of an NO inhibitor at pH = 6.5. Infected macrophages were 
pre-incubated with the NO inhibitor L-NMMA (0.4 mM) for 2 h, following which HMW 
chitosan at concentrations 1.64, 4.9,14.8, 44.4, 133.3 and 400 µg/ml was added and 
the cells were incubated for a further 24 h. Chitosan activity against intracellular 
amastigotes was evaluated as described in section (vii). Values are expressed as % 
inhibition of infection relative to untreated controls. After 24 h, there was no significant 
difference in the activity of chitosan after inhibition of NO (p >0.05 by t-test). Experiment 
was conducted in quadruplicate cultures, data expressed as mean +/- SD. Experiment 
was reproduced a further two times and confirmed the results (data not shown). *Initial 
macrophage infection rate was >80% after 24 h.  
Table 2.13. NO production in uninfected and L. major infected BMMs after 
exposure to chitosan in the presence of NO inhibitor at pH=6.5 
 NO μM after 24 h in: 
Chitosan µg/ml 
Uninfected BMMs pre-
treated with NO 
inhibitor 
Infected BMMs pre-
treated with NO 
inhibitor 
1.64 1.4 ± 0.4 0.15 ± 0.1 
4.9 1.5 ± 0.3 0.16 ± 0.1 
14.81 1.9 ± 0.5 0.17 ± 0.1 
44.4 1.6 ± 0.2 0.15 ± 0.1 
133.3 1.2 ± 0.4 0.14 ± 0.1 
400 1.0 ± 0.6 0.15 ± 0.1 
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Positive control (NO) = 
BMMs treated with 10 
µg/ml LPS 
1.4 ± 0.3 0.16 ± 0.1 
Negative control =  
BMMs not exposed to 
chitosan or to LPS 
1.7 ± 0.3 0.13 ± 0.1 
Experiments were conducted in quadruplicate, data is expressed as mean +/- SD 
(experiment was reproduced a further two times with confirmed similar data (not 
shown). NO was measured after 24 h of exposure to HMW chitosan. 
2.9.8. Cellular uptake of HMW chitosan and inhibition of endocytosis 
We found that the activation of M1 macrophages by HMW chitosan did not play a 
role in its activity against intracellular amastigotes therefore, we investigated 
whether the anti-leishmanial effects of HMW chitosan against intracellular 
amastigotes after 4 h and 24 h exposure were dependent on the direct activity of 
chitosan following its entry into the macrophages at pH=6.5.  No significant 
difference was observed in the activity of chitosan against intracellular 
amastigotes when it was added after prior phagocytosis inhibition with 
cytochalasin D (p > 0.05 by t-test). In contrast, dynasore (an inhibitor of 
pinocytosis, a clathrin-mediated endocytosis (CME) inhibitor) did significantly 
affect chitosan mediated parasite killing at pH = 6.5 as shown in Fig. 33(p< 0.05 
by t-test). The same activity was seen at pH 7.5. – see Fig 2.14, panel C.  We 
found that cytochalasin caused 94 and 84% phagocytosis inhibition of fluorescent 
latex beads (Sigma-Aldrich, UK) after 4 h and 24 h respectively and dynasore 
caused 95 and 90% pinocytosis inhibition of pHrodo™ Red dextran (Mw= 10,000 
MW, Thermo Fisher, UK) after 4h and 24h respectively (Table 2.14), The two 
inhibitors had no activity against intracellular L. major amastigotes at the 
concentrations used. Pinocytosis (CME) played a critical role in the efficacy of 
HMW chitosan against intracellular amastigotes. 
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Figure  2.14. Activity of HMW chitosan against L. major infected BMMs* after 4 h, 
pH=6.5 (A), 24 h, pH=6.5 (B) and at 24 h, pH=7.5 with or without phagocytosis inhibitor 
or pinocytosis (CME) inhibitor. We found that chitosan requires pinocytosis (CME) not 
phagocytosis by BMMs for killing of L. major amastigotes at pH = 6.5 and 7.5. BMMs 
were infected with stationary-phase promastigotes. Some of the infected macrophages 
were pre-incubated with cytochalasin D (phagocytosis inhibitor) or dynasore 
(pinocytosis (CME) inhibitor) and exposed to various concentrations (1.64, 4.9,14.8, 
44.4, 133.3 and 400 µg/ml ) of chitosan for 4 h and 24 h, followed by microscopic 
counting of the number of infected macrophages. There was no significant difference 
in the activity of HMW chitosan after inhibition of phagocytosis (p >0.05 by t-test). While 
a significant inhibition of chitosan mediated parasite killing occurred in the presence of 
dynasore at two pH values (p >0.05 by t-test). Values are expressed as % inhibition of 
infection relative to untreated controls. Experiment was conducted in quadruplicate 
cultures, data expressed as mean +/- SD>. Experiment was reproduced a further two 
times and confirmed the results (data not shown). *Initial macrophage infection rate 
was >80% after 24 h. 
 
 
 
 
88 
 
Table 2.14. Phagocytosis and pinocytosis by L. major infected BMMs in the 
presence of the uptake inhibitors 
 
Number of latex beads ± SD *105/mg 
protein 
Concentration of dextran ± 
SD µg/mg protein 
Time/Hour 
Without 
cytochalasin D 
With            
cytochalasin D 
Without 
dynasore 
With 
dynasore 
4 108 ± 8 6 ± 1 4.9 ± 0.5 0.2 ± 0.1 
24 456 ± 30 73 ± 8 18.9 ± 1 1.8 ± 0.2 
Experiments were conducted in triplicate, data is expressed as mean +/- SD (experiment was 
reproduced a further two times with confirmed similar data (not shown). 
 
 
2.9.9. Fluorescence microscopy of the uptake of chitosan by macrophages 
Rhodamine-labelled chitosan was used to track the delivery of chitosan to the 
parasitophorous vacuole (PV) of Leishmania infected macrophages. Fig 2.15 
illustrates the cellular uptake of chitosan by L. major-GFP- or L. mexicana-GFP- 
infected BMMs after 4 h and 24 h rhodamine-labelled chitosan exposure. There 
was co-localization of chitosan and intracellular amastigotes after 4 h and 24 h 
with nMDP colour index 0.7 and 1 respectively (see nMDP material and methods). 
The uptake of chitosan increased in a time-dependent manner. Fig 2.15 (Panels 
D and E) shows this uptake after 4 h and 24 h respectively, and the accumulation 
of chitosan in PVs (shown as yellow that indicates co-localization of rhodamine 
and GFP). Fig 2.15 (Panel F) also shows that the inhibition of pinocytosis (CME) 
with dynasore prevented the uptake of chitosan with a negative nMDP colour 
index that represents no co-localization of chitosan and amastigotes. This is also 
supporting evidence for the uptake by pinocytosis as seen in Fig 2.14. 
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Figure  2.15. Fluorescence microscopy images of the cellular uptake of rhodamine-
labelled chitosan over 4 and 24 h at pH=6.5 by BMMs infected with L. major (XA) or 
with L. mexicana (XB). Green represents intracellular amastigotes, red represents 
labelled chitosan and yellow represents merged red chitosan and green Leishmania.  
Panels A-F represent the following: Infected BMMs unexposed to chitosan after 4 h 
(panel A) or 24 h (panel B); Infected BMMs exposed to chitosan after 4 h (panel D) or 
24 h (panel E); Infected BMMs unexposed to chitosan after 24 h (panel C) and Infected 
BMMs exposed to chitosan and pinocytosis inhibitor (dynasore) after 24 h (panel F) 
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2.10. Discussion 
The literature on the anti-leishmanial activity of chitosan and its derivatives is 
limited, especially pertaining to its mechanism of action (124, 214, 215). In this 
study, we assessed the anti-leishmanial activity of various forms of chitosan, 
including low, medium and high molecular weight chitosan, and chitosan 
derivatives. Chitosan derivatives are generally produced by chemical 
modification of the amino or hydroxyl groups of chitosan for the optimization 
of the physicochemical properties. We found that chitosan and its derivatives 
had minimal cytotoxicity against KB-cells with LD50 values ≥700 µg/ml and 
other macrophages (PEMs, BMMs and THP-1) at pH 7.5 or 6.5. This data 
supports previous reports of chitosan’s low cytotoxicity against CCRF-CEM 
(human lymphoblastic leukaemia) and L132 (human embryonic lung) cells with 
similar LD50 values (173).  
We determined that a lower pH 6.5, compared to 7.5, enhanced by 7-20 times 
the anti-leishmanial activity of chitosan and its derivatives against L. major and 
L. mexicana promastigotes and amastigotes. This higher activity of chitosan 
at the lower pH 6.5 could be due to its greater ionisation (protonation of the 
amino groups; PKa of chitosan≈6.3). The greater positive charge could 
increase the chitosan antimicrobial activity by interacting with the negatively 
charged microbial membrane – in accordance with the first postulated 
mechanism of antimicrobial activity (124, 174). A higher chitosan activity at 
lower pH (pH ≈ 5) has previously been reported against Escherichia coli and 
Salmonella typhimurium (216, 217). Our study is the first to show the pH 
dependence of the anti-leishmanial activity of chitosan and its derivatives and 
could explain why literature reports of the anti-leishmanial activity of chitosan 
have shown such variability, with EC50 values ranging from 70 to 240 μg/ml 
against L. infantum, L. amazonensis and L. chagasi promastigotes and 
amastigotes (122, 127, 129, 191, 218, 219). For example, in one study, the 
EC50 of chitosan against L. infantum amastigotes (in PEMs) in RPMI 1640 
medium was 100.81 μg/ml, but the pH at which the experiment was conducted 
was not mentioned (127). Moreover, Malli et al (2019) reported that chitosan 
solution (LMW) showed no activity until 100 µg/ml against L. major 
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promastigotes or amastigotes without mentioning the pH of the 
experiment(220).  
Influence of pH was also seen when the anti-leishmanial activity of chitosan 
(of the different molecular weights) and chitosan derivatives were compared. 
While the different chitosans and derivatives showed minor differences in their 
anti-leishmanial activity at pH 7.5, the derivatives were 3 to 5 times less active 
than the HMW, MMW, LMW and fungal chitosan at lower pH 6.5. This reduced 
activity could be due to the lower number of amino groups on the chitosan 
derivatives (see Fig 2.3). These derivatives are more soluble at a higher pH 
and have similar activity to chitosan, but at a lower pH the higher protonation 
of the chitosan improves the anti-leishmanial activity significantly (221, 222). 
Carboxymethyl chitosan had no anti-leishmanial activity - most of the amino 
groups on this derivative have been substituted by carboxymethyl moieties 
making the molecule negatively charged (223) . 
HMW, MMW, LMW and fungal chitosan have a wide range of molecular 
weights. To allow like-for-like comparison, EC50 values were recalculated in 
terms of molarity using estimated molecular weights (HMW: MW= 342.5 KDa, 
MMW: MW=250 KDa, LMW: MW= 120 KDa and fungal chitosan MW=130 
KDa) at pH = 6.5. Based on molarity (Table 2.7 and 2.8), HMW chitosan was 
significantly more active against L. major and L. mexicana promastigotes and 
amastigotes and further studies were conducted using HMW chitosan. The 
higher anti-leishmanial activity of HMW chitosan compared to MMW and LMW 
chitosan mirrors its greater antibacterial activity in another study against 
Escherichia coli, Pseudomonas aeruginosa and Staphylococcus aureus (224). 
HMW has a long chain, and therefore more glucosamine units, and possesses 
more amino groups (Fig 2.3) resulting in more protonated groups (-NH 3+) than 
MMW and LMW(224) which could explain its greater potency. 
We also showed that the anti-leishmanial activity of chitosan is significantly 
greater against L. major infected PEMs or BMMs compared to differentiated 
THP-1 cells in the order PEMs>BMMs>THP-1 cells underlining the need to 
take the host cell into consideration when conducting similar experiments.  
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In order to understand the potential anti-amastigote mechanism(s) of chitosan, 
we investigated whether the activity of HMW chitosan against the intracellular 
amastigotes was via direct uptake into the host cell and localisation in the 
parasitophorous vacuole or indirectly via the activation of M1 macrophages,, 
given that the cellular immune responses in cutaneous leishmaniasis play a 
critical role in self-cure (225, 226).                                                                                                                                                                                                                                 
The activation of M1 macrophages by Th1 lymphocyte subpopulation, which 
produces different cytokines, primarily IFN-γ and TNF-α is crucial for the 
elimination of the intracellular Leishmania via the triggering of an oxidative 
burst and therefore, the host cells increase the production of ROS and NO 
which are responsible for killing of the parasite (38, 39). We found that HMW 
chitosan stimulated TNF-α production by macrophages and this would be 
expected to be an indicator of an M1 macrophage that would have greater 
leishmanicidal activity. Our results show that chitosan stimulated BMMs, 
PEMs and THP-1 ROS production with a peak after 4 h and led to a significant 
increase in the TNF-α and NO production after 24 h in a bell-shaped response. 
Similar findings have been reported showing that HMW chitosan had in vitro 
stimulatory effect on PEMs (from male rats) NO production (126) and LMW 
chitosan stimulated RAW264.7 macrophage TNF- α production (184). Another 
study demonstrated that LMW chitosan induced ROS production in an 
epithelial, human breast cancer cell line (227). The bell-shaped responses are 
consistent with a study that showed that chitosan stimulated NO and TNF-α 
production in peritoneal macrophages in a dose-dependent manner and their 
levels tended to decrease at higher concentrations of chitosan (320μg/ml 
)(228). This type of response has also been reported previously for tucaresol 
for both its immunomodulatory and activity against experimental L. donovani 
infections, albeit at lower doses (229). We found that BMMs had high levels 
expression of TNF-α, NO and ROS and this could be explained as BMMs are 
more homogenous than PEMs, and they are characterised with their high 
yield, homogeneity and long lifespan (230). 
BMMs were chosen to evaluate if the anti-leishmanial activity of HMW chitosan 
is through indirect way (through the immunostimulatory effects) or direct way 
(by the uptake of chitosan by macrophages) or both of them, as these 
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macrophages are more homogenous than PEMs cells (203). Despite the 
observed chitosan-induced ROS and NO production there was no evidence 
that this contributed to the anti-leishmanial activity in our study – the inhibitors 
we used to mitigate their production had no effect on the ability of chitosan to 
kill intracellular Leishmania amastigotes (Figs 2.11 and 2.13).  This led us to 
investigate the cellular uptake of HMW chitosan and its relationship to the anti-
leishmanial activity.   
The uptake of the large charged molecule HMW chitosan has not been 
systematically studied before and there is no clear evidence of its penetrating 
cell membranes or of its uptake mechanism. Macrophages are known to take 
up extracellular materials and plasma by endocytosis. Endocytosis mainly 
occurs via two different cellular uptake mechanisms: pinocytosis or 
phagocytosis, where pinocytosis is fluid-phase endocytosis and phagocytosis 
is the process of engulfing large particles (231). Inhibition of pinocytosis (CME) 
significantly reduced the anti-leishmanial activity of HMW chitosan. Therefore, 
in our study pinocytosis (CME) was considered to be the main mechanism for 
the uptake of HMW chitosan by BMMs, indicating a direct anti-leishmanial 
effect of this molecule against amastigotes. Other researches have also 
reported pinocytosis as the pathway for the uptake of chitosan of different 
molecular weights by HEK293 epithelial cells  (232). The fluorescence imaging 
in our study showed that in BMMs HMW chitosan is taken up into the 
parasitophorous vacuole (PV) where the Leishmania amastigotes reside, with 
the labelled chitosan being internalized within 4 h and increasing up to 24 h 
later. This scenario is consistent with another study where rhodamine 
isothiocyanate- chitosan (RITC-chitosan 98-10 K) was found to be directly 
delivered to the U937 macrophage lysosome after 24 h (233). The 
accumulation of chitosan in the PV might be due to chitosan's relatively high 
pKa 6.3, making it more soluble and protonated in the acidic contents of the 
vacuole. This is consistent with a study using bafilomycin to inhibit acidification 
and prevent chitosan accumulation within macrophages (233). 
In summary, our studies indicate that chitosan and its water-soluble derivatives 
showed anti-leishmanial activity against both L. major and L. mexicana 
promastigotes and amastigotes in a pH-dependent manner. At pH 6.5 HMW 
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chitosan is more active than MMW and LMW chitosan and chitosan 
derivatives, in particular those where the amino groups are substituted. In 
addition, HMW chitosan activated M1 macrophages, stimulating them to 
produce NO and ROS. However, the anti-leishmanial activity of chitosan was 
not due to such immune activation, as an NO inhibitor and a ROS scavenger 
failed to reduce the anti-leishmanial activity. Instead, the anti-leishmanial 
activity was related to direct uptake of chitosan into the parasitophorous 
vacuole by pinocytosis (CME). HMW chitosan demonstrated effective in vitro 
anti-leishmanial activity with minimal cytotoxicity and future work will focus on 
in vivo studies, formulations and routes for drug administration. 
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3. Preparation and characterisation of amphotericin B loaded 
chitosan nanoparticles  
3.1. Introduction  
As mentioned in Chapter 1, the polyene antibiotic AmB (a standard treatment 
for systemic fungal infections) was classified as a second line treatment for VL 
and MCL, particularly for pentavalent antimonial resistant Leishmania. 
However, the toxic side effects of AmB restrict its use. Great efforts have been 
spent to develop drug delivery systems (DDs) of AmB, to reduce its toxicity 
and improve the efficacy of the drug, such as AmBisome®, a liposomal 
formulation of AmB, which is significantly less toxic than the free drug and is 
effective against VL and CL and then has been promoted as first line for VL in 
the Indian subcontinent (ISC), However, the drawbacks are (i) high cost, where 
donated free of charge by WHO for VL, not for CL and (ii) need for cold chain 
due to stability guaranteed only up to 25oC (54, 55, 56, 58, 234). Polymeric 
nanoparticles technology has also gained a great interest in the DDs field, 
giving opportunities for controlled drug release, drug protection of enzymatic 
degradation and retention period of drug. We mentioned in Chapter 1 that 
chitosan nanoparticles are gaining a lot of attention in DDs in the medical field 
as they are both biodegradable and biocompatible (119). There are different 
methods for the preparation of chitosan nanoparticles and they are 
summarised in Fig 3.1.   
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Figure  3.1. Preparation methods of chitosan nanoparticles. (A) Emulsion cross-
linking in which chitosan is stabilized by s surfactant and then is emulsified in an oil 
phase (water-in-oil emulsion) such as chitosan aqueous solution in toluene, using 
Span 80® as emulsifier) and is then reacted with an appropriate cross linking agent 
(e.g. formaldehyde, glutaraldehyde, genipin, glyoxal etc.) followed by washing and 
drying of the nanoparticles, (B) ionotropic gelation which represents the method we 
used and will be described in details, (C) emulsion-droplet coalescence in which 
chitosan solution is dispersed in liquid paraffin oil to prepare an emulsion and then 
sodium hydroxide solution is added to the first emulsion under high speed mixing 
which produces nanoparticles which are centrifuged and dried, (D) precipitation in 
which a compressed air nozzle is used to inject chitosan solution into basic organic 
solvent (sodium hydroxide, NaOH methanol or ethanediamine) , (E) reverse 
micelles in which a surfactant (e.g. sodium 10 bis (ethyl hexyl) sulfosuccinate or 
cetyl trimethylammonium bromide) is dissolved into an organic solvent (e.g. n-
hexane) to which aqueous chitosan solution is added under continuous stirring. 
Subsequently, a cross-linking agent (e.g. glutaraldehyde) is added and maintained 
under stirring overnight, and the organic solvent is removed by evaporation(F) 
spray drying in which an aqueous acetic acid solution of chitosan is prepared then, 
drugs are suspended or dissolved in the chitosan solution and then a cross-linking 
agent (glutaraldehyde or sodium tripolyphosphate. Small droplets are formed upon 
the atomization and the formation of flowing particles with evaporation of solvent. 
These techniques except ionotropic gelation frequently require the use of organic 
solvents or heat, which are undesirable steps and may affect encapsulated drug 
and may increase cytotoxicity effects (171, 235, 236)  
 
 
The ionotropic gelation method is described as an easy and simple technique 
in which, nanoparticles are formed by an electrostatic interaction between the 
cationic amino groups of chitosan and negatively charged anions of other 
compounds (such as tripolyphosphate sodium (TPP), dextran sulphate, 
chondroitin sulphate, etc) with mechanical stirring at room temperature leading 
to spherical nanoparticles. The use of different pH values of media and ratios 
F) 
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of chitosan and polyanions can result in the synthesis of particles at different 
sizes and surface charges. This technique has many advantages such as the 
usage of aqueous condition, low toxicity and not changing the chemistry of the 
encapsulated drug (120, 237). Moreover, these nanoparticles can be prepared 
in small and different sizes and charges, they can be used for different routes 
of administration and offer a sustained drug release (112).  
All nanoparticles used in our study were prepared using the inotropic gelation 
method. Chitosan nanoparticles were prepared via the interaction between the 
oppositely charged groups of chitosan (positive amino groups) and TPP 
(polyanions) or dextran sulphate (negative groups) (Fig 3.2, give structure of 
TPP and dextran sulphate). Dextran sulphate is a biodegradable and 
biocompatible polysaccharide with a negative charge and is soluble in water. 
These properties enable dextran sulphate to produce nanoparticles when 
interacts  with positively charged molecules to give positively or negatively 
charged nanoparticles according to the mass ratios used (238). Because of 
the biodegradability, biocompatibility and the possibility of dextran to interact 
with chitosan to produce negative charged nanoparticles, we chose dextran 
suphate as a cross-linker.  
 Tripolyphosphate sodium (TPP) is a popular and commonly used polyanion 
to prepare chitosan nanoparticles because of its safety (TPP is approved as 
safe by the FDA; Sec. 182.1810 sodium tripolyphosphate (239)) and gelation 
properties and furthermore, TPP has a role in the stability of nanoparticles 
(122, 240). Because of the safety profile and the ability of TPP to interact with 
chitosan to produce positive charged nanoparticles, we chose TPP as an 
another cross-linker.  
There are several possible mechanisms for drug (AmB) release from chitosan 
nanoparticles as shown in Fig 3.3 and chitosan nanoparticles show a pH-
dependent drug release because of its solubility. Therefore, the aims of this 
chapter were (i) to produce two types of chitosan nanoparticles containing 
AmB, one by using TPP to obtain positively charged nanoparticles and the 
other with dextran sulphate to obtain negatively charged nanoparticles, both 
with smallest possible sizes. After optimizing the preparation parameters, the 
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aims were (ii) to characterise the produced blank and AmB loaded 
nanoparticles in terms, of size, charge, morphology and stability and (iii) to 
evaluate the amphotericin B loading and drug release from the amphotericin 
B loaded chitosan TPP or dextran sulphate nanoparticle. 
 
 
 
 
 
Figure  3.2. Chemical structure of TPP and dextran sulphate (241) 
 
 
 
 
Figure  3.3. Mechanisms of drug release from chitosan nanoparticles. a) In 
diffusion release, a permeation of the drug is happening through the interior of the 
matrix of polymer to the near medium, b) in the swelling release, an absorption of 
water into the polymer is occurred until the dissolving of polymer, c): erosion release 
which can be homogenous (at the same rate throughout the matrix) and 
heterogeneous (erosion of the polymer from the surface towards the inner core). 
Polymer degradation may be due to the surrounding media or the presence of 
enzymes.  (120)  
 
 
 
 
 
Dextran sulphate  TPP 
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3.2. Material and methods 
3.2.1. Preparation of blank chitosan nanoparticles  
Nanoparticles were prepared by inotropic gelation by mixing positively 
charged chitosan with negatively charged TPP or dextran sulphate as shown 
schematically in Fig 3.4. 
1- HMW chitosan (MW=310-375 KDa, Sigma, UK) was dissolved at various 
concentrations (0.33, 1, 3 and 9 mg/ml) in 1% aqueous acetic solution 
(Sigma, UK). The pH of the resulting chitosan solution was adjusted to 
pH of 3, 4, 5, 6 and 7 by adding NaOH solution (Sigma, UK) and this 
enabled investigation into the influence of pH on particles formation.  
2- The sodium tripolyphosphate (TPP, Mw= 367.85 g/mol,Fisher scientific, 
US) and dextran sulphate (Mw= 40 kDa, Sigma, UK) solutions were 
prepared by dissolving TPP or dextran sulphate in double-distilled 
water at various concentrations 
3- The nanoparticles were formed at chitosan: TPP or chitosan: dextran 
sulphate mass ratios of 3:1, 5:1, 10:1, 20:1, 1:1, 1:3, 1:5 ,1:10 and 1:20). 
TPP or dextran sulphate aqueous solution (10 ml) was added dropwise 
using a 10 ml syringe into the chitosan solution (10ml) under magnetic 
stirring (Fig 3.4). Directly after adding the TPP or dextran sulphate 
solution, the nanoparticles suspension was sonicated to reduce the 
particles size by using a probe sonicator Soniprep 150 (Richmond 
Scientific Ltd, Lancashire, UK); the diameter of the microprobe was 
3mm, operating at an output frequency of 23kHz with an amplitude of 
14-16 nm for 15 mins (15 mins was found to be the optimal time after 
testing for 1, 5, 15 and 20 min) with 1 min rest after every 5 min of 
sonication to decrease possible overheating of the sample and resulting 
degradation of the AmB. Subsequently, the nanoparticle suspension 
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was filtered through a 0.2 µm size syringe filter (Millex, Merck Millipore, 
UK) to remove aggregates and larger particles. The nanoparticles were 
concentrated by centrifugation (8,000 x g) using high recovery 
centrifugal filters (Spin-X UF concentrators,20 ml, 30 kDa, Corning, 
UK).  
4- The nanoparticles suspension was analysed directly by using a 
Zetaziser (Malvern Instruments Ltd., UK) to determine the size, 
polydispersity index (PDI) and zeta potential of the nanoparticles. 
Nanoparticles were then lyophilised using a freeze dryer (Micro 
Modulyo, Richmond Scientific, UK). In this process, D-mannitol (Mw= 
182.17 g/mol, Sigma, UK) 5% or sucrose (Mw=342.3 g/mol, Sigma, UK) 
5% v/v was used as a cryoprotectant to protect the nanoparticles from 
the freezing and desiccation stresses (the stress of freezing and 
dehydration) (242). After 48 hours, lyophilized nanoparticles were 
collected, weighed and stored at 4°C for further analysis. The 
lyophilized blank nanoparticles were white cotton-like substance.  
3.2.2. Preparation of AmB loaded chitosan nanoparticles  
The optimal parameters determined for producing blank nanoparticles which 
gave the smallest sizes and PDI (which refers to homogeneity of  nanoparticle 
size (243)) were chosen to prepare the AmB loaded chitosan nanoparticles 
(Fig 3.4). 
1-  10 mg of AmB (Purity ≥ 95%, Cambridge Bioscience, UK) was 
dissolved in 0.5 ml of DMSO (high-performance liquid chromatography 
grade; Fisher Chemical, United Kingdom) and sonicated in a Camlab 
TransSonic T460/H water bath for 15 min at room temperature. 
- AmB is insoluble in water at pH 6 to 7. It is soluble in DMSO (30–40 
mg/ml) and in dimethylformamide (2–4 mg/ml). Molecular weight of 
AmB is 924.08 g/mol and logP is -0.66.  
2-  To prepare AmB loaded chitosan-TPP nanoparticles, AmB solution 
(0.5 ml of 10 mg) was added to 10 ml of TPP solution (6 mg in 10 ml 
distilled water) and this solution was added dropwise to 10 ml of HMW 
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chitosan solution (30 mg in 10 ml AC 1%) of pH of 5 under magnetic 
stirring.  
3- To prepare AmB loaded chitosan-dextran sulphate nanoparticles, AmB 
solution (0.5 ml of 10 mg) was added to 10 ml of dextran solution (30 
mg in 10 ml double distilled water) and this solution was added 
dropwise to 10 ml of HMW chitosan solution (10 mg in 10 ml AC 1%) of 
pH of 5 under magnetic stirring. 
4-  Subsequently, nanoparticle suspension was sonicated directly after 
adding the gelation material, filtered, purified and freeze dried (using a 
cryoprotectant) as described for blank nanoparticles in section 3.3.1. 
The lyophilised AmB loaded nanoparticles were yellow cotton-like 
material. Each experiment was repeated three times. 
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Figure  3.4. Schematic representation for Blank nanoparticles and AmB loaded 
chitosan nanoparticles with TPP or dextran sulphate (244, 245) 
3.2.3. Physicochemical properties of the nanoparticles (size, charge and 
morphology) 
1- The size of the nanoparticles was measured by dynamic light scattering 
(DLS) using a Zetaziser ( Malvern Instruments Ltd., UK) with the 
following parameters: dispersant: water, dispersant refractive indices 
(RI): 1.33, viscosity (cP):0.8872, material RI: 1.33, temperature 
(°C):25.0,  measurement position (mm):3 and attenuator: 9. The result 
is expressed as Z-Average (nm) and polydispersity index (PDI). Z -
average reflects the intensity weighted mean hydrodynamic size of the 
particles measured by DLS. PDI represents the distribution of the 
nanoparticles sizes in the sample (243). DLS is identified as technique 
for measuring the size and size distribution of molecules and particles 
which are dispersed or dissolved in liquid and measures hydrodynamic 
diameter based on the light dispersion properties of samples Tyndall 
effect (light scattering) and Brownian motion (the random motion of 
particles suspended in a fluid because of the bombardment by the 
solvent molecules that surround them). DLS gives the PDI value which 
reflects the size distribution of the nanoparticles which is classified to 
monomodal (one population) or plurimodal (several populations) and 
monodisperse (narrow distribution) or polydisperse (broad distribution) 
assuming that lower PDI less than 0.4 refers to a homogenous 
population and 0.1 or less to higher homogeneity in the particle 
population (246, 247). 
2- Zeta-potential (representing surface charge of nanoparticles) of the 
nanoparticles was measured by the Zetaziser with same parameters 
for the sizing except for measurement position being (mm):2 mm and 
attenuator:11. Zetaziser measures the zeta potential through the 
monitoring of the mobility of charged particles on the surface of the 
nanoparticles by application of an electrical potential (248). Data 
analysis was performed using the Malvern ZetaSizer software. 
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Measurements were repeated three times for sizes and 6 times for zeta-
potential for each sample. 
3- The morphology of the nanoparticles was examined using a scanning 
electron microscopy (SEM, UCL, School of Pharmacy ) and a 
transmission electron microscopy (TEM, UCL, School of Pharmacy) 
For the SEM, a fragment of sample was attached to a self-adhesive 
carbon disc mounted on a 25 mm aluminium stub. The stub was coated 
with 25 nm of gold using a sputter coater. The stub was then placed 
into a FEI Quanta 200 FEG SEM for imaging at 5kV accelerating 
voltage using secondary electron detection (249).  
Liquid samples for TEM were dropped with a Pasteur pipette onto a 
copper grid coated with a carbon/formvar support film. After 15 
seconds, a filter paper was blotted off to remove the excess sample. 
Then a drop of negative stain (1% uranyl acetate) was added and 
blotted after 15 seconds. The grid was placed into a specimen holder 
and inserted into a Phillips/FEI CM 120 BioTwin TEM for imaging at 
200kV (250).  
3.2.4. Stability of nanoparticles regarding size and zeta potential  
This stability was evaluated by keeping nanoparticles in distilled water, PBS 
or RPMI (pH 7.5 or pH 5) and in mouse (BALB/c) plasma (pooled female, 
BioIVT, UK) in rubber-capped glass vials at temperatures of 4, 34 or 37 °C for 
30 days. Particle sizes and zeta-potential were measured after 0, 1, 7 and 30 
days.  
Stability of dried nanoparticles was identified by resuspending them in water 
after 0, 1, 7 and 30 days and measuring their size and charge and they were 
highly stable.   
3.2.5. Determination of drug encapsulation efficiency and AmB loading 
and release 
Nanoparticles were prepared as described in section 4-2-2. Following 
sonication of the suspensions in the probe sonicator and filtration, the AmB 
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loaded nanoparticle suspension was centrifuged (8,000 x g) to remove the free 
AmB by using High recovery centrifugal filters (Spin-X UF concentrators,30 
kDa, Corning, UK). Filtrates and supernatants were collected and analysed for 
AmB concentrations by HPLC as described in section 3.3.6.1. Because of the 
molecular weight cut-off of the filtration tubes, only the free drug could pass 
through the membrane. The encapsulation efficiency (EE), drug loading (122) 
and yield (118) were calculated using the following equations: 
                   Mass of total AmB – mass of free AmB 
EE% =                                                                                        ₓ 100 
                                 Mass of total AmB 
                                       Mass of total AmB – mass of free AmB 
Drug loading % =                                                                                         ₓ 100                         
                                     Mass of chitosan + dextran sulphate or TPP 
 
 
 
                          Mass of nanoparticles after freeze-drying  
Yield % =                                                                                       ₓ 100                                          
                  Mass of AmB + chitosan+ dextran sulphate or TPP 
 
Additionally, the AmB loading was evaluated again after freeze drying by 
dissolving the yielded yellow powder in DMSO, in acidic pH 3 (by using 1% 
(v/v) acetic acid), and then by measuring the quantity of AmB by HPLC as 
described previously in Chapter 3, in section 3.3.6.1. There was no significant 
difference in the loading value between these two methods, and the data in 
the thesis will be expressed according to the first method (using High recovery 
centrifugal filters).  
3.2.6. In vitro release of AmB 
The release of AmB from chitosan-TPP or chitosan-dextran sulphate 
nanoparticles was evaluated by the dialysis method. One ml of the 
nanoparticles suspension (1 mg/ml AmB equivalent prepared in double 
distilled water) was added to either one ml of PBS containing 5% DMSO or 
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one ml of mouse (BALB/c) plasma (pooled female, BioIVT, UK) containing 
DMSO (5%) (for the solubility of AmB) (118). Subsequently, this 2 ml was 
placed in a dialysis bag (molecular mass cut off =12−14 kDa, Sigma, UK) and 
dialyzed against 50 ml of PBS containing 5% DMSO at pH of 7.5, 6.5 or 5. 
After immersing the dialysis bag in the release medium, the dialysis set up was 
left under stirring at 4, 34 or 37 °C for 168 h. The temperatures 4, 34 and 37 
°C were chosen to mimic the storage, skin and body temperatures 
respectively, while pH 5 was chosen to simulate the release in the endosomal 
compartment of macrophages,  pH 7.4 to simulate physiological conditions 
(251) and pH 6.5 to mimic our in vitro study (anti-leishmanial activity) 
conditions.  
 After 6, 24, 48, 72, 96,120, 144 and 168 h the total dialysis medium was 
replaced with fresh medium to avoid saturation of AmB, (maintaining strict sink 
conditions throughout the experiment). Release media was processed to 
quantify the released AmB using HPLC as described in section3.3.6.1. The 
results were expressed as a cumulative percentage release of the total amount 
of AmB (%w/w) versus time according to the equation. 
 
                                                                          Mass of released AmB at time t (mg) 
Cumulative release (%) =                                                                                                       ₓ100 
                                                                              Mass of total AmB (1 mg) 
 
 
Mass of released AmB at time t is a cumulative amount. For instance, mass of 
released AmB after 48h is the total amount released at 6, 24 and 48 h.   
3.2.6.1. Quantification of AmB by HPLC  
AmB was analysed by using a 1260 Infinity Agilent HPLC system. The column 
and settings used in our study are summarized in Table 3.1 (252). A stock 
solution of AmB was prepared by dissolving 1 mg of AmB in DMSO. Standard 
solutions were achieved by diluting this stock solution in PBS containing 5% 
DMSO.  
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Table 3.1. HPLC parameters for AmB quantification  
HPLC column 
Injection 
volume 
(μL) 
 
Flow 
rate 
(ml/min) 
Mobile phase 
Detector 
wavelength 
nm 
Retention 
time 
(min) 
Phenomenex; 
Synergi–Hydro RP 
(250x4.6 mm; 5 μm) 
20 1 
5mM 
EDTA•2Na in 
methanol 
450 7.65 
 
3.3. Results 
3.3.1. Effects of the initial concentration of chitosan and sonication 
time on the quality of the nanoparticles 
3.3.1.1. Conditions that resulted in poor quality nanoparticles  
Precipitation and poor quality of both types of nanoparticles were shown at pH 
values of 7 and 3 of chitosan solution at all tested conditions. Chitosan 
solutions at concentrations (0.3 or 9 mg/ml), at all tested pH with different mass 
ratios and after sonication of the nanoparticles suspension for 1, 5, 15 or 20 
mins, gave poor quality nanoparticles with (high PDI>0.8) and with different 
peaks as seen in Table 3.2. Similarly, chitosan solutions at concentrations (1 
or 3 mg/ml) at all pH values with different mass ratios and after sonication of 
the nanoparticles suspension for 1 or 5 mins produced poor quality 
nanoparticles (Table 3.2). Finally, chitosan solutions at concentrations (1 or 3 
mg/ml) at all pH values with a mass ratio between chitosan and TPP (20:1, 
1:1, 1/3, 1:5, 1:10 or 1:20) or a mass ratio between chitosan and dextran 
sulphate (1:5, 1:10, 1:20, 10:1 or 20:1) and after sonication for 1, 5 , 15 or 20 
mins caused a precipitation of particles or poor quality nanoparticles with a 
high PDI of 1.
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Table 3.2. Conditions which did not produce good quality nanoparticles 
Chitosan 
mg/ml 
pH 
Chitosan: TPP or chitosan: 
dextran sulphate mass ratio 
Sonication 
time mins 
Resulted nanoparticles 
Related 
figure 
0.3 
3, 4, 
5, 6 
or 7 
3:1, 5:1, 10:1, 20:1, 1:1, 1:3, 1:5 
,1:10 and 20:1 
1, 5, 15 or 
20 
Poor quality nanoparticles, had a high polydispersity regarding 
sizes. These samples were deemed not suitable for further 
study as they might contain large particles or aggregates 
3.5, a) 
1 
 
3 or 
7 
3:1, 5:1, 10:1, 20:1, 1:1, 1:3, 1:5 
,1:10 and 20:1 
1, 5, 15 or 
20 
Poor quality nanoparticles, had a high polydispersity regarding 
sizes. These samples were deemed not suitable for further 
study as they might contain large particles or aggregates 
 
4, 5 
or 6 
3:1, 5:1, 10:1, 20:1, 1:1, 1:3, 1:5 
,1:10 and 20:1 
1 or 5 
Poor quality nanoparticles with high PDI and very large 
nanoparticles with size≈ 800nm 
3.5, b) 
4, 5 
or 6 
Chitosan: TPP (20:1, 1:1, 1:3, 1:5, 
1:10 or 1:20) 
Chitosan: dextran sulphate (1:5, 
1:10, 1:20, 10:1 or 20:1) 
15 or 20 
A precipitation of particles or poor quality nanoparticles with 
high PDI of 1 
 
 
3 
3 or 
7 
3:1, 5:1, 10:1, 20:1, 1:1, 1:3, 1:5 
,1:10 and 20:1 
1, 5, 15 or 
20 
Poor quality nanoparticles, had a high polydispersity regarding 
sizes. These samples were deemed not suitable for further 
study as they might contain large particles or aggregates 
 
4, 5 
or 6 
3:1, 5:1, 10:1, 20:1, 1:1, 1:3, 1:5 
,1:10 and 20:1 
1 or 5 
Poor quality nanoparticles with high PDI and very large 
nanoparticles with size≈ 800nm 
3.5, b) 
4, 5 
or 6 
Chitosan: TPP (20:1, 1:1, 1:3, 1:5, 
1:10 or 1:20) 
Chitosan: dextran sulphate (1:5, 
1:10, 1:20, 10:1 or 20:1) 
15 or 20 
A precipitation of particles or poor quality nanoparticles with 
high PDI of 1 
 
9 
3, 4, 
5, 6 
or 7 
3:1, 5:1, 10:1, 20:1, 1:1, 1:3, 1:5 
,1:10 and 20:1 
1, 5, 15 or 
20 
Poor quality nanoparticles, had a high polydispersity regarding 
sizes. These samples were deemed not suitable for further 
study as they might contain large particles or aggregates 
3.5, c) 
Experiment was reproduced further two times with confirmed similar data 
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Figure  3.5. Poor quality nanoparticles at different conditions. a) at initial chitosan concentration 0.3 mg/ml and all other different 
parameters, b) at initial chitosan concentration 1 or 3 mg/ml and sonication for 1 or 5 mins and c) at initial chitosan concentration 9 
mg/ml other different parameters. There are several populations of particles, some are small in size e.g. less than 100 nm and some 
are large about 1 µm. Each colour represents one measurement as each sample was measured 3 times.   
 
a) b) 
c) 
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3.3.1.2. Conditions that resulted in good quality nanoparticles   
Chitosan solutions at concentrations (1 or 3 mg/ml) at pH (4, 5 or 6) with a 
mass ratio between chitosan and TPP (3:1, 5:1 or 10:1) or a mass ratio 
between chitosan and dextran sulphate (1:3, 1:1, 3:1 or 5:1 ) and after 
sonication of the nanoparticles suspension for 15 mins gave good quality 
nanoparticles with (low PDI<0.4) (lower PDI means more homogenous and 
stable nanoparticles (210))  with one peak; with different Z-Averages according 
to the conditions that would be discussed later (Fig 3.6 and Fig 3.7). Sonication 
of the nanoparticles suspension for more than 15 mins (for example 20 mins) 
produced no significant changes in the quality (PDI) or physicochemical 
properties (sizes and charges) of the nanoparticles. 
 
 
Figure  3.6. Good quality chitosan-dextran sulphate nanoparticles with one peak 
(one population of nanoparticles at initial chitosan concentration 3 mg/ml and 
sonication for 15 mins. Chitosan-dextran sulphate nanoparticles  (Size = 145.8 nm, 
PDI =0.2). Each colour represents one measurement as each sample was done in 
three measurements. 
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Figure  3.7. Good quality chitosan-TPP nanoparticles with one peak (one 
population of nanoparticles at initial chitosan concentration 3 mg/ml and sonication 
for 15 mins. Chitosan – TPP nanoparticles (Size = 43.47 nm, PDI =0.2). Each colour 
represents one measurement as each sample was done in three measurements. 
Our results indicated that the optimal parameters to obtain good quality 
nanoparticles (for both types of nanoparticles with TPP or with dextran 
sulphate) are: initial concentration of chitosan with 1 or 3 mg/ml and sonication 
time of the nanoparticles suspension for 15 mins as sonicating for more than 
15 mins gave same results regarding quality (PDI), size and charge.   
3.3.2. Effects of pH of chitosan solution and the mass ratio on the size 
and charge of good quality nanoparticles   
Chitosan and TPP with parameters (chitosan 3 mg/ml at pH 5 and TPP 0.6 
mg/ml) produced the smallest and most quality nanoparticles of chitosan-TPP 
nanoparticles (with lowest PDI, homogenous suspension) with size 48 ± 6 nm, 
PDI = 0.1 ± 0.03 and positive charge (zeta potential = 32.1 ± 1.2 mv) (Table 
3.3). However, chitosan and dextran sulphate with parameters (chitosan 1 
mg/ml at pH 5 and dextran sulphate 3 mg/ml) produced the smallest and most 
quality nanoparticles of chitosan-dextran sulphate nanoparticles with size 145 
± 6 nm, PDI = 0.1± 0.05 and negative charge (zeta potential = -15.5 ± 1mv) 
(Table 3.4).   
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Table 3.3. Effect of pH and concentration of chitosan and mass ratio of the reactants on the physicochemical properties of blank 
chitosan-TPP nanoparticles 
Chitosan TPP 
Ch:TPP mass ratio Ch:TPP Molarity ratio pH Particle sizes nm PDI Zeta potential mv 
mg/ml µM mg/ml µM 
 
1 
 
0.002 
0.3 0.81 3:1 1:405 
4 
 
100 ± 9 0.3 ± 0.1 17 ± 1 
0.2 0.53 5:1 1:265 120 ± 8 0.3 ± 0.1 18.9 ± 1 
0.1 0.27 10:1 1:135 170 ± 9 0.3 ± 0.1 19.8 ± 0.9 
0.3 0.81 3:1 1:405 
5 
 
95 ± 10 0.3 ± 0.1 13.5±1 
0.2 0.53 5:1 1:265 108 ± 11 0.2 ± 0.05 17.5±0.5 
0.1 0.27 10:1 1:135 169 ± 9 0.3 ± 0.1 19.2±0.3 
0.3 0.81 3:1 1:405 
6 
 
135 ± 11 0.2 ± 0.05 11.2±0.2 
0.2 0.53 5:1 1:265 149 ± 12 0.3 ± 0.1 15.5±2 
0.1 0.27 10:1 1:135 190 ± 9 0.2 ± 0.04 17.5±0.9 
 
3 
 
0.008 
1 2.72 3:1 1:340 
4 
141 ± 10 0.2 ± 0.05 23.9 ± 1.2 
0.6 1.6 5:1 1:200 99 ± 6 0.2 ±0.02 34.3 ± 0.9 
0.3 0.81 10:1 1:101 220 ± 15 0.2 ±0.02 44.8 ± 1.9 
1 2.72 3:1 1:340 
5 
 
140 ± 9 0.2±0.03 22.9 ± 1.8 
0.6 1.6 5:1 1:200 48 ± 6 0.1 ±0.03 32.1 ± 1.2 
0.3 0.81 10:1 1:101 178 ± 12 0.3±0.02 40.2 ± 1.3 
1 2.72 3:1 1:340 
6 
 
174 ± 9 0.1 ±0.05 16.2 ± 1.2 
0.6 1.6 5:1 1:200 155 ± 8 0.2 ± 0.02 18.3 ±1.1 
0.3 0.81 10:1 1:101 340 ± 19 0.3 ± 0.1 18.7 ±1.1 
Data expressed as mean +/- SD (experiment was reproduced three times with confirmed similar data). The smallest size and PDI of these nanoparticles 
were 48 ± 6 nm and 0.1 ± 0.03 with positive surface charge (zeta potential = +32.1 ± 1.2) 
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Table 3.4. Effect of pH and concentration of chitosan and mass ratio of the reactants on the physicochemical properties of blank chitosan-dextran 
sulphate nanoparticles 
Chitosan (Ch) Dextran sulphate(Dx) 
Ch:Dx mass ratio Ch:DX Molarity ratio pH sizes nm PDI Zeta potential mv 
mg/ml µM mg/ml µM 
1 0.002 
3 0.075 1:3 1:37.5 
4 
160 ± 6 0.2 ± 0.05 -17.5 ± 1 
1 0.025 1:1 1:12.5 177 ± 9 0.3 ± 0.1 -8 ± 0.5 
0.3 0.007 3:1 1:3 190 ± 9 0.3 ± 0.1 +6 ± 1 
0.2 0.005 5:1 1:2.5 185 ± 8 0.3 ± 0.1 +8 ± 0.1 
3 0.075 1:3 1:37.5 
5 
145 ± 6 0.1 ± 0.05 -15.5 ± 1 
1 0.025 1:1 1:12.5 169 ± 9 0.3 ± 0.1 -7 ± 0.7 
0.3 0.007 3:1 1:3 170 ± 5 0.2 ± 0.04 +4 ± 1 
0.2 0.005 5:1 1:2.5 185 ± 8 0.3 ± 0.1 +5± 0.1 
3 0.075 1:3 1:37.5 
6 
230 ± 6 0.2 ± 0.04 -12 ± 1 
1 0.025 1:1 1:12.5 200 ± 6 0.4 ± 0.1 -6 ± 0.5 
0.3 0.007 3:1 1:3 210 ± 7 0.3 ± 0.1 +3 ± 0.5 
0.2 0.005 5:1 1:2.5 220 ± 5 0.4 ± 0.1 +4 ± 1 
3 0.008 
9 0.225 1:3 1:28 
4 
340 ± 12 0.3 ± 0.1 -33±7 
3 0.075 1:1 1:9.3 307 ± 12 0.3 ± 0.1 -10 ± 2 
1 0.025 3:1 1:3 332 ± 9 0.2 ± 0.04 +8 ± 2 
0.6 0.015 5:1 1:1.8 303 ± 6 0.4 ± 0.1 +10 ± 3 
9 0.225 1:3 1:28 
5 
270 ± 10 0.2 ± 0.05 -35±7 
3 0.075 1:1 1:9.3 279 ± 11 0.3 ± 0.1 -15 ± 4 
1 0.025 3:1 1:3 290 ± 11 0.3 ± 0.1 +6 ± 2 
0.6 0.015 5:1 1:1.8 285 ± 10 0.2 ± 0.05 +7 ± 1 
9 0.225 1:3 1:28 
6 
380 ± 10 0.2 ± 0.05 -39±7 
3 0.075 1:1 1:9.3 400 ± 11 0.3 ± 0.1 -19 ± 4 
1 0.025 3:1 1:3 380 ± 11 0.2 ± 0.05 +3 ± 2 
0.6 0.015 5:1 1:1.8 450 ± 10 0.2 ± 0.03 +4 ± 1 
data expressed as mean +/- SD (experiment was reproduced three times with confirmed similar data). The smallest size and PDI of these nanoparticles 
were 145 ± 6 nm and 0.1 ± 0.05 with negative surface charge (zeta potential = -15.5 ± 1) 
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3.3.3. Effects of AmB loading and freeze-drying with and without 
cryoprotectants on physicochemical properties and the morphology of 
the nanoparticles  
1- AmB loading increased the size of blank chitosan-TPP and dextran 
sulphate nanoparticles by 18.75% and 13% respectively. However, 
such loading did not cause any significant change to the zeta potential 
and PDI of both types of nanoparticles (Table 3.5) (p >0.05 by t-test). 
Freeze drying process without the use of a cryoprotectant (sucrose or 
D-mannitol) resulted in poor quality nanoparticles with various sizes 
for both blank and AmB loaded chitosan-TPP and chitosan-dextran 
sulphate nanoparticles. In contrast, the use of sucrose as a 
cryoprotectant produced good quality nanoparticles and caused 
39.5%, 17%, 21% and 6% increase in size for blank chitosan-TPP 
nanoparticles, blank chitosan-dextran sulphate nanoparticles, loaded 
AmB chitosan-TPP nanoparticles and loaded AmB chitosan-dextran 
sulphate nanoparticles respectively and did not lead to a significant 
difference in the zeta potential or PDI (p >0.05 by t test).  
2- D-mannitol as a cryoprotectant produced good quality nanoparticles, 
but caused 108%, 38%, 73% and 15.8% increase in size for blank 
chitosan-TPP nanoparticles, blank chitosan-dextran sulphate 
nanoparticles, loaded AmB chitosan-TPP nanoparticles and loaded 
AmB chitosan-dextran sulphate nanoparticles respectively and did not 
lead to a significant difference in the zeta potential (p >0.05 by t test). 
When the two cryoprotectants are compared, sucrose produced 
significantly smaller nanoparticles with lower PDI for both types of 
nanoparticles, p < 0.05 t-test) (Table 3.5, Fig 3.8).  
3- The morphological characteristics of blank chitosan-TPP or chitosan-
dextran sulphate nanoparticles and AmB loaded nanoparticles were 
examined using TEM and SEM which showed a spherical structure for 
both chitosan-TPP or chitosan-dextran sulphate nanoparticles. The 
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TEM and SEM measured size of the four formulations, which was 
comparable to values measured by DLS. The incorporation of AmB 
into the nanoparticles did not change the shape of these 
nanoparticles, just increased the sizes (Fig 3.9 and Fig 3.10).  
 
Table 3.5. Effect of cryoprotectants used during freeze drying on the 
physicochemical properties of unloaded and AmB loaded chitosan nanoparticles 
 
 
Nanoparticles  
Chitosan 
-TPP 
AmB 
loaded 
chitosan
– TPP 
Chitosan 
– dextran 
sulphate 
AmB 
loaded 
chitosan 
– 
dextran 
sulphate 
Size 
nm 
Before lyophilizing 48 ± 6 57 ± 7 145 ± 6 164 ± 5 
After 
lyophilizat
ion 
+ 
sucros
e 5% 
67 ± 7 69 ± 8 170 ± 9 174 ± 8 
+ D-
mannit
ol 5% 
100 ± 9 99 ± 9 200 ±10 200 ± 6 
PDI 
Before lyophilizing 0.1 ± 0.01 0.1 ± 0.03 
0.15 ± 
0.01 
0.16 ± 
0.01 
After 
lyophilizin
g 
+ 
sucros
e 5% 
0.25 ± 
0.05 
0.2 ± 0.01 
0.29 ± 
0.04 
0.26 ± 
0.01 
+ D-
mannit
ol 5% 
0.39 ± 
0.07 
0.4 ± 0.01 
0.42 ± 
0.06 
0.45 ± 
0.05 
Zeta 
potenti
al mv 
Before lyophilizing 32.1 ± 1.2 29 ± 2 -15.5 ± 1 -14 ± 2 
After 
lyophilizin
g 
+ 
sucros
e 5% 
28.5 ±1.9 25.5 ± 1 -12.9 ± 3 -11 ± 1 
+ D-
mannit
ol 5% 
27 ± 2 24 ± 1 -12.5 ± 2 -12 ± 2 
Data expressed as mean +/- SD (experiments were repeated three times with 
confirmed similar data). Sucrose more effectively protected the nanoparticles in 
comparison with D-mannitol (p < 0.05 by t-test). 
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Figure  3.8. Effectiveness of sucrose 5% and D-mannitol 5% as a cryoprotectant 
for freeze drying of blank and AmB loaded chitosan nanoparticles suspensions. 
1: Blank chitosan-TPP nanoparticles before lyophilizing, 2: Blank chitosan-TPP 
nanoparticles after lyophilizing + sucrose 5%, 3: Blank chitosan-TPP 
nanoparticles after lyophilizing + D-mannitol 5%, 4: AmB  loaded chitosan-TPP 
nanoparticles before lyophilizing, 5: AmB loaded chitosan-TPP nanoparticles 
after lyophilizing + sucrose 5%, 6: AmB loaded chitosan-TPP nanoparticles after 
lyophilizing + D-mannitol 5%, 7: Blank chitosan-dextran nanoparticles before 
lyophilizing, 8: Blank chitosan-dextran nanoparticles after lyophilizing + sucrose 
5%, 9: Blank chitosan-dextran after lyophilizing + D-mannitol 5%, 10: AmB 
loaded chitosan-dextran nanoparticles before lyophilizing, 11: AmB loaded 
chitosan-dextran after lyophilizing + sucrose 5%, 12: AmB  loaded chitosan-
dextran nanoparticles after lyophilizing + D-mannitol 5%. data expressed as 
mean +/- SD (experiment was reproduced three times with confirmed similar 
data).   
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Figure  3.9. TEM micrographs of unloaded and amphotericin B loaded chitosan  
nanoparticles. A: Unloaded chitosan–TPP nanoparticles, B: AmB loaded chitosan–
TPP nanoparticles, C: Unloaded chitosan – dextran sulphate nanoparticles, D: AmB 
loaded chitosan–dextran sulphate nanoparticles. TEM images indicate the 
nanoparticles to be spherical. Magnification: 40000x  
 
A B 
C D 
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3.3.4. Stability of physicochemical properties of AmB loaded chitosan 
nanoparticles 
Both AmB loaded chitosan-TPP and chitosan-dextran sulphate nanoparticles 
did not show any significant change in their size or zeta potential at 
temperatures of 4, 34 and 37 °C when incubated in different media (water, 
PBS or RPMI at pH 7.5 or 6.5) or in mouse (BALB/c) plasma at 4 °C for a 
period of 30 days which indicated a high stability of these nanoparticles 
(Tables 3.6 and 3.7, Fig 3.11). Moreover, no significant difference in PDI was 
identified after 30 days in these different conditions.  
  
  
Figure  3.10. SEM micrographs of unloaded and amphotericin B loaded chitosan 
nanoparticles. A: Unloaded chitosan–TPP nanoparticles, B: AmB loaded 
chitosan–TPP nanoparticles, C: Unloaded chitosan – dextran sulphate 
nanoparticles, D: AmB loaded chitosan–dextran sulphate nanoparticles. SEM 
images indicate the nanoparticles to be spherical and with similar sizes with the 
zetasizer . Magnification 50000x 
A B 
C D 
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Figure  3.11. Size of AmB loaded chitosan-TPP nanoparticle (A) and AmB loaded 
chitosan-dextran sulphate nanoparticle (B) in different media over time. The 
nanoparticles were stable in size after 30 days of storage in different media and 
temperatures. Data expressed as mean +/- SD (experiment was reproduced three 
times with confirmed similar data). 
121 
 
Table 3.6. Variations of physicochemical properties of AmB loaded chitosan-TPP nanoparticles in different media upon storage at different 
temperatures 
 
Day 0 Day 1 Days 7 Days 30 
Size 
nm 
PDI 
Zeta 
potential 
mv 
Size 
nm 
PDI 
Zeta 
potential 
mv 
Size 
nm 
PDI 
Zeta 
potential 
mv 
Size 
nm 
PDI 
Zeta 
potential 
mv 
Water at 4, 
34 or 37 ° C 
70 ± 6 0.1± 0.02 25.5 ± 1 74 ± 5 0.2 ± 0.01 23.4 ± 1 73 ± 5 0.2 ± 0.1 24.0 ± 1 76 ± 5 0.2 ± 0.1 23.9 ± 1 
PBS at 4, 34 
or 37 ° C 
73± 5 0. ± 0.01 23.3 ± 1 75 ± 4 0.1 ± 0.02 22.9 ± 2 77 ± 4 0.2 ± 0.1 22.5 ± 1 79 ± 5 0.2 ± 0.1 21.9 ± 1 
RPMI 
(pH=7.5) at 
4, 34 or 37 ° 
C 
75 ± 6 0.2 ± 0.1 24.1± 1 79 ± 7 0.2 ± 0.05 22.9 ± 1 80 ± 7 0.2 ± 0.1 22.8 ± 1 81± 6 0.2± 0.1 22.1 ± 1 
RPMI 
(pH=6.5) at 
4, 34 or 37 ° 
C 
68 ± 7 0.1 ± 0.01 32 ± 6 74 ± 5 0.2 ± 0.09 30 ± 4 77 ± 5 0.1 ± 0.1 29 ± 3 77 ± 9 0.2± 0.1 30 ± 3 
Plasma at 4 
° C 
75 ± 7 0.1 ± 0.01 29 ± 6 77 ± 6 0.2 ± 0.03 30 ± 4 79 ± 8 0.2 ± 0.1 29 ± 3 80 ± 7 0.3 ± 0.1 29 ± 4 
data expressed as mean +/- SD (experiment was reproduced three times with confirmed similar data). No significant difference was shown in the 
size, PDI or zeta potential between two types of the nanoparticles after 30 days storage (p >0.05 by t – test). 
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Table 3.7. Variations of physicochemical properties of AmB loaded-chitosan dextran sulphate nanoparticles in different media upon storage at 
different temperatures 
 
Day 0 Day 1 Days 7 Days 30 
Size 
nm 
PDI 
Zeta 
potential 
mv 
Size 
nm 
PDI 
Zeta 
potential 
mv 
Size 
nm 
PDI 
Zeta 
potential 
mv 
Size 
nm 
PDI 
Zeta 
potential 
mv 
Water at 4, 
34 or 37 ° C 
180 ± 6 0.2± 0.1 -14 ± 5 187 ± 5 0.2± 0.1 -16 ± 5 186 ± 5 
0.2± 
0.1 
-17 ± 5 
186 ± 
5 
0.2± 0.1 -17 ± 5 
PBS at 4, 34 
or 37 ° C 
177 ± 5 0.2 ± 0.1 -15 ± 5 178 ± 4 0.2 ± 0.1 -14 ± 5 183 ± 4 
0.2 ± 
0.1 
-17 ± 5 
182 ± 
4 
0.2 ± 0.1 -17 ± 5 
RPMI 
(pH=7.5) at 
4, 34 or 37 ° 
C 
180 ± 6 0.2 ± 0.1 -20 ± 5 183 ± 7 0.2 ± 0.1 -17 ± 5 183 ± 7 
0.2 ± 
0.1 
-19 ± 5 
180 ± 
7 
0.2 ± 0.2 -19 ± 5 
RPMI 
(pH=6.5) at 
4, 34 or 37 ° 
C 
175 ± 7 0.2 ± 0.1 -11 ± 5 178 ±5 0.2 ± 0.1 -14 ± 5 177 ± 5 
0.2 ± 
0.1 
-13 ± 5 
181 ± 
5 
0.2 ± 0.1 -13 ± 5 
Plasma at 4 
° C 
177 ± 7 0.2 ± 0.1 -15 ± 5 179 ±5 0.2 ± 0.1 -17 ± 5 181 ± 5 
0.3 ± 
0.1 
-13 ± 5 
187 ± 
6 
0.2 ± 0.1 -14 ± 5 
data expressed as mean +/- SD (experiment was reproduced three times with confirmed similar data). No significant difference was shown in 
the size, PDI or zeta potential between two types of the nanoparticles after 30 days storage (p >0.05 by t – test). 
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3.3.5. Nanoparticles loading and encapsulation properties 
Both types of nanoparticles had a high encapsulation efficiency of more than 
90%. The fluffy yellow yield was more than 90% for both types (Table 3.8). 
There was no significant difference in AmB loading between chitosan TPP and 
dextran sulphate nanoparticles (p>0.05 by t-test) (Fig 3.12). 
 
Table 3.8. Percentage of AmB loading, encapsulation and yield 
Type of nanoparticles EE %  AmB loading %  Yield %  
AmB loaded chitosan-TPP nanoparticles 94 ± 5 26 ± 1 93 ± 6 
AmB loaded chitosan-dextran sulphate  
nanoparticles 
92 ± 8 23 ± 2 92 ± 6 
data expressed as mean +/- SD (experiment was reproduced three times with 
confirmed similar data). No significant difference was shown between AmB loaded 
chitosan-TPP and dextran sulphate nanoparticles (p>0.05 by t-test). AmB loaded 
chitosan-TPP nanoparticles size= 69 ± 8 nm and AmB loaded chitosan-dextran 
sulphate nanoparticles size= 174 ± 8 nm  
 
The encapsulation efficiency AmB loading Yield  
0
20
40
60
80
100
%
AmB loaded chitosan-TPP nanoparticles
AmB loaded chitosan-dextran sulfate nanoparticles
 
Figure  3.12. Comparison of AmB encapsulation, loading and yield of the two types 
of nanoparticles. No significant difference was shown between AmB loaded 
chitosan-TPP and dextran sulphate nanoparticles regarding the encapsulation, 
loading and yield (p>0.05 by t-test). Data expressed as mean +/- SD (experiment 
was reproduced three times with confirmed similar data). AmB loaded chitosan TPP 
nanoparticles size= 69 ± 8 nm and AmB loaded chitosan dextran sulphate 
nanoparticles size= 174 ± 8 nm  
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3.3.6. In vitro release of AmB from the nanoparticles 
AmB release from the two types of nanoparticles is shown in Fig 3.13 and 
Table 3.9. The chitosan-TPP and chitosan-dextran sulphate nanoparticles 
showed a slow release within 7 days in PBS (at two pH values of 7.5 and 6.5) 
at three temperatures 4, 34 and 37 ° C and in mouse (BALB/c) plasma at 37 ° 
C. Chitosan-TPP nanoparticles released AmB significantly quicker than 
chitosan-dextran sulphate nanoparticles at the different conditions 
(nanoparticle suspended in plasma or PBS and at different pHs and 
temperatures) (p<0.05, one-way-ANOVA). Neither AmB loaded chitosan-TPP 
nanoparticles nor AmB loaded chitosan-dextran sulphate nanoparticles 
showed any significant difference in the drug release after storing at 34 ° C or 
37 ° C (p>0.05 by t -test) (Fig 3.13, Table 3.9). However, the pH influenced the 
drug release significantly with both types of nanoparticles, showing higher 
cumulative releases at the lower pH of 5 than at higher pH of 6.5 or 7.5 (p<0.05 
by t-test) (Table 3.9 and Fig 3.13).  
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Table 3.9. In vitro cumulative release of AmB from the two formulations at different conditions 
Type 
6 h 
% 
24 h 
% 
48 h 
% 
72 h 
% 
96 h 
% 
120 h 
% 
144 h 
% 
168 h 
% 
AmB loaded chitosan–dextran 
sulphate nanoparticles 
 
PBS, pH 
7.4 
4 °C 0.1 ±0.05 1±0.05 2.2±0.4 5.2±1 7.5±2 9.5±2 11±2 15±2 
34 ° C 0.3±0.1 2.5±0.2 5.2±1 8.5±2 10±3 13.5±2 16.4±3 20±3 
37 ° C 0.1±0.02 2±0.1 4.4±1 6.9±1 9.1±2 12.5±3 15.5±3 18.5±2 
PBS, pH 
6.5 
4 ° C 0.2±0.02 2±0.2 3.1±1 4.9±1 6.9±1 8.9±1 11.5±2 15.9±2 
34 ° C 0.4±0.1 4±0.5 7.3±2 9.2±3 13.1±3 15±2 17.2±4 21.2±2 
37 ° C 0.1±0.05 2.9±0.4 5.4±1 7.9±2 10.1±2 12.2±2 16.5±3 19.5±3 
PBS, pH 
5 
4 ° C 0.2±0.05 3.5±1 9.5±2 16.1±4 17.2±3 20.2±3 21.1±4 32.2±4 
34 ° C 0.5±0.1 7.5±2 14.5±3 20.9±5 23±4 24.9±3 27.5±4 41.9±5 
37 ° C 0.3±0.1 6.5±1 13.5±3 20.1±4 21.2±5 24.2±3 26.1±3 38.2±4 
Plasma 37 ° C 0.2±0.05 4.1±1 8.1±1 9.2±2 10.1±2 12±2 14.9±2 22.9±3 
AmB loaded chitosan –TPP 
nanoparticles 
PBS, pH 
7.4 
4 ° C 0.5±0.1 5.1±1 9.2±1 11.5±2 13.8±2 15.9±1 18.9±2 22.9±3 
34 ° C 1.2±0.3 9.9±2 15.6±2 20.6±3 24.5±5 26±4 28.9±5 32.5±2 
37 ° C 1 ±0.2 10 ±2 14.9 ±3 19.5 ±2 23.5 ±5 24.5 ±3 27.5 ±4 31.5 ±5 
PBS, pH 
6.5 
4 ° C 0.3±0.1 4.1±1 10.2±2 12.5±2 15.8±5 17.9±2 19.9±3 24.5±3 
34 ° C 1.5±0.3 10.5±2 16.4±4 21.9±4 26.3±5 27.8±3 29.8±5 32.5±3 
37 ° C 1.2±0.4 9.8±1 15.2±3 20.2±3 24.1±5 25.6±4 28±4 32.6±2 
PBS, pH 
5 
4 ° C 0.9±0.2 16.5±3 19.8±3 25.5±4 26.2±4 34.5±4 40.2±6 47.5±4 
34 ° C 1.5±0.4 21.2±4 27.2±5 31.2±3 34.6±6 39.8±5 41.9±5 50.8±6 
37 ° C 1.7±0.4 20.2±3 26.5±6 30.2±4 33.1±4 40.2±5 45.2±5 51.2±6 
Plasma 37 ° C 1.7±0.3 11.2±2 14.5±4 20.9±2 25.3±3 27.3±4 29.9±4 33.6±5 
AmB solution 
PBS, pH 
7.4 
4 ° C 84±2 100±1 0 0 0 0 0 0 
34 ° C 85±2 100±2 0 0 0 0 0 0 
37 ° C 86±3 100±2 0 0 0 0 0 0 
PBS, pH 
6.5 
4 ° C 83±1 100±1 0 0 0 0 0 0 
34 ° C 86±2 100±3 0 0 0 0 0 0 
37 ° C 88±4 100±2 0 0 0 0 0 0 
4 ° C 84±1 100±2 0 0 0 0 0 0 
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PBS, pH 
5 
34 ° C 85±1 100±2 0 0 0 0 0 0 
37 ° C 87±2 100±2 0 0 0 0 0 0 
Plasma 37 ° C 85±2 100±2 0 0 0 0 0 0 
Data expressed as mean +/- SD (experiment was reproduced three times with confirmed similar data). Both types of nanoparticles showed 
significantly more cumulative release in the low pH of 5 than in higher pH of 6.5 or 7.5(p<0.05 by t-test). The AmB release from chitosan-
TPP nanoparticles was faster than chitosan dextran sulphate nanoparticles (p < 0.05 by t – test).  AmB loaded chitosan-TPP nanoparticles 
size= 69 ± 8 nm and AmB loaded chitosan-dextran sulphate nanoparticles size= 174 ± 8 nm  
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Figure  3.13. In vitro release profile of AmB loaded chitosan nanoparticles at 37 ° C. A: AmB loaded chitosan-dextran sulphate nanoparticles 
in PBS (pH of 5, 6.5 or 7.5) and mouse (BALB/c) plasma, B: AmB loaded chitosan-TPP nanoparticles in PBS (pH of 5, 6.5 or 7.5) and mouse 
A - dextran sulphate  B - TPP 
C - comparison 
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(BALB/c) plasma and C:  comparison of AmB release from AmB solution, AmB loaded chitosan-TPP nanoparticles and AmB loaded chitosan 
dextran sulphate nanoparticles in PBS at pH 5 and 7.5. Data expressed as mean +/- SD (experiment was reproduced three times with 
confirmed similar data). AmB loaded chitosan-TPP nanoparticles size= 69 ± 8 nm and AmB loaded chitosan-dextran sulphate nanoparticles 
size= 174 ± 8 nm 
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3.4. Discussion 
Blank and AmB loaded chitosan-TPP and chitosan-dextran sulphate 
nanoparticles were successfully produced via the inotropic gelation method. 
Homogeneously dispersed nanoparticles with different sizes from 50 nm to 
around 400 nm, with low PDI, and with positive or negative surface charge 
were synthesised. The effects of experimental conditions and parameters 
(initial concentration of chitosan, chitosan: TPP or chitosan: dextran sulphate 
mass ratios, pH of chitosan solution and sonication time) on the 
physicochemical properties of the nanoparticles (size, PDI and charge) were 
determined. The aim was to create positively and negatively charged 
nanoparticles with the smallest size and lowest PDI. The PDI value indicates 
dispersion homogeneity and the distribution of the nanoparticles sizes in the 
sample and high PDI means variable ranges of sizes in the sample while lower 
PDI reflects constantly sized nanoparticles (253). We aimed and succeeded 
in synthesising the smallest sizes for both types of nanoparticles, as smaller 
nanoparticles with size 100 nm showed a 2.5-fold higher uptake in Caco-2 
cells than larger particles with size 1 µm and a 6-fold higher uptake than 
particles sized 10 µm (254). Additionally, nanoparticles with small size have 
exhibited maximum deposition of their content in the skin dermis (after topical 
application) and small nanoparticles can facilitate macrophage targeting 
residence in the skin (after intravenous injection) (32, 246, 255, 256). 
Subsequently, smaller nanoparticles in literatures offered higher uptake rates, 
more permeability through skin and higher targeting to skin and these 
properties are substantial in CL treatment.  
A paper reported that negatively charged nanoparticles are taken up 
significantly more than positively charged nanoparticles by Caco-2 epithelial 
cells (257).   
This encouraged us to prepare two types of chitosan nanoparticles (positive 
and negative charged nanoparticles with smallest possible size).  
 
Influence of reactant mass ratio on the nanoparticles  
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We indicated that the optimal mass ratio to obtain good quality nanoparticles 
with smallest size and lowest PDI was 5:1 for chitosan: TPP (at chitosan 3 
mg/ml) and this was consistent with literatures (258, 259). It was shown that 
at this ratio, TPP anions are adequately incorporated into chitosan and as a 
result, a further boost in the cross-linking and tightening of the chitosan chains 
within the particle result, which explains the decrease in the nanoparticles 
sizes, as previously speculated by Masarudin et al (2015) (253). Regarding 
dextran sulphate, a mass ratio 1:3 of chitosan: dextran sulphate (at chitosan 1 
mg/ml) gave the smallest nanoparticles size and the lowest PDI and this is 
similar with another published report published by Tiyaboonchai et al (238). 
As a more concentration of dextran sulphate in comparison with chitosan might 
increase the level of complexation of the nanoparticles and the chitosan chains 
can become entangled to a great extent (238, 260).  
 
Influence of initial concentration of chitosan on the nanoparticles  
We showed that using a high initial concentration of chitosan (9 mg/ml) led to 
poor quality and aggregation of nanoparticles and this was in agreement with 
a previously published report (261). At this high concentration of chitosan, 
more molecules of chitosan tend to entangle with each other and crosslink with 
counter ion (TPP) or sulphate groups of dextran sulphate to form larger 
particles (261) and moreover, this aggregation could be attributed to the higher 
number of positive groups as these positive groups can make the chitosan 
chain to stretch because of the intra chitosan chain repulsion (133, 262, 263). 
  
Influence of pH of chitosan solution on the nanoparticles  
Additionally, the pH of chitosan solution played an important role in the quality 
of the nanoparticles. The synthesized nanoparticles were aggregated and of 
poor quality at pH 3 and pH 7. At pH 3, chitosan is highly protonated with high 
charge density. While at pH 7, chitosan has a low charge and is partially 
solubilized. The greater positive charge at pH 3 can make the chitosan chain 
stretch because of the intra molecular repulsion while at higher pH of 7, there 
is a large reduction in the protonation degree of the nanoparticles and that 
large leads to reduce the inter particles electrostatic repulsion among these 
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nanoparticles. Therefore, there is a higher possibility of the aggregation (133, 
262).  
 
Zeta potential of the nanoparticles and the Influence of sonication 
duration on the nanoparticles  
Zeta potential of the nanoparticles increased with increasing concentration 
and with decreasing pH of the initial chitosan solution used. This increase in 
zeta potential values could be explained as; the higher concentration of 
chitosan leads to more total amino groups and consequently more protonated 
positive -NH3+ on the surface of the nanoparticles and lower pH of chitosan 
solution results in more positive amino groups (133, 262). To assess the 
influence of sonication time on the physicochemical characteristics of 
nanoparticles, the prepared nanoparticle dispersions were subjected to 
sonication for 1, 5, 15 and 20 mins. The sonication duration had a critical role 
in the quality of nanoparticles as sonicating for 15 mins resulted in favoured 
nanoparticles and this was in accordance with other reports. Too little 
sonication duration is insufficient to break the aggregation of the nanoparticles 
and after 20 mins the aggregation cannot be further broken so size and PDI 
remain constant (264, 265, 266). 
 
The freeze drying process of the nanoparticles  
The freeze drying process causes many stresses related to freezing and 
dehydration and these stresses can destabilize the nanoparticles suspensions 
and lead to poor quality and aggregation of the nanoparticles (242). This is 
what we found in our study. Therefore, it is recommended to use protectants 
for the nanoparticles to protect them from the freeze and dry stress. The most 
common cryoprotectants used in literatures are sugars as they can form a 
glassy matrix that can protect the nanoparticles from the mechanical stress 
and avoid aggregation, so we used D-mannitol and sucrose in our study. We 
determined that sucrose had a greater protective (2-3 x) effect on both types 
of nanoparticles than D-mannitol. A similar finding has previously been 
reported that sucrose is more successful than D-mannitol in protecting the 
nanoparticles from the lyophilisation (267) possibly due to the fact that sucrose 
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does not crystallize during lyophilisation process, unlike D-mannitol, as 
previously reported (242). 
 
Stability of the nanoparticles and their AmB encapsulation and loading 
properties  
We found that blank and AmB loaded chitosan-TPP or chitosan-dextran 
sulphate nanoparticles were stable in terms of size and zeta potential for 30 
days at different temperatures (4, 34 and 37 ° C) and in different media (water, 
PBS, RPMI and mouse (BALB/c) plasma). Another published report showed 
that sizes of AmB loaded chitosan-TPP nanoparticles were stable for 6 months 
in water at 4° C and at room temperature and chitosan-dextran nanoparticles 
were stable in terms of sizes and zeta potential for 4 weeks (240, 268). The 
encapsulation efficacy of AmB in both types of nanoparticles was around 90% 
and similar data was reported for AmB encapsulation in chitosan nanoparticles 
with TPP (80%) or with chondroitin sulphate (90%) (122, 240). While the 
loading of AmB was 23% and 26% w/w for chitosan-TPP and chitosan-dextran 
sulphate nanoparticles respectively with two times more loading in comparison 
with chitosan chondroitin sulphate nanoparticles (122). 
 
AmB release from the nanoparticles  
The release profiles of AmB from AmB solution (as a control) through synthetic 
membrane was significantly higher than from AmB loaded chitosan-TPP or 
chitosan-dextran sulphate nanoparticles (p<0.05 by t test). The nature of the 
complexation agent (TPP or dextran sulphate) did not influence the slow AmB 
release from both types of nanoparticles in PBS and mouse plasma. The 
nanoparticles stability in plasma (size and charge) and slow release of AmB in 
plasma would ensure that AmB does not bind to low density plasma 
lipoproteins thereby avoiding any potential AmB toxicity. This is consistent with 
another study of stability of a noncovalent complex of amphotericin B (AmB) 
with poly(α-glutamic acid) (PGA) in mouse CD/1 serum (118). Both types of 
chitosan nanoparticles exhibited a pH-dependent AmB release, with a greater 
release at a low pH of 5 than at higher pH of 7.5. This is likely to be due to the 
higher solubility of chitosan in acidic media (269). 
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Drug release from chitosan-TPP nanoparticles was faster than from chitosan-
dextran sulphate nanoparticles and this could be explained as chitosan-TPP 
nanoparticles are significantly smaller than chitosan-dextran sulphate 
nanoparticle. The resulting larger surface area to volume ratio of chitosan-TPP 
nanoparticles would allow greater AmB release from the surface of the 
nanoparticles as more of the drug is closer to the surface (254). The negatively 
charge of chitosan-dextran sulphate nanoparticles would also play a role in 
slower release which reported previously of insulin release (270).   
3.4.1. Conclusion 
In summary, we successfully prepared two different types of AmB loaded 
chitosan nanoparticles, one smaller size nanoparticle with positive surface 
charge and the other with larger size and negative charge. The synthesized 
nanoparticles were able to efficiently encapsulate AmB. Different parameters 
such as chitosan concentration, chitosan: TPP or chitosan: dextran sulphate 
mass ratio and chitosan solution pH significantly affected the physicochemical 
characterization of the nanoparticles. Both positive and negative nanoparticles 
showed a high stability in terms of size and at different temperatures. As 
expected, these nanoparticles exhibited a prolonged AmB release. Therefore, 
they appear to be good candidates for further investigation into their anti-
leishmanial activity by different routes of administration.  
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4. In vitro and in vivo activity of chitosan formulations in 
experimental cutaneous leishmaniasis 
4.1. Introduction 
The intravenous AmB (as mentioned in the introduction) is one of the available 
second-line drugs for leishmaniasis which acts by forming pores in the cell 
membrane of Leishmania via complexation with ergosterol. However, the use 
of the conventional deoxycholate amphotericin B (Fungizone) is clinically 
limited because of the infusion-related side effects such as, fever, nausea, 
vomiting, rigours and two more serious effects: anaemia and nephrotoxicity 
(271, 272). A great interest of research to develop the drug delivery system of 
AmB in leishmaniasis treatment arises. Accordingly, liposomal formulation 
(AmBisome®, size= 70-80 nm (272, 273)) with a better tolerated profile and 
low toxicity issues was developed and approved by FDA for the treatment of 
VL. It has showed clinical effectivity in CL patients, in multiple doses (3 mg/kg 
daily for a total of 21 mg/kg) (272, 274). Although AmBisome® is on the WHO 
Essential Medicines List, this formulation has some limitations in terms of the 
high price (at least 200 USD$ per vial of 50 mg, is donated by Gilead via WHO 
for free for VL, not for CL ), the need for cold chain, shelf-life related issues, 
slow infusion and the difficult to access the drug in many countries (170, 275, 
276). Moreover, AmBisome® has a complex production process and an 
increase in particles size and a change in the drug content upon storage of 
AmBisome® have been reported (during 72 h of storage) (276, 277). 
Other drug delivery systems (DDs) used in the Leishmania field encounter 
some disadvantages summarised in Table 4.1, in addition to accumulation of 
lipid in liver and spleen caused by the lipidic formulations that may cause 
pathological conditions (278).  
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Table 4.1. Disadvantages of different DDs (67, 112, 279, 280, 281, 282, 283, 
284) 
DDs Disadvantages 
Liposomes 
High cost, low stability and using an organic solvent in the 
preparation 
Niosomes 
Instability, leaking of entrapped drug and Hydrolysis of 
encapsulated drugs which limiting the shelf life of the 
dispersion 
Nanodiscs 
Lack of size control, using an organic solvent and other 
drawback is the precipitation under low pH<6 
Emulsions 
The need to use a high concentration of surfactants and 
cosurfactant, stability highly influenced by pH and 
temperatures and desorption of surfactants  
Solid lipid 
nanoparticle 
Organic solvent, low drug loading efficiency, fast drug burst 
release and the possibility of drug expulsion during storage 
because of the crystalline structure  
 
Polymeric nanoparticles, prepared by inotropic gelation method (formed by 
interactions between two oppositely charged molecules ), have gained a great 
interest in the DDs, with advantages over other DDs as their preparation is 
usually at lower costs, simple, quick ,does not require the use of organic 
solvents (generally) and the long shelf life of these nanoparticles at room 
temperature (114)  
In Chapter 3, we successfully synthesised two types of AmB loaded 
nanoparticles (one was positively charged by using TPP and the other was 
negatively charged by using dextran sulphate) by using ionotropic gelation 
methods without using any organic solvents. This process was fast, simple 
and with low cost of 55 USD$ approx. for 1 g of AmB nanoparticles. These 
nanoparticles, in contrast to liposomal formulations, showed a high stability in 
different media (water, PBS, RPMI and mouse (BALB/c) plasma) at different 
temperatures for a period of 30 days, and they showed a slow drug release in 
these media. All these characteristics of AmB loaded chitosan nanoparticles 
(the high stability for a long time in different conditions in terms of size and 
charge, slow drug release, easy preparation method and low cost etc), made 
them a suitable candidate for further investigations for CL treatment.  
In the literature, chitosan nanoparticles have shown a good activity against a 
wide range of microbes and are sometimes more active than chitosan solution 
(MMW and HMW) (Table 4.1). Some studies showed that both chitosan 
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solution and chitosan nanoparticles have the same antimicrobial mechanism 
i.e. by interacting with microbial cell membrane or binding with microbial DNA 
(285). AmB encapsulated in different types of chitosan nanoparticles has been 
evaluated against leishmaniasis with promising results in vitro and in vivo and 
the studies are summarised in Table 4.2. Most of these studies used positively 
charged nanoparticles with a size greater than 100 nm. In contrast, we decided 
to investigate smaller nanoparticles (for possible skin permeation, and as 
smaller size of nanoparticles facilitates a passive transport from blood vessels 
to tissues when administrated intravenously and can enhance the 
extravasation in the inflamed lesions on the skin and can facilitates 
macrophage targeting residence in the skin (255, 256) ), with positive charge 
(when prepared with TPP) or negative charge (when prepared with dextran 
sulphate) to identify any influence of nanoparticle charge.   
Therefore, this chapter aimed to evaluate: 
(i) the in vitro activity of blank and amphotericin B loaded chitosan TPP 
or dextran sulphate nanoparticles against L. major and L. mexicana 
promastigotes and amastigotes  
(ii) the in vivo anti-leishmanial activity of blank and amphotericin B 
loaded chitosan TPP or dextran sulphate nanoparticles (through 
intravenous route) in murine models of CL caused by L. major  
(iii) the permeation of these nanoparticles and chitosan solution through 
BALB/c skin by a Franz diffusion study.  
We did not include HMW chitosan solution in the intravenous route of the in 
vivo study as its diluted acid solutions were too viscous and this makes it very 
difficult and not suitable for mice intravenous route (HMW chitosan viscosity is 
800-2000 cP, 1 wt. % in 1% acetic acid) (286, 287).  
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Table 4.2. Antimicrobial activity of chitosan nanoparticles (285) 
Nanoparticles Microbes Results 
Chitosan nanoparticles 
(Chitosan, MW 220 
KDa) 
Staphylococcus aureus 
Escherichia coli 
Chitosan nanoparticles were 
more effective than chitosan 
solution and 
doxycycline(288) 
Chitosan nanoparticles 
(LMW) 
Streptococcus mutans 
 
Inhibited biofilm formation 
(289) 
 
Chitosan-silver 
nanocomposites 
(HMW) 
Staphylococcus aureus 
 
A synergistic antimicrobial 
activity between chitosan 
and silver nanomaterials 
(290) 
Chitosan nanoparticles 
(Chitosan, MW 310 
KDa) 
Candida albicans 
 
Chitosan nanoparticles were 
more active than chitosan 
with lower MIC50 (291) 
AmB loaded chitosan 
nanoparticles (LMW) 
Candida albicans 
 
Chitosan nanoparticles 
showed similar activity to 
AmB with 
higher corneal 
penetration(292) 
138 
 
Table 4.3. Anti-leishmanial activity of AmB loaded chitosan nanoparticles 
DDS Preparation method Nanoparticles 
properties 
Toxicity Ant-leishmanial activity 
Nanoemulsion 
based chitosan 
nanocapsule 
entrapping AmB 
First, an oil-in-water 
(o/w) nanoemulsion 
was formulated by 
modified spontaneous 
emulsification solvent 
evaporation. Secondly 
nanocarrier was 
generated by coating 
with chitosan 
deposition on the 
water-oil surface 
Size= 146 ± 9 nm 
Zeta potential= 
+29±0.8 mV 
AmB DDS was 
significantly less 
toxic against the 
J774A cell line 
 
In vitro: EC50 for AmB DDs, AmBisome® 
and Fungizone was 0.19±0.04, 0.29 ± 0.03 
and 0.48 ± 0.05 μg/ml respectively against 
L. donovani promastigotes 
 
In vivo: L. donovani infected hamster 
model received (i.p.) AmB-loaded 
formulations at 1 mg/kg on 5 consecutive 
days. AmB DDS, AmBisome® and 
Fungizone caused 86 ±2%, 
70 ±3 % and 56 ±4% inhibition of 
amastigotes in spleen. (219) 
 
Chitosan-coated solid 
lipid nanoparticles were 
developed and loaded 
with 
amphotericin B 
Solvent emulsification-
evaporation 
Size= 159 ±25 nm In mice model, 
AmB DDS was 
significantly ten-
fold less toxic than 
pure AmB solution 
and was safe up to 
AmB concentration 
equivalent to 5 
mg/kg body weight. 
 
In vitro: EC50 of AmB DDs, AmBisome® 
and Fungizone was 0.046±0.02, 
0.157±0.03 and 0.320±0.08 μg/ml 
respectively against L. donovani 
amastigotes infecting adherent mouse 
macrophage cell line J774A.1 (259) 
AmB loaded pluronic 
F127 (PF 127) micelles 
coated with chitosan 
Thin film hydration Size= 139 ± 3 to 
170 ± 53 nm                               
Zeta potential= 
+11.0 ± 2 to +53 ± 
5 mV 
AmB DDS was ten-
fold less toxic than 
pure AmB solution 
against J774A.1 
cell 
In vitro: EC50 of AmB DDS, and AmB 
solution 0.05 and 0.09 μg/ml respectively 
against L. donovani amastigotes infecting 
macrophage cell line J774A.1(293) 
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AmB loaded chitosan 
nanoparticles 
Inotropic gelation 
method (between 
chitosan positively 
charged and 
chondroitin sulphate 
negatively charged 
Size= 136±11 nm 
Zeta potential= 
+8.4 to +30.2 mV 
Cytotoxicity against 
murine 
macrophages of 
AmB DDs was 
nearly ten-fold less 
compared to pure 
AmB solution 
In vitro: EC50 of AmB DDS and AmB was 
1±0 and 0.1±0 respectively (AmB DDS 
was less active) against L. amazonensis 
and 0.1±0 and 0.1±0 μg/ml respectively 
against L. chagasi (AmB DDS had similar 
activity to AmB). AmB DDs and AmB 
caused 90% and 89% 
reduction of L. amazonensis internalized 
macrophages (%)(122) 
AmB loaded chitosan 
nanoparticles 
Inotropic gelation 
method (between 
chitosan positively 
charged and 
chondroitin sulphate 
negatively charged 
Size= 136±11 nm 
Zeta -potential= 
+8.4 to +30.2 mV 
Cytotoxicity against 
murine 
macrophages of 
AmB DDs was 
nearly ten-fold less 
compared to pure 
AmB 
In vivo: L. amazonensis infected BALB/c 
mice received (i.v.)1 mg of drug/kg daily 
for 10 days. AmB DDs treated mice 
showed a smaller lesion size which was 
sustained up to 30 days after the 
treatment compared with AmB treated 
group(83) 
AmB loaded chitosan 
nanoparticles 
Phase separation 
method by mixing 
chitosan - TPP 
nanoparticles with AmB 
solution under stirring 
for 7 days 
Size= 112 nm 
Zeta potential= 
+8mV 
Mortality in mice 
received (i.p.) AmB 
solution 10 mg/kg 
was 10% while 0% 
in mice received 
AmB nanoparticles 
(10 mg/kg AmB 
equivalent) every 
other day for 3 
weeks 
In vitro: L. major promastigote killing (%): 
82% at 20 µg/mL. L. major amastigote 
killing (%): 78% at 20 µg/mL. 
In vivo: L. major infected BALB/c mice 
received (i.p.) AmB nanoparticles of 10 
mg/kg while the positive control mice 
received AmBisome® of 50mg/kg. There 
was no significant difference in the efficacy 
of the two formulations and caused 100% 
reduction of lesion size. (294) and 
https://www.dovepress.com/comparative-
analysis-between-four-model-
nanoformulations-of-amphoteric-peer-
reviewed-article-IJN 
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4.2. Material and methods 
4.2.1. Preparation of blank and AmB loaded chitosan nanoparticles 
All nanoparticles in this study were prepared and characterised as described 
in Chapter 3 in sections 3-2-1- and 3-2-2-, within the parameters (10 ml of 
HMW chitosan solution (30 mg in 10 ml AC 1%),10 mg of AmB (Purity ≥ 95%, 
Cambridge Bioscience, UK) dissolved in 0.5 ml of DMSO (pure AmB), 10 ml 
of TPP solution (6 mg in 10 ml DS water) or 10 ml of dextran solution (30 mg 
in 10 ml double distilled water). After freeze drying the nanoparticle 
suspension, the white (blank nanoparticles) or yellow (AmB loaded 
nanoparticles) product was reconstituted in double distilled water. After this, 
these nanoparticles were characterised by size, charge and AmB loading as 
described in Chapter 3. Additionally, the AmB loading was evaluated again 
after freeze drying by dissolving the yielded yellow powder in DMSO, in acidic 
pH 3 (by using 1% (v/v) acetic acid), and then measuring the quantity of AmB 
by HPLC as described previously in Chapter 3, section 3.3.6.1. There was no 
significant difference in the loading value between this method and the 
previously used one in Chapter 3, section 3-2-5- (p<0.05 by t-test).  
AmB (Purity ≥ 95%, Cambridge Bioscience, UK) dissolved in DMSO at a 10 
mM stock and diluter for proper concentrations in RPMI-1640 with 10% HiFCS 
(pure AmB). 
AmBisome® (a liposomal formulation of AmB, Gilead Sciences international 
Ltd, UK) was prepared according to the manufacturer’s instructions. Briefly, a 
suspension of AmB liposome was prepared in cold sterile MilliQ water to obtain 
an initial concentration of 4 mg/ml. The suspension was shaken and incubated 
at 65ºC for 10 mins and then cooled to room temperature. Further dilution to 
the required concentration of AmBisome® was done with 5% dextrose (w/v) 
(71). 
4.2.2. Red blood cells haemolysis  
Blood samples were obtained from two human donors (O+) (volunteers, Queen 
Mary, University of London) drawn directly into EDTA tubes to prevent 
coagulation. Blood samples were centrifuged at 500 x g for 5 min and the 
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plasma aspirated and discarded. The remaining red blood cells (RBCs) were 
then washed three times in buffered saline (10 mM Tris, 150 mM NaCl, pH 
7.4) prior to the assay. The RBCs were diluted to a density of 5x108 cells/ml 
and exposed to 1000, 500, 250, 125, 65.5, 31.25, 15.62 and 7.81 μg/ml of 
chitosan solution (HMW chitosan), blank chitosan-TPP nanoparticles, AmB 
loaded chitosan-TPP nanoparticles (AmB equivalent), blank chitosan-dextran 
sulphate nanoparticles, AmB loaded chitosan-dextran sulphate nanoparticles 
(AmB equivalent) and pure AmB in 96 well plates (200 μl in each well) for 1 h 
at 37°C. The plate was centrifuged for 5 mins at 500 x g to pellet intact RBCs.  
100 μl of supernatant from each well was transferred into a clear, flat-bottomed 
96-well plate and cell lysis was determined spectrophotometrically (540 nm). 
Phosphate buffer was used as a negative control and 20% Triton X-100 was 
used as a positive control representing 100% haemolysis. The results were 
expressed as the mean percentage reduction in human red blood cells 
compared with non-treated control wells, and represented by the 50% 
haemolytic concentration (RBC50) (295) 
4.2.3. In vitro cytotoxicity assays 
Cytotoxicity of chitosan formulations against KB cells was evaluated at 
concentrations of 2000, 1000, 500, 250, 125, 65.5, 31.25 and 15.62 μg/ml of 
blank chitosan-TPP nanoparticles, blank chitosan-dextran sulphate 
nanoparticles, AmB loaded chitosan-TPP nanoparticles (AmB equivalent) and 
AmB loaded chitosan-dextran sulphate nanoparticles (AmB equivalent). 
Cytotoxicity was evaluated in RPMI 1640 at two pH values (at normal pH of 
RPMI 7.5 and at a lower pH 6.5). Pure AmB, AmBisome® and chitosan solution 
(HMW chitosan) were included in this experiment for comparison. 
Podophyllotoxin (Sigma, UK) was included as a positive control at a starting 
concentration of 0.05 μM. Cytotoxicity was evaluated by a cell viability assay 
using the resazurin sodium salt solution (AlamarBlue, Sigma, UK) as 
described in Chapter 2, section 2.8.5. 
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4.2.4. In vitro 72-hour activity of chitosan and its derivatives against 
extracellular L. major and L. mexicana promastigotes 
The activity of chitosan formulations against L. major and L. mexicana 
promastigotes was evaluated at concentrations 486, 162, 54, 18, 6, 2, 0.66, 
0.22, 0.072, 0.024 and 0.008 μg/ml of blank chitosan-TPP nanoparticles, blank 
chitosan-dextran sulphate nanoparticles, AmB loaded chitosan-TPP 
nanoparticles (AmB equivalent) and AmB loaded chitosan-dextran sulphate 
nanoparticles (AmB equivalent). The anti-leishmanial activity was evaluated in 
RPMI 1640 at two pH values (7.5 and 6.5). Pure AmB, AmBisome® and 
chitosan solution (HMW chitosan) were included in this experiment for 
comparison. See Chapter 2, section 2.8.6 for full details.  
4.2.5. In vitro 72- hour activity of chitosan and its derivatives against 
intracellular amastigotes of L. major and L. mexicana 
The activity of chitosan formulations against L. major and L. mexicana 
intracellular amastigotes was evaluated at concentrations 486, 162, 54, 18, 6, 
2, 0.66, 0.22, 0.072, 0.024 and 0.008 μg/ml of blank chitosan-TPP 
nanoparticles, blank chitosan-dextran sulphate nanoparticles, AmB loaded 
chitosan-TPP nanoparticles (AmB equivalent) and AmB loaded chitosan-
dextran sulphate nanoparticles (AmB equivalent). The anti-leishmanial activity 
was evaluated in RPMI 1640 at two pH values (7.5 and 6.5). Pure AmB, 
AmBisome® and chitosan solution (HMW chitosan) was included in this 
experiment for comparison. PEMs were used as a macrophage model of 
intracellular amastigotes. See Chapter 2, section 2.8.7 for full details.  
 
Similarly, the host cell dependence of the anti-L. major amastigotes activity 
of chitosan formulations (blank chitosan-TPP nanoparticles, AmB loaded 
chitosan-TPP nanoparticles and AmB loaded chitosan-dextran sulphate 
nanoparticles) was evaluated by using two further host cell types (bone 
marrow macrophages (BMMs) and differentiated THP-1 cells). See Chapter 2, 
section 2.8.8 for full details.  
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4.2.6. Evaluation of the in vivo anti-leishmanial activity of chitosan 
formulations 
A pre-toxic study of AmB loaded nanoparticles was done before starting the 
treatment. This toxic study was done by using female BALB/c mice aged 6 to 
8 weeks, at 18-20g (Charles River, UK) and these mice were injected 
intravenously with 100 μL of AmB loaded chitosan-TPP nanoparticles or AmB 
loaded chitosan-dextran sulphate nanoparticles starting with concentration 20 
mg/kg of AmB and then 2-fold decrease. All mice monitored closely and 
immediately after administration and then regularly until 48 hours post-dose 
for two weeks. The safest doses were chosen for the treatment; 5 mg/kg of 
AmB for AmB loaded chitosan-TPP nanoparticles and 10 mg/kg of AmB 
loaded chitosan-dextran sulphate nanoparticles. 
4.2.6.1. In vivo L. major model of CL 
Female BALB/c mice aged 6 to 8 weeks, at 18-20g, were purchased from 
Charles River Ltd. These mice were maintained under specific conditions (they 
were kept in controlled rooms with humidity of 55% and temperature of 26°C 
and fed water and rodent food ad libitum). Luciferase-expressing L. major 
JISH118 (Ppy RE9H+L. major JISH118) amastigotes were harvested and 
isolated from mouse skin lesions previously infected with Leishmania 
promastigotes (at a low passage number). Harvested amastigotes were 
transformed to promastigotes by keeping them at 26°C in Schneider’s insect 
medium + 10% HiFCS. Promastigotes were passaged every week and used 
at a low passage number ( ≤3) to infect experimental mice due to the potential 
decrease in virulence with increasing passage number and extended culture 
(166). 
For this study, mice were shaved and then infected with 200 μl of 4x107 of 
stationary-phase luciferase-expressing L. major JISH118 (Ppy RE9H+L. major 
JISH118) promastigotes subcutaneously on the rump above the tail. After 7 
days of infection, small nodules started to be visible at the site of injection and 
the lesion size was recorded daily by using a digital calliper; 10 days post 
infection the lesions measured 5 mm approximately in diameter. The infected 
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mice were allocated in 8 groups (5 mice in each group) with similar average 
lesion diameters (P >0.5, one-way-ANOVA) after which, the administration of 
formulations was started as described below: 
 in vivo experiment 1 
Group 1 Negative control: untreated, uninfected 
Group 2 The positive control group (G2): mice received 10 doses of 100 μL of 
paromomycin at a dose of 50 mg/kg intraperitoneally (i.p.) for 10 
consecutive days, a regimen with proven efficacy in this CL model 
(77, 202)   
Group 3 Group 3 (G3): mice received 5 doses of 100 μL of AmBisome® ( size= 
70-80 nm) (272, 273), 10 mg/kg intravenously (i.v.) over 10 days, 
alternate day dosing on days 0, 2, 4, 6, and 8. 
Group 4 Group 4 (G4): mice received 5 doses of 100 μL of blank chitosan-
TPP nanoparticles (equivalent to AmB-loaded) intravenously (i.v.) 
over 10 days, alternate day dosing 
Group 5 Group 5 (G5): mice received 5 doses of 100 μL of AmB loaded 
chitosan-TPP nanoparticles (5 mg/kg of AmB) intravenously (i.v.) 
over 10 days, alternate day dosing 
Group 6 Group 6 (G6): mice received 5 doses of 100 μL of blank chitosan-
dextran sulphate nanoparticles (equivalent to AmB-loaded) 
intravenously (i.v.) over 10 days, alternate day dosing 
Group 7 Group 7 (G7): mice received 5 doses of 100 μL of AmB loaded 
chitosan-dextran sulphate nanoparticles (10 mg/kg of AmB) 
intravenously (i.v.) over 10 days, alternate day dosing 
Group 8 Group 8 (G8): mice received 5 doses of 100 μL of chitosan 
nanoparticle vehicles (water) intravenously (i.v.) for over 10 days, 
alternate day dosing 
 
At day 9 (one day after the last dose was administered), the experiment was 
terminated, mice were humanely killed and skin samples were harvested by 
surgical removal from the areas containing the localized CL lesion and non-
CL-infected skin on the back (control site) of the same mouse ( Fig 4.1 ), stored 
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at -80oC for further experiments (the biodistribution of AmB and for qPCR and 
determination of burden). Treatment efficacy was evaluated by measuring the 
lesion size progression and parasite load (bioluminescence signal).  
A second, repeated in vivo experiment was conducted with 35 mice were used 
(in vivo experiment 2). This experiment was performed for reproducibility and 
to study the dose-response effect of AmB loaded chitosan-TPP nanoparticles. 
Ten days post infection, the lesions measured 5 mm approximately in diameter 
and mice were allocated to 7 different experimental groups to ensure 
comparable lesion sizes in each group (5 mice in each group).  
Mice were then treated for 10 days, receiving injections containing one of the 
following regimens: 
Group 1 Control group (G1): untreated, infected mice 
Group 2 The positive control group (G2): mice received 10 doses of 100 
μL of paromomycin 50 mg/kg intraperitoneally (i.p.) for 10 
consecutive days, a regimen with proven efficacy in this CL model 
(77, 202) 
Group 3 mice received 5 doses of 100 μL of AmBisome® 10 mg/kg 
intravenously (i.v.) over 10 days, alternate day dosing on days 0, 
2, 4, 6, and 8. 
Group 4 mice received 5 doses of 100 μL of AmB loaded chitosan-TPP 
nanoparticles (5 mg/kg of AmB) intravenously (i.v.) over 10 days, 
alternate day dosing 
Group 5 mice received 5 doses of 100 μL of AmB loaded chitosan-TPP 
nanoparticles (2.5 mg/kg of AmB) intravenously (i.v.) over 10 
days, alternate day dosing 
Group 6 mice received 5 doses of 100 μL of AmB loaded chitosan-TPP 
nanoparticles (1.25 mg/kg of AmB) intravenously (i.v.) over 10 
days, alternate day dosing 
Group 7 mice received 5 doses of 100 μL of blank chitosan-TPP 
nanoparticles (equivalent to 5 mg/kg AmB-loaded) intravenously 
(i.v.) over 10 days, alternate day dosing 
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After which the experiment was carried out as previously described.  
Both blank and AmB loaded chitosan nanoparticles were suspended in 
distilled water, characterizes (size, charge, AmB loading) and used freshly for 
the in vivo study.  
- Fungizone (a conventional deoxycholate formulation of AmB) was not 
included in both in vivo experiments as controls, because Wijnant et al 
(2017) found that the highest tolerated dose of Fungizone was 1 
mg/kg/i.v. (which did not cause acute toxicity to BALB/c mice) and 
demonstrated that Fungizone (1 mg/kg/QAD for 10 days; i.v.) did not 
cause a significant reduction in lesion sizes or parasite load in murine 
(BALB/c) models of L. major (170).  
 
Figure 4.1. Schematic representation of skin samples used in the study (166) 
4.2.6.2. Measurement of lesion size 
The lesion size was measured daily using digital calipers by determining the 
width and length of the lesion and then calculating the average (mm). One -
way ANOVA with post-hoc Tukey test was performed to analyse the statistical 
differences between the average diameters per group (166). 
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4.2.6.3. Measurement of the bioluminescence signal 
The luciferase substrate; luciferin (D-Luciferin potassium salt, Xenogen, CA 
and Gold Biotechnology, St. Louis, MO) was injected (sc) into the mice at 10 
mins before the acquiring of bioluminescent signal. After 7 mins of injection, 
the mice were anaesthetized by inhalation with 3% isoflurane with 100% 
oxygen at a flow rate of 2.5 l/min until no movement was shown (3 mins 
approx.). Mice were then imaged and the images were acquired by using a 
Living Image software (version 4). Emitted photons were gathered by auto 
acquisition with a charge couple device (CCD) camera (PerkinElmer IVIS 
Spectrum In vivo Imaging System) using the medium resolution (medium 
binning) mode. A circular region of interest (ROI) encompassing the nodular 
area on the rump was drawn to quantify the bioluminescence, expressed as 
radiance and results were expressed in numbers of photons/sec (296). 
4.2.6.4. Quantification of AmB in skin samples  
Each frozen skin sample was cut into fine, long pieces, weighed and then 
inserted into microcentrifuge tubes. A spatula of 2 mm zirconium oxide beads 
(Next Advance, United Kingdom) (about 100 mg) was added with 1 ml of PBS 
to each tube. After which, the skin sample was homogenised in 3 cycles of 30 
seconds of 6800 rpm using a Precellys 24 homogenizer (Bertin Technologies, 
France) to obtain a smooth homogenate. Then 100 ul of the homogenate was 
added to 250ul of a mixture of methanol: DMSO (84:16) plus 200 ng/ml 
tolbutamide (analytical standard; Sigma, United Kingdom) for drug extraction 
and tolbutamide was used for protein precipitation, in 96-well plates. Then, 
these 96-well plates were shaken for 10 mins at 200 rpm and centrifuged at 
4°C at 6600 rpm for 15 mins. Two hundred microliters of supernatant were 
stored at -80°C until further analysis for quantification of AmB by HPLC as 
described previously in Chapter 3, in section 3.3.6.1. A calibration curve for 
the HPLC was prepared of AmB concentrations in untreated healthy skin 
homogenate (this homogenate was prepared as described by grinding the skin 
by using the zirconium oxide beads and the blender, shaking and centrifuging 
the samples) (170).  
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4.2.7. Skin permeation study by Franz diffusion cell (FDC) assay 
25 female BALB/c mice (6 to 8 weeks old) at 18-20g, were shaved and infected 
with 200 μl of 4x107 of stationary phase L. major JISH118 promastigotes 
subcutaneously on the rump above the tail. After 7 days of infection small 
nodules started to be visible at the site of injection and the lesion size was 
recorded daily by using a digital calliper. Ten days post infection, the lesions 
measured approximately 5 mm in diameter. The mice were humanely killed 
and 2 circular discs of skin (infected and uninfected skin- 15mm diameter 
approximately) were excised per mouse; the infected skin piece containing the 
Leishmania lesion was cut from the dorsal area above the tail and the 
uninfected piece above the lesion on the higher back of same mouse was 
collected (Fig 4.1). Forceps were used to gently remove fat and muscle from 
the skin samples and these samples were stretched carefully on Whatman 
filter papers. They were then mounted between the donor and receptor 
compartment of the Franz cell device (Fig 4.2.) and kept in place by a clamp. 
PBS with 2% hydroxypropyl-β-cyclodextrin (CD, Sigma, UK) was sonicated for 
30 mins then added to the receptor compartment (as AmB is soluble in CD at 
37 μg/ml) together with a small magnetic stirrer. The Franz cells were 
incubated in a warm water bath on a magnetic stirrer plate set at a speed of 
800 rpm until the skin reached temperature 34°C. The Franz cells were 
examined for air bubbles and leakage (166). 100 µl of each formulation (Pure 
AmB as a control (3.96 ± SD mg of amphotericin B/ml), AmB loaded chitosan 
TPP nanoparticles (3.93 ± SD mg of amphotericin B/ml)) and AmB loaded 
chitosan dextran sulphate nanoparticles (3.84 ± SD mg of amphotericin B/ml)) 
was applied to each donor compartment. 100 µl of receptor fluid was taken at 
regular time intervals and was replaced with 100 µl of fresh PBS with 2% CD 
and stored at -80oC to be analysed later by HPLC to quantify AmB. After 24 h 
the experiment was terminated, and the Franz cells were disassembled. Donor 
chambers were washed with 1 ml of methanol: DMSO (84:16) which was then 
stored at -80oC for further AmB analysis by HPLC. A dry cotton swab was used 
to remove any residual AmB on the surface of skin.  This was then stored at -
80oC for further quantification of AmB. The skin samples were also stored at -
80oC for further experiments. The cumulative amount of drug permeated as a 
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function of time was plotted and the linear portion of the graph was used to 
calculate the flux and lag time (Fig 4.14). the permeability coefficient (Kp) was 
calculated by using Equation 5.  
 
 
 
Figure 4.2. Franz diffusion cell used for the permeation studies (166) 
4.2.7.1. Quantification of AmB by HPLC  
The amount of AmB in the wash was quantified by HPLC using parameters 
described in Chapter 3 in section 3-2-7- ; standard solutions of AmB were 
achieved by diluting AmB in methanol: DMSO (84:16) solution.  
The amount of AmB in the cotton swab was quantified by HPLC using 
parameters described in Chapter 3 in section 3-2-7-. Firstly, the cotton swab 
was soaked in 1 ml of methanol: DMSO (84:16) solution for 24 h and then 
analysed.  For the calibration curve, a dry cotton swab was soaked in 1 ml of 
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methanol: DMSO (84:16) solution for 24 h and then this solution was used to 
prepare a standard solution of AmB. 
To extract AmB from the skin disc, the skin was homogenised as described 
below:  
Each frozen skin sample was cut into fine, long pieces, weighed and then 
inserted into microcentrifuge tubes. A spatula-full of 2 mm zirconium oxide 
beads (Next Advance, United Kingdom) (about 100 mg) was added with 1 ml 
of PBS to each tube. The skin sample was homogenised in 3 cycles of 30 
seconds at 6800 rpm using the Precellys homogeniser (Bertin Technologies) 
to obtain a smooth homogenate. 100 ul of homogenate was then added to a 
250 µl of mixture of methanol: DMSO (84:16) plus 200 ng/ml tolbutamide 
(analytical standard; Sigma, United Kingdom) for drug extraction protein 
precipitation in 96-well plates. These 96-well plates were shaken for 10 mins 
at 200 rpm then centrifuged at 4°C at 6600 rpm for 15 mins. 200uL of 
supernatant was stored at -80°C until further analysis for quantification of AmB 
by HPLC as described previously in Chapter 3. A calibration curve for the 
HPLC was prepared with AmB concentrations in untreated healthy skin 
homogenate (this homogenate was prepared as described by grinding the skin 
using the zirconium oxide beads and the Precellys blender, shaking and 
centrifuging the samples) (170).  
4.2.7.2. Fluorescence microscopy of skin sections post formulation 
application 
To visualise the nanoparticles, formulations with rhodamine-labelled chitosan 
were prepared in a similar manner to unlabelled particles and then were 
characterised regarding size and zeta-potential using the Zeta-sizer and 
applied to infected and uninfected mouse skin using FDC (blank rhodamine-
labelled chitosan-TPP nanoparticles equivalent to 3.93 ± SD mg of 
amphotericin B/ml loaded in AmB loaded chitosan TPP nanoparticles and 
blank rhodamine-labelled chitosan-dextran sulphate nanoparticles equivalent 
to 3.84± SD mg of amphotericin B/ml loaded in AmB loaded chitosan TPP 
nanoparticles) as described above. After the experiment, the cells were 
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dismantled and skin tissue fixed in tris-zinc fixative overnight as described by 
Accart et al (2014) (297). After 24 hours the skin samples were embedded in 
gelatin and immersed in OCT before storage at -80°C. Cryosections of 5 µm 
were cut using a cryostat (Leica CM1950). 
For immunohistochemistry, the sections were defrosted and submerged in 
PBS (37°C) for 30 minutes to dissolve the gelatine after which they were 
submerged in PBS for 5 minutes, counterstained with DAPI and mounted in 
Prolong Gold (Thermofisher Scientific). Sections were examined using a Zeiss 
Axio Scan Z1 with a x 20 objective.  
4.2.8. Statistical analysis.  
For the efficacy experiment, ANOVA (1-way for parasite load and 
intralesional AmB levels, 2-way repeated measures for lesion size) followed 
by Tukey’s multiple comparison test were used. A P value of <0.05 was 
considered statistically significant. All analyses were performed with 
GraphPad Prism version 7.02.   
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4.3. Results 
4.3.1. Haemolysis activity of chitosan nanoparticles  
The haemolytic activity of blank and AmB loaded chitosan TPP or dextran 
sulphate nanoparticles was clearly observed in a dose-dependent manner as 
shown in Fig 4.3. Pure AmB was significantly more haemolytic (around 18-
fold) than both types of AmB loaded nanoparticles (p<0.05 by an extra sum-
of-squares F test) (Table 4.4). On the other hand, AmBisome® is less toxic 
against RBCs than both types of AmB loaded nanoparticles (p<0.05 by an 
extra sum-of-squares F test) (Table 4.4). 
 
Table 4.4. In vitro haemolytic activity of chitosan formulations after 1h of 
incubation 
Compound Properties RBC50 µg/ml RBC90 µg/ml 
Amphotericin B (pure 
AmB) 
Purity ≥95%, 
MW 924.1 
11.3 ± 2 40.88 ± 5 
AmBisome® 
Liposomal AmB, 
Size= 70-80 nm 
525.8 ± 6 1782 ± 8 
HMW chitosan 
MW=310-375 
KDa 
810.1 ± 7 3367 ± 9 
Blank chitosan-TPP 
nanoparticles 
Size= 67 ± 7 nm, 
Zeta potential= 
28.5 ±1.9 mv 
623.7 ± 6 3639 ± 10 
AmB loaded chitosan-TPP 
nanoparticles 
Size= 69 ± 8 nm, 
Zeta potential= 
25.5 ± 1 mv 
209.5 ± 5 1129 ± 10 
Blank chitosan-dextran 
sulphate nanoparticles 
Size= 170 ± 9 
nm, Zeta 
potential= -12.9 
± 3 mv 
621.4 ± 8 3341 ± 16 
AmB loaded chitosan-
dextran sulphate 
nanoparticles 
Size= 174 ± 8 
nm, Zeta 
potential= -11 ± 
1mv 
202.8 ± 8 931.4 ± 8 
Experiments were conducted in triplicate cultures, data expressed as mean +/- SD 
(experiment was reproduced further two times with confirmed similar data and 
data not shown). A statistically significant difference was found in RBC50 values 
between AmB loaded chitosan nanoparticles and pure AmB (p<0.05 by an extra 
sum-of-squares F test). 
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Figure 4.3. Dose-response curves of haemolytic activity of chitosan nanoparticles (blank and AmB loaded nanoparticles) after 1h of 
incubation. Data are expressed as means ± SD from triplicates, statistically significant difference in RBC50 values between pure AmB 
and AmB loaded nanoparticles (pure AmB is significantly more toxic AmB loaded nanoparticles) (P <0.05 by an extra sum-of-squares 
F test)). 
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4.3.2. Cytotoxicity of blank and AmB loaded chitosan nanoparticles 
against KB cells in RPMI (pH 7.5 and pH 6.5) 
The cytotoxicity of blank and AmB loaded chitosan TPP or dextran sulphate 
nanoparticles against KB cells was clearly observed in a dose-dependent 
manner at two pH values (7.5 and 6.5) as shown in Fig 4.4. No significant 
difference in the cytotoxicity was observed for all formulations at pH of 7.5 and 
pH of 6.5 (pH did not have an effect on the cytotoxicity) (p>0.05 by t-test) 
(Table 4.5). Both types of blank chitosan nanoparticles showed a significantly 
less cytotoxicity than AmB loaded chitosan nanoparticles (p<0.05 by an extra 
sum-of-squares F test). AmB loaded chitosan TPP or dextran sulphate 
nanoparticles were significantly less toxic than pure AmB (6-fold less toxic 
against KB cells) (p<0.05 by an extra sum-of-squares F test). However, no 
significant difference was observed in the cytotoxicity between AmB loaded 
nanoparticles and AmBisome® (p>0.05 by an extra sum-of-squares F test) 
(Table 4.5).  
 
 
Table 4.5. In vitro cytotoxicity of chitosan formulations against KB cells at two pH 
values after 72h of incubation 
Compound 
 pH=7.5 pH=6.5 
Properties 
LD50 
µg/ml 
LD90 
µg/ml 
LD50 
µg/ml 
LD90 µg/ml 
Podophyllotoxin  0.7 ± 0.03 2 ± 0.3 0.8 ± 0.04 2 ± 0.4 
Amphotericin B (pure 
AmB) 
Purity ≥95%, 
MW 924.1 
59 ± 2 228 ± 2 60 ± 2 225 ± 3 
AmBisome® 
Liposomal 
AmB, Size= 
70-80 nm 
401 ± 2 1568 ± 2 401 ± 3 1568 ± 2 
HMW chitosan 
MW=310-
375 KDa 
894 ± 4 2840 ± 3 825 ± 2 2864 ± 2 
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Blank chitosan-TPP 
nanoparticles 
Size= 67 ± 7 
nm, Zeta 
potential= 
28.5 ±1.9 
mv 
728 ± 2 2858 ± 4 696 ± 3 2588 ± 4 
AmB loaded chitosan-
TPP nanoparticles 
Size= 69 ± 8 
nm, Zeta 
potential= 
25.5 ± 1 mv 
356 ± 5 1354 ± 5 348 ± 3 1318 ± 5 
Blank chitosan-
dextran sulphate 
nanoparticles 
Size= 170 ± 
9 nm, Zeta 
potential= -
12.9 ± 3 mv 
949 ± 6 2915 ± 6 917 ± 2 2806 ± 1 
AmB loaded chitosan-
dextran sulphate 
nanoparticles 
Size= 174 ± 
8 nm, Zeta 
potential= -
11 ± 1mv 
366 ±3 1113 ± 3 366 ± 3 1131 ±4 
TPP 
MW= 
367.864 
g/mol 
840± 8 1400± 8 850± 8 1500± 8 
Dextran sulphate MW= 40 KDa >1200  >1200  
Experiments were conducted in triplicate cultures, data expressed as mean +/- SD (experiment 
was reproduced further two times with confirmed similar data and data not shown). Blank or 
AmB loaded chitosan nanoparticles had a similar toxicity at both pH values (6.5 and 7.5) toward 
KB-cells (p >0.05 by t-test).  A statistically significant difference was found in LD50 (50% lethal 
dose) values between AmB loaded chitosan nanoparticles and pure AmB (p<0.05 by an extra 
sum-of-squares F test). 
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Figure 4.4. Dose-response curves of the cytotoxicity against KB-cells. KB cells were cultured in the presence of different concentrations 
of chitosan formulations. The toxicity of drugs was measured after 72 hours by measuring the inhibition of metabolic activity. Values are 
expressed as % inhibition of KB cells relative to untreated controls. Statistically significant difference in LD50 values between pure AmB 
and AmB loaded nanoparticles against KB-cells (AmB is significantly more toxic AmB loaded nanoparticles) (P <0.05 by an extrasum-of-
squares F test)). 
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4.3.3. Activity of blank and AmB loaded chitosan nanoparticles against 
L. major and L. mexicana promastigotes in RPMI (pH 7.5 and pH 6.5) 
Both chitosan solution and blank chitosan TPP nanoparticles were significantly 
more active at lower pH (6.5) than at higher pH (7.5) (p< 0.05 by t-test), 
chitosan solution was more active than blank chitosan-TPP nanoparticles at 
two pH values (p< 0.05 by t-test) (Fig 4.5.). Blank chitosan-dextran sulphate 
nanoparticles had no activity against Leishmania promastigotes up to a 
concentration of 486 µg/ml at two pH values. At both pH values (7.5 and 6.5) 
pure AmB, AmB loaded chitosan-TPP nanoparticles and AmB loaded 
chitosan-dextran sulphate nanoparticles showed a similar anti-promastigote 
activity without a significant difference in their activity at these two pH values 
(p >0.05 by t-test). They were significantly more active against Leishmania 
promastigotes than AmBisome® (p<0.05 by an extra sum-of-squares F test) 
(Table 4.6). L. major promastigotes were more sensitive than L. mexicana to 
pure AmB, AmB loaded chitosan-TPP nanoparticles and AmB loaded 
chitosan-dextran sulphate nanoparticles (p<0.05 by an extra sum-of-squares 
F test).   
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Table 4.6. In vitro activity of chitosan formulations against promastigotes at two pH values 
Compound 
 
Properties 
 
pH=7.5 * pH=6.5* 
L. major** L. mexicana** L. major** L. mexicana** 
EC50 µg/ml EC90 
µg/ml 
EC50 µg/ml EC90 
µg/ml 
EC50 µg/ml EC90 
µg/ml 
EC50 µg/ml EC90 
µg/ml 
Amphotericin B 
(pure AmB) 
Purity ≥95%, MW 
924.1 
0.06 ± 0.003 0.3 ± 0.02 0.2 ± 0.004 0.4 ± 0.03 0.06 ± 0.003 0.3 ± 0.02 0.2 ± 0.004 0.4 ± 0.03 
AmBisome® 
Liposomal AmB, 
Size= 70-80 nm 
1 ± 0.08 7 ± 0.3 1.8 ± 0.1 7 ± 0.07 1.1 ± 0.08 7 ± 0.1 1.9 ± 0.1 7 ± 0.01 
HMW chitosan MW=310-375 KDa 106 ± 7 539 ± 31 141 ± 31 556 ± 5 7.1 ± 0.5 56 ± 4 13.5 ± 0.8 163 ± 27 
Blank chitosan-
TPP nanoparticles 
Size= 67 ± 7 nm, 
Zeta potential= 
28.5 ±1.9 mv 
164 ± 6 443 ± 10 185 ± 10 443 ± 0.8 28 ±1.5 169 ± 11 38 ± 0.8 173 ± 10 
AmB loaded 
chitosan-TPP 
nanoparticles 
Size= 69 ± 8 nm, 
Zeta potential= 
25.5 ± 1 mv 
0.08 ± 0.003 0.5 ± 0.02 0.3 ± 0.02 0.7 ± 0.02 0.06 ± 0.003 0.4 ± 0.02 0.2 ± 0.004 0.4 ± 0.02 
Blank chitosan-
dextran sulphate 
nanoparticles 
Size= 170 ± 9 nm, 
Zeta potential= -
12.9 ± 3 mv 
No activity up to 486 
AmB loaded 
chitosan-dextran 
sulphate 
nanoparticles 
Size= 174 ± 8 nm, 
Zeta potential= -11 
± 1mv 
0.09 ± 0.003 0.4 ± 0.01 0.5 ± 0.02 1 ± 0.07 0.06 ± 0.003 0.3 ± 0.02 0.4 ± 0.02 1.5 ± 0.04 
TPP 
MW= 367.864 
g/mol 
No activity up to 486 
Dextran sulphate MW= 40 KDa No activity up to 486 
Experiments were conducted in triplicate cultures, data expressed as mean +/- SD (experiment was reproduced further two times with confirmed similar data 
not shown). *Statistically significant differences were found for the EC50 values of chitosan or blank chitosan-TPP nanoparticles at pH=6.5 and pH=7.5 
(p<0.05 by using t-test). **L. major promastigotes were significantly more susceptible to pure AmB and AmB loaded chitosan nanoparticles than L. mexicana 
((p<0.05 by an extra sum-of-squares F test)). Pure AmB and AmB loaded chitosan TPP or dextran sulphate nanoparticles had a similar anti-leishmanial 
activity. 
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Figure 4.5. Dose-response curves of the activity of blank and AmB loaded chitosan nanoparticles against Leishmania promastigotes at two 
pH values. A: L. major; B: L. mexicana. Promastigotes were cultured in the presence of different concentrations of chitosan nanoparticles. 
The activity of drugs was measured after 72h by the resazurin solution. Values are expressed as % inhibition of promastigotes relative to 
untreated controls. No statistically significant difference was observed in EC50 values of AmB loaded chitosan nanoparticles and pure AmB 
against L. mexicana or L. major promastigotes (p>0.05 by t-test). 
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4.3.4. Activity of blank and AmB loaded chitosan nanoparticles against 
L. major and L. mexicana amastigotes infecting PEMs 
Both chitosan solution and blank chitosan-TPP nanoparticles were 
significantly more active at lower pH (6.5) than at higher pH (7.5) (p< 0.05 by 
t-test) (Fig 4.6.). Chitosan solution was more effective against amastigotes 
than blank chitosan-TPP nanoparticles at higher pH of 7.5 (p<0.05 by an extra 
sum-of-squares F test), However, both have a similar activity against 
Leishmania amastigotes at lower pH of 6.5 (p>0.05 by an extra sum-of-
squares F test). Blank chitosan-dextran sulphate nanoparticles had no activity 
against Leishmania amastigotes to concentration up to 486 µg/ml at two pH 
values. Pure AmB, AmB loaded chitosan-TPP nanoparticles and AmB loaded 
chitosan-dextran sulphate nanoparticles showed similar anti-amastigotes 
activity against both L. major and L. mexicana amastigotes at two pH values 
(7.5 and 6.5) without a significant difference in their activity at these two pH 
values (p >0.05 by t-test) and they were significantly more effective against 
Leishmania amastigotes than AmBisome® (p<0.05 by an extra sum-of-
squares F test). Pure AmB and AmB loaded chitosan-TPP nanoparticles and 
AmB loaded chitosan-dextran sulphate nanoparticles showed higher anti 
amastigote activity against L. major than L. mexicana (p<0.05 by an extra sum-
of-squares F test) (Table 4.7).   
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Table 4.7. In vitro activity of chitosan formulations against intracellular amastigotes at two pH values 
Compound 
 
Properties 
 
pH=7.5 * pH=6.5* 
L. major** L. mexicana** L. major** L. mexicana** 
EC50 µg/ml EC90 
µg/ml 
EC50 µg/ml EC90 µg/ml EC50 µg/ml EC90 
µg/ml 
EC50 
µg/ml 
EC90 µg/ml 
Amphotericin B 
(pure AmB) 
Purity ≥95%, MW 
924.1 
0.09± 0.003 0.5 ± 0.04 0.3 ± 0.003 0.7 ± 0.02 0.09 ± 0.003 0.5 ± 0.02 0.5 ± 0.04 0.6 ± 0.04 
AmBisome® 
Liposomal AmB, 
Size= 70-80 nm 
1.2 ± 0.07 8 ± 0.3 1.8 ± 0.08 12 ± 1 1.3 ± 0.08 7 ± 0.1 1.8 ± 0.07 13 ± 1 
HMW chitosan MW=310-375 KDa 105 ± 7 1192± 58 123 ± 5 2206 ± 5 10 ± 0.3 127 ± 5 16 ± 0.7 165 ± 27 
Blank chitosan-TPP 
nanoparticles 
Size= 67 ± 7 nm, 
Zeta potential= 28.5 
±1.9 mv 
162 ± 10 828 ± 43 177 ± 7 4020 ± 352 13 ± 0.5 122 ± 19 21 ± 0.9 284 ± 10 
AmB loaded 
chitosan-TPP 
nanoparticles 
Size= 69 ± 8 nm, 
Zeta potential= 25.5 
± 1 mv 
0.14± 0.009 1 ± 0.09 0.5 ± 0.01 1.8 ± 0.1 0.06 ± 0.003 0.5 ± 0.08 0.3 ± 0.01 1.8 ± 0.02 
Blank chitosan-
dextran sulphate 
nanoparticles 
Size= 170 ± 9 nm, 
Zeta potential= -12.9 
± 3 mv 
No activity up to 486 
AmB loaded 
chitosan-dextran 
sulphate 
nanoparticles 
Size= 174 ± 8 nm, 
Zeta potential= -11 ± 
1mv 
0.16± 0.008 1.4 ± 0.02 0.5 ± 0.01 1.8 ± 0.05 0.16 ± 0.007 0.9 ± 0.04 0.4 ± 0.01 1.8 ± 0.05 
TPP MW= 367.864 g/mol No activity up to 486 
Dextran sulphate MW= 40 KDa No activity up to 486 
Experiments were conducted in quadruplicate cultures, data expressed as mean +/- SD (experiment was reproduced further two times with confirmed similar 
data not shown). *Statistically significant differences were found for the EC50 values of chitosan or blank chitosan TPP nanoparticles at pH=6.5 and pH=7.5 
(p<0.05 by using t-test). ** L. major amastigotes were significantly more susceptible to pure AmB and AmB loaded chitosan nanoparticles than L. mexicana 
((p<0.05 by an extra sum-of-squares F test)). Pure AmB, AmB loaded chitosan TPP and dextran sulphate nanoparticles had a similar anti-leishmanial activity. 
 
162 
 
 
4.6. Dose-response curves of the activity of blank and loaded chitosan nanoparticles against Leishmania amastigotes at two 
pH values. A: L. major; B: L. mexicana. PEMs were infected with stationary-phase promastigotes and exposed to various 
concentrations of chitosan and its derivatives, followed by microscopic counting of the number of infected macrophages*. 
Values are expressed as % inhibition of infection relative to untreated controls. No statistically significant difference was 
observed in EC50 values of AmB loaded chitosan nanoparticles and pure AmB against L. mexicana or L. major amastigotes 
at pH=6.5 or pH=7.5 (p>0.05 by t-test). 
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4.3.5. Host cell dependence of the anti-leishmanial activity of chitosan 
nanoparticles at pH of 6.5   
EC50 and EC90 values of blank chitosan-TPP nanoparticles, AmB loaded 
chitosan-TPP nanoparticles and AmB loaded chitosan-dextran sulphate 
nanoparticles against amastigotes infecting three different macrophage 
populations are summarized in Table 4.8. There was a significant difference 
in the activity of chitosan formulations depending on the type of macrophage; 
as blank chitosan-TPP nanoparticles, AmB loaded chitosan-TPP 
nanoparticles and AmB loaded chitosan-dextran sulphate nanoparticles were 
significantly more active against intracellular amastigotes in PEMs and BMMs 
compared to differentiated THP-1 cells (p<0.05 by an extra sum-of-squares F 
test) (Table 4.8). 
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Table 4.8. Activity of chitosan formulations against L. major amastigotes in three different macrophage cultures after 72 h at 
pH of 6.5 
 Pure AmB 
AmB loaded chitosan-
dextran sulphate 
nanoparticles 
AmB loaded chitosan-
TPP nanoparticles 
blank chitosan-TPP 
nanoparticles 
Host cell / 
infection 
rate %             
at 24 h 
EC50 µg/ml EC90 µg/ml EC50 µg/ml EC90 µg/ml EC50 µg/ml EC90 µg/ml EC50 µg/ml EC90 µg/ml 
PEMs /         
> 80% 
0.08 ± 0.01 0.4 ± 0.1 0.08 ± 0.004 0.4 ± 0.1 0.09 ± 0.004 0.5 ± 0.1 12 ± 1 156 ± 9 
BMMs /               
> 80% 
0.09 ± 0.02 0.6 ± 0.1 0.09 ± 0.02 0.6 ± 0.1 0.09 ± 0.01 0.5 ± 0.1 14 ± 2 207± 14 
THP-1/             
> 80% 
0.2 ± 0.05 3.4 ± 0.4 0.2 ± 0.06 3.3 ± 0.3 0.2 ± 0.06 2.9 ± 0.4 26 ± 4 306 ± 9 
Experiments were conducted in quadruplicate cultures, data expressed as mean +/- SD (experiment was reproduced further two times 
with confirmed similar data and data not shown), statistically significant difference in EC50 as chitosan formulations were significantly more 
active in PEMs and BMMs compared with THP-1 cells (p<0.05 by an extra sum-of-squares F test). % infection rate gives the percentage 
of infected macrophages.  
165 
 
4.3.6. In vivo anti-leishmanial activity (intravenous route route) 
We assessed the efficacy of blank and AmB loaded chitosan nanoparticles 
(two types) in murine models of CL caused by L. major, by analysing the lesion 
sizes and bioluminescence signal progression among the groups.  
4.3.6.1. In vivo experiment 1 
4.3.6.1.1. Evaluation of the lesion size progression  
Fig 4.7. shows the progression of the mean lesion size for each group as a 
function of time. Blank chitosan-dextran sulphate nanoparticles and 
nanoparticles vehicles did not cause any reduction in the progression of the 
lesion size compared to the untreated controls. Both AmBisome® (10 
mg/kg/QAD for 10 days; i.v.) and blank chitosan-TPP nanoparticles reduced 
the lesion size at the end of the treatment with 36% and 34% respectively, 
reduction compared to the untreated controls without a significant different in 
their efficacy (p>0.05 by one-way ANOVA). AmB loaded chitosan-TPP 
nanoparticles (5 mg/kg/QAD for 10 days; i.v.) were the most effective 
compared with other chitosan formulations and caused a 87% reduction of 
lesion sizes and was significantly more effective than AmBisome® with 2.4 
times greater activity (p<0.05 by one-way ANOVA). There was no significant 
difference in the anti-leishmanial efficacy between AmB loaded chitosan-TPP 
nanoparticles (5 doses) and paromomycin (50 mg/kg,10 doses, positive 
control, 10 doses) with 87% and 93% respectively, reduction of lesion sizes 
(p>0.05 by one-way ANOVA). 
Group 7 received one dose of AmB loaded chitosan-dextran sulphate 
nanoparticles (10 mg/kg, i.v.) for the reason that the day following this dose, 
mice looked unwell and showed signs of a piloerection and weight loss. 
Therefore, no more doses were administered. After two days, two mice had 
died and without any signs of potential CL-related mortality such as severe 
ulceration, dissemination of the lesion. We just kept monitoring the lesion sizes 
of the other three mice.  
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Figure 4.7. Amphotericin B nanoparticles efficacy in the lesion cure model in BALB/c mice infected with luciferase-expressing L. major 
parasites.  Female BALB/c mice were infected with stationary-phase promastigotes in the rump above the tail (n = 5 per group).  At 10 days 
post-inoculation, animals presenting with CL nodules were dosed with paromomycin (G2) as a positive control (50 mg/kg/QD for 10 days; i.p.), 
AmBisome® (G3) as a comparison group (10 mg/kg/QAD for 10 days; i.v.), blank chitosan-TPP nanoparticles equivalent to AmB loaded 
nanoparticles(G4) (QAD for 10 days; i.v.), AmB loaded chitosan-TPP nanoparticles (G5) (5 mg of AmB/kg/QAD for 10 days; i.v.), blank chitosan-
dextran sulphate nanoparticles equivalent to AmB loaded nanoparticles (G6) (QAD for 10 days; iv), AmB loaded chitosan-dextran sulphate 
nanoparticles (G7) (10 mg of AmB/kg/ one dose; i.v.) or the nanoparticles vehicle (G8) (distilled water, QAD for 10 days; i.v.). (G1) represents 
untreated infected group. During treatment, lesion size was measured daily. The average lesion size represents the mean ± SD. ANOVA (1 
way for parasite load and repeated measures for lesion size) followed by Turkey’s multiple-comparison tests was used to compare outcomes 
among the groups. A p-value < 0.05 was considered statistically significant ((*) p<0.05, (**) p<0.05 and (***) p>0.05). (A) represents mean 
lesion size progression in function of time since the start of treatment, (B) represents the mean lesion size at day 9 (one day after the last dose 
was administered), (C) represents the % reduction in lesion size compared with G1 (untreated infected group) at day 9, (D) represents images 
of untreated group on day 9 (lesions are circled) and (E) represents images of G4 on day 9 (infection sites are circled and it is clear the healing 
effects of treatment on the lesions). 
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4.3.6.1.2. Evaluation of the parasite load (bioluminescent signal)  
Bioluminescence signal progression in all treatment groups is shown in Fig 
4.8. The reduction of parasite loads in the skin followed a similar trend of the 
lesion size with a good correlation between lesion size and bioluminescent 
signal identified by Pearson correlation coefficients (using GraphPad Prism). 
AmB loaded chitosan-TPP nanoparticles (5 mg/kg/QAD for 10 days; i.v.) were 
the most effective compared with other chitosan formulations with 99% 
reduction in parasite loads (bioluminescent signal) at the end of the treatment 
compared to the untreated controls and with similar reduction to the Group 2 
treated with the positive control (paromomycin, 50 mg/kg,10 doses; i.p.) 
(p>0.05 by one-way ANOVA). There was no significant difference between 
AmBisome® (10 mg/kg/QAD for 10 days; i.v.) and blank chitosan-TPP 
nanoparticles with 72% and 62% respectively, reduction (p>0.05 by one-way 
ANOVA). Blank chitosan-dextran sulphate nanoparticles did not cause any 
reduction in the signal at the end of treatment. We did not image Group 7 as 
the mice did not look healthy to be anaesthetized and imaged.  
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Figure 4.8. Amphotericin B nanoparticles efficacy as measured by the bioluminescence signal (parasite load) at the infection site in BALB/c 
mice infected with luciferase-expressing L. major parasites. Female BALB/c mice were infected with stationary-phase promastigotes in the 
rump above the tail (n = 5 per group).  At 10 days post-inoculation, animals presenting with CL nodules were dosed with paromomycin (G2) 
as a positive control (50 mg/kg/QD for 10 days; i.p.), AmBisome® (G3) as a comparison group (10 mg/kg/QAD for 10 days; i.v.), blank chitosan-
TPP nanoparticles equivalent to AmB loaded nanoparticles(G4) (QAD for 10 days; i.v.), AmB loaded chitosan-TPP nanoparticles (G5) (5 mg 
of AmB/kg/QAD for 10 days; i.v.), blank chitosan-dextran sulphate nanoparticles equivalent to AmB loaded nanoparticles (G6) (QAD for 10 
days; i.v.), or the nanoparticles vehicle (G8) (distilled water, QAD for 10 days; i.v.). (G1) represents untreated infected group. The 
bioluminescence signal was measured three times: start of treatment, after two doses of treatment and lastly on the day after the administration 
of the last dose. The data represents the mean ± standard error. ANOVA (1 way for parasite load and repeated measures for lesion size) 
followed by Turkey’s multiple-comparison tests was used to compare outcomes among the groups. A p-value < 0.05 was considered 
statistically significant ((*) p<0.05, (**) p<0.05 and (***) p>0.05). (A) represents the bioluminescence signal in function of time since the start 
of treatment, (B) represents the bioluminescence signal on the day after the administration of the last dose (day 9). (C) represents the % 
reduction in the signal compared with G1 (untreated infected group) at day 9. (D) represents the correlation between lesion size and the 
bioluminescence signal on the day after the administration of the last dose and (E) represents the bioluminescent images of mice on day 9 
(24 h after the last drug dose administration). Emitted photons were gathered by auto acquisition with a charge couple device (CCD) camera 
(PerkinElmer IVIS Spectrum In vivo Imaging System) using the medium resolution (medium binning) mode. 
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4.3.6.1.3. Intralesional amphotericin B levels 
We measured the levels of the active compound (AmB) within the infected 
lesion (rump skin) and control skin (uninfected skin, back skin) at the end of 
the experiment (Fig 4.9.). AmB levels were significantly higher (between 13 
and 20-fold) in lesions sites (rump skin) compared to control skin (uninfected 
skin, back skin) in both Group 3 and Group 5 (p<0.05 by one-way ANOVA). 
After multiple dosing of either AmBisome® (G3, 10 mg/kg/QAD for 10 days; 
i.v.) or AmB loaded chitosan-TPP nanoparticles (G5, 5 mg of AmB/kg/QAD for 
10 days; i.v.), intralesional AmB levels were significantly lower (6.8-fold) in 
Group 3 than in Group 5 (p<0.05 by one-way ANOVA). We could not detect 
any AmB levels as expected in samples from untreated group (G1) and 
positive control (G2). 
 
 
Figure 4.9. Multiple dose skin pharmacokinetics of AmB loaded chitosan-TPP 
nanoparticles and AmBisome®. L. major-infected BALB/c mice received 
intravenous doses of AmBisome® (G3, 10 mg/kg/QAD for 10 days; i.v.) and AmB 
loaded chitosan-TPP nanoparticles (G5, 5 mg of AmB/kg/QAD for 10 days; i.v.).  
24 hours after the last dosing, AmB levels in skin were determined. The CL lesion 
was localized on the rump, while the back skin of same mice was used as lesion-
free, healthy control site. Each point represents the mean and standard error of the 
mean (n=5 per group). (A) represents intralesional AmB and (B) represents a 
comparison between infected and uninfected skin AmB concentration. The data 
represents the mean ± standard error. ANOVA followed by Turkey’s multiple-
comparison tests was used to compare outcomes among the groups. A p-value < 
0.05 was considered statistically significant ((*) p<0.05 and (**) p<0.05).  
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4.3.6.2. In vivo experiment 2 (dose-response effect) 
4.3.6.2.1. Evaluation of the lesion size progression  
Fig 4.10. shows the progression of the mean lesion size for each group as a 
function of time. Our data were similar and reproducible with previous in vivo 
experiment 1 regarding the efficacy of AmB loaded chitosan-TPP 
nanoparticles (5 mg of AmB/kg/QAD for 10 days; i.v.). In a mouse model of CL 
caused by L. major, AmB loaded chitosan-TPP nanoparticles efficacy showed 
a dose-response activity in reduction of lesion sizes at doses of 1.25, 2.5 and 
5 mg of AmB/kg/QAD for 10 days; i.v., which caused 29%, 40% and 83% 
respectively, reduction in lesion sizes at the end of the treatment compared to 
the untreated controls. Similar to in vivo experiment 1, there was no significant 
difference in the efficacy of AmBisome®, blank chitosan-TPP nanoparticles 
and AmB loaded chitosan-TPP nanoparticles (2.5 AmB/kg/QAD for 10 days; 
i.v.) with 40%, 35% and 40% respectively, reduction of lesion sizes (p>0.05 by 
one-way ANOVA). Paromomycin (positive control) and AmB loaded chitosan-
TPP nanoparticles (5 AmB/kg/QAD for 10 days; i.v.) were the most effective 
in reduction of lesion sizes and there was no statistically significant difference 
between the two treated groups with 89% and 83% respectively, reduction of 
lesion sizes at the end of the treatment compared to the untreated controls 
(p>0.05 by one-way ANOVA). 
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Figure 4.10. Amphotericin B nanoparticles efficacy in the lesion cure model in BALB/c mice infected with luciferase-expressing L. major 
parasites.  Female BALB/c mice were infected with stationary-phase promastigotes in the rump above the tail (n = 5 per group).  At 10 days 
post-inoculation, animals presenting with CL nodules were dosed with paromomycin (G2) as a positive control (50 mg/kg/QD for 10 consecutive 
days; i.p.), AmBisome® (G3) as a comparison group (10 mg/kg/QAD for 10 days; i.v.), AmB loaded chitosan-TPP nanoparticles (G4) (5 mg of 
AmB/kg/QAD for 10 days; i.v.), AmB loaded chitosan-TPP nanoparticles (G5) (2.5 mg of AmB/kg/QAD for 10 days; i.v.), AmB loaded chitosan-
TPP nanoparticles (G6) (1.25 mg of AmB/kg/QAD for 10 days; i.v.) and blank chitosan-TPP nanoparticles equivalent to AmB loaded 
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nanoparticles (5 mg/kg) (G7) (QAD for 10 days; i.v.). (G1) represents untreated infected group. During treatment, lesion size was measured 
daily. The average lesion size represents the mean ± standard error. ANOVA (1 way for parasite load and repeated measures for lesion size) 
followed by Turkey’s multiple-comparison tests was used to compare outcomes among the groups. A p-value < 0.05 was considered 
statistically significant ((*) p<0.05, (**) p>0.05, (***) p<0.05 and (****) p>0.05). (A) represents mean lesion size progression in function of time 
since the start of treatment, (B) represents mean lesion size on the day after the administration of the last dose and (C) represents the % 
reduction in lesion size compared with G1 (untreated infected group) at day 9. 
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4.3.6.2.2. Evaluation of the parasite load (bioluminescent signal)  
Bioluminescence signal progression in all treatment groups is shown in Fig 
4.11. The reduction of parasite loads in the skin follows a similar trend of the 
lesion size with a good correlation between lesion size and bioluminescent 
signal identified by Pearson correlation coefficients (using GraphPad Prism). 
In a mouse model of CL caused by L. major, AmB loaded chitosan-TPP 
nanoparticles efficacy showed a dose-response activity in reduction of the 
parasite loads at doses of 1.25, 2.5, and 5 mg of AmB/kg/QAD for 10 days; 
i.v., which caused 48%, 75% and 99%, respectively, reduction in parasite 
loads (bioluminescent signal) at the end of the treatment compared to the 
untreated controls. Paromomycin and AmB loaded chitosan-TPP 
nanoparticles (5 mg of AmB/kg/QAD for 10 days; i.v.) were the most effective 
compounds with 99% reduction of the signal at the end of the treatment.  
There was no significant difference in the efficacy of AmBisome® and AmB 
loaded chitosan-TPP nanoparticles (2.5 AmB/kg/QAD for 10 days; i.v.) in 
reducing parasite load with 80% and 75% respectively, reduction of 
bioluminescent signal (p>0.05 by one-way ANOVA). Blank chitosan-TPP 
nanoparticles caused a 65% reduction in parasite loads (bioluminescent 
signal). 
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Figure 4.11. Amphotericin B nanoparticles efficacy on the bioluminescence signal (parasite load) at the infection site in BALB/c mice infected with 
luciferase-expressing L. major parasites. Female BALB/c mice were infected with stationary-phase promastigotes in the rump above the tail (n = 5 per 
group).  At 10 days post-inoculation, animals presenting with CL nodules were dosed with paromomycin (G2) as a positive control (50 mg/kg/QD for 10 
consecutive days; i.p.), AmBisome® (G3) as a comparison group (10 mg/kg/QAD for 10 days; AmB loaded chitosan-TPP nanoparticles (G4) (5 mg of 
AmB/kg/QAD for 10 days; i.v.), AmB loaded chitosan-TPP nanoparticles (G5) (2.5 mg of AmB/kg/QAD for 10 days; i.v.), AmB loaded chitosan-TPP 
nanoparticles (G6) (1.25 mg of AmB/kg/QAD for 10 days; i.v.) and blank chitosan-TPP nanoparticles equivalent to AmB loaded nanoparticles (5 mg/kg) 
(G7) (QAD for 10 days; i.v.). (G1) represents untreated infected group. During treatment, lesion size was measured daily. The bioluminescence signal was 
measured three times: start of treatment, after two doses of treatment and lastly on the day after the administration of the last dose.  The data represents 
the mean ± standard error. ANOVA (1 way for parasite load and repeated measures for lesion size) followed by Turkey’s multiple-comparison tests was 
used to compare outcomes among the groups. A p-value < 0.05 was considered statistically significant ((*) p<0.05, (**) p>0.05, (***) p<0.05 and (****) 
p>0.05). (A) represents the bioluminescence signal in function of time since the start of treatment, (B) represents mean the bioluminescence signal on the 
day after the administration of the last dose (day 9), (C) represents the % reduction in the signal compared with G1 (untreated infected group) at day 9. (D 
represents the correlation between lesion size and the bioluminescence signal on the day after the administration of the last dose and (E) represents the 
bioluminescent images of mice on day 9 (24 h after the last drug dose administration). Emitted photons were gathered by auto acquisition with a charge 
couple device (CCD) camera (PerkinElmer IVIS Spectrum In vivo Imaging System) using the medium resolution (medium binning) mode. 
E 
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4.3.6.2.3. Intralesional amphotericin B levels 
We measured the drug levels of the active compound AmB within the infected 
lesion (rump skin) and control skin (uninfected skin, back skin) at the end of 
the experiment (Fig 4.12.). After multiple dosing of either AmBisome® (G3) or 
AmB loaded chitosan-TPP nanoparticles (G4 or G5 or G6), intra-lesional AmB 
levels were significantly lower (6.7-fold) in Group 3 (received AmBisome® at 
10 mg/kg/QAD for 10 days) than in Group 4 (received AmB loaded chitosan-
TPP nanoparticles at 5 mg of AmB/kg/QAD for 10 days; i.v.) (p<0.05 by one-
way ANOVA). There was no significant difference in the intra-lesional AmB 
levels between Group 3 and Group 5 (received AmB loaded chitosan-TPP 
nanoparticles at 2.5 mg of AmB/kg/QAD for 10 days; i.v.) (p>0.05 by one-way 
ANOVA) and these levels of AmB were significantly higher in these two groups 
than in Group 6 (received AmB loaded chitosan-TPP nanoparticles at 1.25 mg 
of AmB/kg/QAD for 10 days; i.v.) (p<0.05 by one-way ANOVA). AmB levels 
were significantly higher in lesions sites (rump skin) compared to control skin 
(uninfected skin, back skin) (p<0.05 by one-way ANOVA) for all treated groups 
with AmB formulations. We could not detect any AmB levels as expected in 
samples from untreated group (G1) and positive control (G2).  
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Figure 4.12. Multiple dose skin pharmacokinetics of AmB loaded chitosan-TPP nanoparticles and AmBisome®. L. major-infected BALB/c mice 
received intravenous doses of AmBisome® (G3, 10 mg/kg/QAD for 10 days; i.v.), AmB loaded chitosan-TPP nanoparticles (G4, 5 mg of 
AmB/kg/QAD for 10 days; i.v.), AmB loaded chitosan-TPP nanoparticles (G5, 2.5 mg of AmB/kg/QAD for 10 days; i.v.) and AmB loaded 
chitosan-TPP nanoparticles (G6, 1.25 mg of AmB/kg/QAD for 10 days; i.v.).  24 hours after the last dosing, AmB levels in skin were determined. 
The CL lesion was localized on the rump, while the back skin of same mice used as lesion-free, healthy control site. Each point represents the 
mean and standard error of the mean (n=5 per group). (A) represents intralesional AmB and (B) represents a comparison between infected 
and uninfected skin AmB concentration. The data represents the mean ± standard error. ANOVA followed by Turkey’s multiple-comparison 
tests was used to compare outcomes among the groups. A p-value < 0.05 was considered statistically significant ((*) p<0.05, (**) p>0.05 and 
(***) p<0.05).  
A B 
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4.3.6.2.4. Dose concentration-response of AmB loaded chitosan-TPP 
nanoparticles in L. major-infected mice  
The intralesional AmB levels were related to the dose levels of treatment with 
AmB loaded chitosan-TPP nanoparticles at concentrations (5 (G4) or 2.5 (G5) 
or 1.25 (G6) mg of AmB/kg/QAD for 10 days; i.v.) (Fig 4.13.a) and to the 
response (indicated by lesion size and parasite load) (Fig 4.13.b and 4.13.c, 
respectively). Fig 3d shows the nonlinear-fit sigmoidal dose-response curve 
plotting the logarithm of these intralesional AmB levels versus relative 
reductions in parasite load and lesion size compared to the untreated controls 
(0 mg/kg). Fig 4.13.e shows the % of relative reduction of lesion size and 
parasite load related to the doses per kg of AmB.  
Correlation was strong between dose concentration and concentration 
response for relative reduction in parasite load and lesion size (identified by 
Pearson correlation coefficients (using GraphPad Prism)). We calculated ED50 
(The required dose to achieve 50% of maximum effect) and ED90 (The required 
dose to achieve 90% of maximum effect) after plotting the logarithm of the 
dose level against percentage response (lesion size or parasite load). ED50 
and ED90 were 2.5 and 8.9 mg/kg, respectively for lesion size. ED50 and ED90 
were 1.3 and 3.8 mg/kg, respectively for parasite load (bioluminescent signal). 
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Figure 4.13. Dose concentration-response relationship of AmB loaded chitosan-TPP nanoparticles in experimental CL. L. major-infected BALB/c mice 
received intravenous doses of AmB loaded chitosan-TPP nanoparticles 0 or 1.25 or 2.5 or 5 of AmB/kg/QAD for 10 days (n = 5 per group).  ; (a) represents 
the resulting intralesional amphotericin B levels, (b) lesion size, and (c) parasite load on the day after the last dose. (d) Outcomes are linked in a logarithmic-
scale dose-response curve plotting drug concentrations against relative reduction in lesion size and parasite load. (e) is the relation between the dose in 
mg/kg and % of reduction of lesion size and parasite load.  Each point represents the means ± SD(n =5 per group). ANOVA followed by Turkey’s multiple-
comparison tests was used to compare outcomes among the groups. A p-value < 0.05 was considered statistically significant. 
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4.3.7. Ex vivo permeability of Leishmania-infected skin in Franz diffusion 
cells   
The permeability of uninfected and L. major infected skin for AmB loaded 
chitosan nanoparticles and fluorescence images of the nanoparticles 
distribution were evaluated in Franz diffusion cells. The cumulative 
concentration of AmB from AmB-loaded chitosan-TPP nanoparticles and 
AmB-loaded chitosan-dextran sulphate nanoparticles in the receptor 
compartment of Franz diffusion cells permeated as a function of time is shown 
in Fig 4.14. When applied as solution, pure AmB did not permeate through 
uninfected or infected skin throughout the 24 h permeation experiment. This 
was in contrast to the nanoparticle formulations, for which AmB could be 
detected in the receptor fluid. At the end of the 24 h experiment, both types of 
AmB loaded chitosan nanoparticles showed approximately a two-fold higher 
permeation of AmB through infected skin than uninfected skin (p<0.05 by t-
test). AmB from AmB loaded chitosan-TPP nanoparticles permeated with 
almost two times more than from AmB loaded chitosan-dextran sulphate 
nanoparticles through both uninfected and infected skin ( p<0.05 by t-test).   
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Figure 4.14. The cumulative amount of AmB permeated per surface area (ug/cm2) 
through uninfected BALB/c mouse skin (n=5) and L. major infected BALB/c mouse 
skin (n=5). Infected skin was more permeable to both types of AmB loaded chitosan 
nanoparticles than uninfected skin (p<0.05 by t-test). The use of AmB loaded 
chitosan-TPP nanoparticles enhanced AmB penetration through both healthy and 
infected skin in more amount than AmB loaded chitosan-dextran sulphate 
nanoparticles (p<0.05 by t-test). 
Lag time, flux and permeability coefficients of the formulations are shown in 
Table 4. 9. There was no significant difference in the lag time for both types of 
AmB nanoparticles between uninfected and infected skin ( p>0.05 by t-test) 
and no significant difference was observed between AmB loaded chitosan-
TPP nanoparticles and AmB loaded chitosan-dextran sulphate nanoparticles 
( p>0.05 by t-test). The flux was 2 times higher for both types of AmB loaded 
chitosan nanoparticles in infected skin compared to uninfected skin. The 
permeability coefficient was 1.75 and 2.5 times higher for AmB loaded 
chitosan-TPP nanoparticles and AmB loaded chitosan-dextran sulphate 
nanoparticles respectively in infected skin compared with uninfected skin. All 
the above indicated that L. major infection of the skin enhanced the permeation 
of both types of nanoparticles and the permeation of AmB nanoparticles is 
slow and poor. 
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Table 4.9. Flux, lag time and the permeability coefficient (kp) for AmB loaded chitosan nanoparticles  
Compounds 
Flux (μg/cm2/h) Lag time (h) Kp (cm/h) 
Uninfected 
skin 
Infected 
skin 
Uninfected 
skin 
Infected 
skin 
Uninfected skin Infected skin 
AmB loaded 
chitosan-TPP 
nanoparticles 
0.06 ± 0.002 0.12 ± 0.005 20 ± 0.1 19.8 ± 0.3 1.8E-05 ± 0.05E-05 3.15E-05 ± 0.15E-05 
AmB loaded 
chitosan-dextran 
sulphate 
nanoparticles 
0.04 ± 0.002 0.09 ± 0.002 20.5 ± 0.1 20.3 ± 0.02 0.9E-05 ± 0.05E-05 2.3E-05 ± 0.06E-05 
Pure AmB 0   0 
Data expressed as mean +/- SD, n=5. No statistically significant difference of lag time was observed between uninfected and infected skin 
for both formulations ( p>0.05 by t-test). Statistically significant differences of flux and kp were observed between uninfected and infected 
skin for both formulations ( p<0.05 by t-test). 
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Table 4.10 shows the distribution of topical AmB from AmB loaded chitosan 
nanoparticles and pure AmB into healthy and L. major infected skin. After the 
24 h permeation experiment, more than 90% of pure AmB stayed on the skin 
without any drug in the receptor fluid. Regarding both types of AmB loaded 
chitosan nanoparticles only a limited amount of AmB passed through the skin 
with 0.23% and 0.42% of AmB from applied AmB loaded chitosan-TPP 
nanoparticles through uninfected and infected skin respectively and 0.12% 
and 0.28% of AmB from applied AmB loaded chitosan-dextran sulphate 
nanoparticles through uninfected and infected skin respectively.  
Table 4.10. Disposition of topically applied AmB loaded chitosan nanoparticles 
on healthy and L. major infected BALB/ c mice skin using Franz diffusion cells 
Applied compounds 
Average % recovered of 
AmB (±SD) 
 
Uninfected 
skin 
L. major 
infected 
skin 
P 
value 
Pure AmB  
on skin (in wash and 
cotton swab) 
94.65 ± 2 92.32 ± 1 >0.05 
in skin (extracted from 
skin homogenate) 
5.35 ± 0.2 7.68 ± 0.2 >0.05 
through skin after 24h (in 
receptor fluid) 
0 0 >0.05 
AmB loaded 
chitosan-
TPP 
nanoparticles 
on skin (in wash and 
cotton swab) 
69.92 ± 1 61.49 ± 1 <0.05 
in skin (extracted from 
skin homogenate) 
29.85 ± 1 38.09 ± 0.5 <0.05 
through skin after 24h (in 
receptor fluid) 
0.23 ± 0.02 0.42 ± 0.05 <0.05 
AmB loaded 
chitosan-
dextran 
sulphate 
nanoparticles 
on skin (in wash and 
cotton swab) 
81.65 ± 2 73.14 ± 2 <0.05 
in skin (extracted from 
skin homogenate) 
18.23 ± 1 26.58 ± 1 <0.05 
through skin after 24h (in 
receptor fluid) 
0.12 ± 0.02 0.28 ± 0.02 <0.05 
The total amount of AmB per Franz diffusion cell recovered at the end of the 
experiment was considered 100%. The amounts of AmB recovered from the 
different sites were expressed as a fraction of this amount. The average (±SD) 
percent for 5 infected mice is shown. p values were determined by a t test. 
 
Fluorescence microscopy of skin sections showed no evidence for the 
penetration of rhodamine labelled chitosan-TPP nanoparticles (size= 72 ± 7 
nm, Zeta potential= 22 ± 2) or rhodamine labelled chitosan-dextran sulphate 
nanoparticles (size= 174 ± 7 nm, Zeta potential= -14 ± 2) or rhodamine labelled 
chitosan solution in excised uninfected and L. major infected mouse skin. The 
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microscope study Indicates that the nanoparticles act as drug delivery vehicle 
and release the AmB rather than permeating alongside the AmB molecules 
(Fig 4.15). 
 
  
Figure 4.15. Fluorescence images of skin penetration (uninfected and L. major 
infected skin) of blank rhodamine labelled chitosan nanoparticles (A) and rhodamine 
labelled chitosan solution (B). We found the same scene for both types of 
nanoparticles and in both uninfected and infected skin. The red signals (refer to 
rhodamine labelled chitosan) indicated that the three formulations remained on the 
surface of skin. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A
A 
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4.4. Discussion  
In vitro haemolytic activity and cytotoxicity of chitosan formulations 
Haemolytic activity of chitosan formulations was determined by using freshly 
obtained human RBCs (295). Pure AmB showed a serious and significant toxic 
effect to RBCs after 1h of incubation. Loading the drug into both types of 
chitosan nanoparticles mitigated these effects, presumably by entrapping and 
retaining the AmB, allowing for slow release of drug. Similar findings have 
been reported for blank and AmB loaded chitosan- chondroitin sulphate 
nanoparticles (122). To evaluate the cytotoxicity of chitosan formulations in 
more details we found that both types of AmB loaded chitosan nanoparticles 
were around 6-fold less toxic than pure AmB against KB-cells and there was 
no significant difference in the cytotoxicity between these AmB loaded 
chitosan nanoparticles and AmBisome® for same reasons mentioned 
previously in terms of drug entrapment and slow release. Chitosan solution 
and blank chitosan nanoparticles (both types) showed a similar cytotoxicity 
against KB-cells and were significantly less toxic than AmB loaded 
nanoparticles. This data supports previous reports of less cytotoxicity of AmB 
loaded chitosan- chondroitin sulphate nanoparticles (136±11 nm, positive 
charge) compared to pure AmB against murine macrophages and the low 
toxicity of chitosan solution and blank nanoparticles against murine 
macrophages (122). Similarly, Jain et al reported that chitosan-coated AmB-
loaded solid lipid nanoparticles (158.9±7.1 nm, positive charge) showed 
significantly less toxic effects against macrophages (J774A.1 cells in 
exponential growth phase) compared to amphotericin B deoxycholate 
(Fungizone) (259). 
 
In vitro anti-leishmanial activity of chitosan formulations 
Consistently with previous data in Chapter 2, lowering pH of RPMI medium 
from 7.5 to 6.5 increased by 7-20 times, the anti-leishmanial activity of chitosan 
solution and blank chitosan-TPP nanoparticles against L. major and L. 
mexicana promastigotes and amastigotes due to the greater ionisation at 
lower pH for both chitosan solution and blank chitosan-TPP nanoparticles 
(positive surface charge). As mentioned in the Chapter 2, increasing the 
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positive charge could enhance the chitosan antimicrobial activity by interacting 
with the negatively charged microbial membrane – in accordance with the first 
postulated mechanism of antimicrobial activity described in the introduction.  
Regarding blank chitosan-TPP nanoparticles, they showed less anti-
leishmanial activity than chitosan solution against L. major and L. mexicana 
promastigotes due to the lower positive charge of these nanoparticles as few 
numbers of the amino groups have been substituted by TPP groups.  On the 
other hand, blank chitosan-TPP nanoparticles showed similar anti-leishmanial 
activity to chitosan solution against L. major and L. mexicana amastigotes at 
a lower pH due to the significant higher uptake of these nanoparticles by 
macrophages than chitosan solution (254). 
Blank chitosan-dextran sulphate nanoparticles did not present any activity 
against L. major and L. mexicana promastigotes and amastigotes at both pH 
values- these nanoparticles have a negative surface charge as the positive 
amino groups on chitosan have been substituted by negatively charged 
sulphate groups.  
However, AmB loaded chitosan nanoparticles (both types, positive or negative 
charged nanoparticles) showed a similar anti-leishmanial activity L. major and 
L. mexicana promastigotes and amastigotes at two pH values due to the high 
activity of AmB and this anti-leishmanial activity was similar to the activity of 
pure AmB and significantly higher than AmBisome®. Ribeiro et al (2014) 
reported that the anti-leishmanial activity of AmB loaded chitosan-chondroitin 
sulphate nanoparticles (136±11 nm, positive charge) was similar in 
comparison to pure AmB against L. amazonensis and L. chagasi 
promastigotes with similar EC50 values to our study (83). Additionally, our EC50 
values against L. major and L. mexicana amastigotes were in accordance with 
another report that found the EC50 values of chitosan-coated AmB-loaded solid 
lipid nanoparticles (158.9±7.1 nm , positive charge), AmBisome® and 
Fungizone were 0.022±0.07, 0.086±0.04, and 0.253±0.03 μg/ml, respectively, 
against L. donovani amastigotes infecting mouse macrophage cell line 
J774A.1 after 72 h of incubation (259).  
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Ribeiro et al (2014) showed that chitosan solution had EC50 values of  66±1 
and 71±1 µg/ml and blank chitosan nanoparticles had EC50 values of  52 ±2 
and 46 ±6 µg/ml against L. amazonensis and L. chagasi promastigotes, 
respectively and these values are different from EC50 values in our study at 
two pH values (Table 4.8 ) and this could be explained as Ribeiro et al used 
different Leishmania species, 48h incubation of compounds with Leishmania 
and did not mention the pH of the experiment (83).  
We were able to develop AmB loaded chitosan-TPP nanoparticles (69 ± 8 nm, 
positive surface charge) and AmB loaded chitosan-dextran sulphate 
nanoparticles (170 ± 9 nm, negative surface charge) which showed similar 
anti-leishmanial activity to pure AmB and higher activity than AmBisome® 
against promastigotes and amastigotes. These nanoparticles did not show 
significant haemolytic activity against RBCs and they were 6-fold less cytotoxic 
against KB-cells than pure AmB. This encouraged us to evaluate their in vivo 
anti-leishmanial activity using the mouse module.  
 
In vivo anti-leishmanial activity of chitosan formulations  
We assessed the efficacy of the chitosan formulations in murine models of CL 
caused by L. major, when administrated intravenously. 
We evaluated the skin distribution of AmB following intravenous dosing with 
AmB loaded chitosan-TPP nanoparticles (1.25, 2.5 or 5 mg of AmB/ml/QAD 
for 10 days; i.v.) and AmBisome® (10 mg/kg/QAD for 10 days; i.v.). AmB 
accumulated in significant higher levels in the localized lesion compared to 
those in healthy skin tissue of the same infected mice; revealing the influence 
of CL skin infection on the drug accumulation. This could be explained by 
localized inflammatory immune response caused by L. major parasites 
multiplying within dermal macrophages of CL infected skin. Therefore, at the 
site of infection, the leaky vasculature could enhance permeability and 
retention effect of the drug and this may promote the local drug accumulation 
(170, 298) and these small nanoparticles could facilitate extravasation through 
the leaky capillaries in the inflamed lesion skin while in the healthy skin, the 
impairment in the extravasation (continuous endothelium with small vessel 
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pores of 6- to 12-nm diameter) could decrease the drug accumulation (299). 
Another explanation is because of the immune response to the CL, phagocytic 
monocytes immigrate from the bloodstream to the infection site (skin lesion) 
and these cells can act as drug reservoirs (16, 19, 300). Similar finding was 
reported by Wijnant et (2018) as AmB levels were 5- to 20-fold higher in L. 
major infected BALB/c mice skin than in healthy skin from same infected mice 
following dosing with AmBisome® or Fungizone.  
However, AmB loaded chitosan-TPP nanoparticles (5 mg/ml/QAD for 10 days; 
i.v.) resulted in significant higher levels of AmB accumulation in infected skin 
than AmBisome® (10 mg/kg/QAD for 10 days; i.v.). There was no difference in 
the quantity of AmB in lesion skin following dosing of AmB loaded chitosan-
TPP nanoparticles (2.5 mg/ml/QAD for 10 days; i.v.) and AmBisome® (10 
mg/kg/QAD for 10 days; i.v.). Similarly, Sarwar et al (2017) reported that the 
oral administration of mannose-anchored thiolated chitosan amphotericin B 
nanocarriers ( 400 nm, positive surface charge) resulted in more AmB levels 
in the systemic circulation and higher pharmacokinetic parameters (AUC,t1/2 
and Cmax) in comparison with same dose of AmBisome® or pure amphotericin 
B (301). Moreover, the same study showed mannose-anchored thiolated 
chitosan amphotericin B nanocarriers (400 nm, positive surface charge) 
promoted the cellular uptake of AmB by 70- and 23-fold in comparison to pure 
AmB and AmBisome®, respectively (301). This could be explained as the 
chitosan nanoparticles are able to retain the AmB inside the macrophages for 
the longer period of time compared AmBisome® and AmB and as mentioned 
that these macrophages could serve as reservoirs for the drug to target the 
infection site (301).  
Blank chitosan-dextran sulphate nanoparticles did not cause any reduction in 
lesion size or parasite load (bioluminescent signal) of the infected mice. 
However, blank chitosan-TPP nanoparticles showed a similar activity in regard 
of lesion size and parasite load (bioluminescent signal) to AmBisome®. Ribeiro 
et al (2014) reported that blank chitosan-chondroitin sulphate nanoparticles 
(104±11 nm, positive charge) caused a significant reduction in lesion size of 
L. amazonensis infected BALB/c mice, when administrated intravenously (83).  
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AmB loaded chitosan-TPP nanoparticles (5 mg/ml/QAD for 10 days; i.v.) 
showed a high effectivity against CL in the mouse module and similar to the 
positive control (paromomycin, 50 mg/kg/QD for 10 consecutive days; i.p.), 
and caused a significant reduction on lesion development and parasite load 
(bioluminescent signal). Additionally, AmB loaded chitosan-TPP nanoparticles 
(2.5 mg/ml/QAD for 10 days; i.v.) resulted in a similar reduction of lesion size 
and parasite load (bioluminescent signal) to AmBisome® (10 mg/kg/QAD for 
10 days; i.v.). The superior efficacy of AmB loaded chitosan-TPP nanoparticles 
(5 mg/ml/QAD for 10 days; i.v.) compared to AmBisome® (10 mg/kg/QAD for 
10 days; i.v.) could be related to higher intralesional drug concentrations 
(described previously) and the effectivity of chitosan nanoparticles against CL.  
Ribeiro et al (2014) reported that AmB loaded chitosan- chondroitin sulphate 
nanoparticles (136±11 nm, positive charge) caused significant reductions in 
the lesion size and in the parasite burden of L. amazonensis infected BALB/c 
mice, when administrated intravenously (1 mg/kg/day for 10 days) and were 
more active than pure AmB at same doses (121).  
There was a good correlation between levels of intralesional AmB 
accumulation and the therapeutic outcomes of AmB loaded chitosan-TPP 
nanoparticles as the anti-leishmanial activity of AmB has a concentration-
dependent response and this due to the concentration-dependency of AmB 
antimicrobial activity (302) and this consistent with Wijnant et al (2018) for 
AmBisome® in CL mouse module (170). 
 
Chitosan formulations for topical administration – skin penetration 
As we mentioned that topical treatment offers several advantages over 
systemic treatment regarding side effects, the direct target for infected lesions, 
less need for patient follow up and better compliance by the patients (303, 304, 
305, 306). Thus, the aim was to develop topical nanoparticles formulations 
(positive and negative charged nanoparticles) containing AmB. There are four 
fundamental factors that control the efficacy of topical treatment of CL: 
(i) The intrinsic efficacy of the compound against Leishmania   
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(ii) The permeability of the compound through the skin to reach the 
dermis where the Leishmania infected macrophages reside (30) 
(iii) Disposition of the drug in the skin  
(iv) The release of the active compound from formulation in the PV of 
infected macrophages in the dermis of infected skin (306) 
Both AmB chitosan-TPP nanoparticles and AmB chitosan-dextran sulphate 
nanoparticles showed a high activity against Leishmania promastigotes and 
amastigotes. Therefore, we investigated their in vitro permeation 
characteristics through uninfected and L. major infected mice skin using Franz 
diffusion cells. 
By using Franz diffusion cells, pure AmB did not permeate through 
uninfected or L. major infected skin. This is consistent with other reports 
(307, 308, 309, 310) and this could be explained as AmB is a big molecule 
(924 g/mol ) and is not soluble in water (307). 
 Briefly to optimise permeation, a given drug should comply with the following 
physicochemical properties : 
 molecular weight < 500 g/mol 
 log p between 1 – 3 
 aqueous solubility > 1 mg/ml 
 hydrogen bonding groups < 2. 
Accordingly AmB is not a a good candidate for topical route,  as its molecular 
weight is > 500 g/mol and log p of AmB is -0.66 and it is not the acceptable 
range for skin permeation (log P between 1-3) and has  12 H-bond donors and 
18 H-bond acceptors (311, 312).This impermeability of AmB through healthy 
or infected skin clarified the unsuccessful treatment after the topical application 
of AmB on L. major infected mice (313). In addition, AmBisome® (liposomal 
AmB) was not efficient delivery topical systems for CL (314) and did not 
present a significant AmB skin deposition, in vitro study (Excised human skin 
from Caucasian female patients) (315).   
In vitro permeation study showed a limited and slow permeation of AmB across 
healthy and infected mice skin when both types of AmB loaded chitosan 
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nanoparticles applied on the skin samples with a long lag time of about 20 h 
indicating a long time for the steady state flux to be reached (which indirectly 
means slow permeation across the stratum corneum). These data were 
confirmed by imaging the permeation of rhodamine labelled chitosan-TPP 
nanoparticles and rhodamine labelled chitosan-dextran sulphate 
nanoparticles across uninfected and L. major infected skin using laser 
microscope which showed that these nanoparticles stayed on the surface of 
skin. Our results were consistent with other reports; Vogt et al reported that 
most of applied 42–300 nm fluorescent silica nanoparticles stayed in the upper 
layers of the excised human skin using conventional fluorescence microscopy 
of skin sections(316). 
Try et al observed a negligible penetration of poly (L-lactide-co-glycolide) 
nanoparticles with two sizes 70 and 300 nm in healthy male Swiss mice skin 
by using confocal laser scanning microscopical examination of skin biopsies 
while nanoparticles have been visualised in the epidermis in inflamed skin 
(inflammation induced by the application of oxazolone to develop atopic 
dermatitis like lesions) (317). Moreover, our data are in agreement  with the 
study of Campbell et al who reported no penetration of fluospheres 
nanoparticles ( carboxy-modified, fluorescent, polystyrene nanoparticles with 
three sizes 20, 100 and 200 nm) through pig skin and these nanoparticles 
remained in the top layers of the stratum corneum after 16 h of the application 
in Franz diffusion cells by using a laser scanning confocal microscopy (318). 
Similar observation regarding the limited permeation of chitosan nanoparticles 
was noticed by Nair et al, that curcumin-encapsulated chitosan nanoparticles 
with sizes ranged from 167.3 ± 3.8 nm to 251.5 ± 5.8 nm had a slow 
permeation and with low amounts using Franz diffusion cells through Strat-M® 
membrane (Strat-M is made of polyester sulfone arranged as multiple layers 
mimicking the skin structure including a tough outer layer manufactured by 
Merck) and the cumulative amount of curcumin permeated at 72 h was 34.3 ± 
1.6 μg cm−2 and 27.7 ± 1.7 μg cm−2 for nanoparticles with sizes 251.5 and 
167.3nm , respectively (319) . Malli et al (2019) reported that the topical 
application of chitosan-Coated Poly (isobutyl cyanoacrylate) ( size=187nm , 
zeta potential =53.8 mv) nanoparticles (prepared by anionic emulsion 
194 
 
polymerization method) gelified by pluronic F127 daily for 3 consecutive weeks 
to BALB/c mice infected with L. major, resulted in partial and not complete 
healing of lesion and could be due to a physical effect of the F127 hydrogel 
(220). 
AmB loaded chitosan nanoparticles offered more permeation of AmB through 
infected than uninfected skin when applied topically and this was consistent 
with another report that showed more permeation of caffeine and ibuprofen 
through L. major infected than uninfected BALB/c mouse skin, using Franz 
diffusion cells (166). The same study reported no permeation of paromomycin 
sulphate through uninfected mice skin while a high permeation through L. 
major infected skin was observed using Franz diffusion cells (166). This could 
be explained as CL lesions cause a damage to the skin barrier and this 
alteration in skin could enhance the penetration of nanoparticles (320). 
Moreover, Leishmania infected skin is characterised by the presence of 
abundant inflammatory cells in the infection site and this could disarrange the 
consistency of the epidermal and dermal skin layers and by ulceration and 
necrosis (307, 310, 321). Trans-epidermal water loss (TEWL) was significantly 
higher in L. major infected skin and this reduced the barrier function of the skin 
and subsequently increased the accumulation of fluid in the interstitial spaces 
cause an oedema that could enhance the permeation of water-soluble 
compounds  (307).  
AmB loaded chitosan-TPP nanoparticles (size= 68 ± 7 nm, Zeta potential= 30 
± 2) presented more permeation of AmB than AmB loaded chitosan-dextran 
sulphate nanoparticles ( size= 168 ± 7 nm, Zeta potential= -15.5 ± 2). Similarly, 
Try et al reported a higher penetration of smaller poly(L-lactide-co-glycolide) 
nanoparticles (70nm) than bigger ones (300 nm) in healthy male Swiss mice 
skin and could be explained as smaller sized nanoparticles can penetrate for 
more distance compared with bigger ones (317). 
Another explanation of this higher penetration as the positive surface charge 
of chitosan-TPP nanoparticles could interact with negative charges in the skin 
and confirm close contact with the skin and make an occlusive barrier that 
enhance the hydration and this facilitates the nanoparticles permeation 
through the skin (322, 323).  
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All of the above regarding the limited and slow permeation of AmB from AmB 
loaded nanoparticles made these nanoparticles unsuitable candidates for 
topical administration. On this basis we did not pursue in vivo evaluation of the 
antileishmanial activity of topical route of these formulations.  
In conclusion, AmB loaded chitosan-TPP nanoparticles showed efficient, 
stability properties and target oriented drug delivery system in an experimental 
model cutaneous leishmaniasis when administered by the i.v. route, these 
nanoparticles were significantly more active than AmBisome® against the 
murine model (female BALB/c mice) of L. major even with lower doses of these 
nanoparticles. AmB loaded chitosan-TPP nanoparticles can specifically target 
the CL lesions more than AmBsiome as they resulted in a higher concentration 
of AmB in the lesion sites in comparison to AmBisome®.  However, Franz 
diffusion cell studies showed poor drug permeation into and through the skin 
of both types of AmB loaded chitosan nanoparticles suggesting that these 
formulations are not an appropriate candidate for topical treatment for CL. Our 
results indicate the need for more extensive studies using the intravenous 
route using different Leishmania species, different mammalian models and 
further extensive toxicity studies. Finally, skin samples from the in vivo study 
are stored for qPCR determination of parasite load and this work fell beyond 
the time line of this project. 
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5. Comparison of in vitro static and dynamic culture systems 
to evaluate the macrophages functions and the anti-
leishmanial efficacy of chitosan formulations ** 
** research in this chapter was performed in collaboration with Alec O’Keeffe, 
who showed in a published paper (I am one of the co-authors) that the infection 
of macrophages by L. major was significantly reduced under slow medium flow 
and faster medium flow (to match the interstitial fluid flow rate in human skin) 
compared to macrophages under static conditions. The replication of 
Leishmania amastigotes and two functions of macrophages (phagocytosis and 
macropinocytosis) were also reduced under two media perfusion conditions, 
see publication, Appendix 2 (Paper 1).  
Alec O’Keeffe completed his PhD on the development of novel predictive 2D 
and 3D in vitro models for ant-leishmanial drug testing, studying the activity 
and accumulation of anti-leishmanial drugs under these different flow 
conditions. Some of his results are included in the discussion for reference.  
5.1.  Media perfusion system: an introduction 
The important effects of fluid flow (blood flow, interstitial flow, etc) on cell 
signalling and morphogenesis have been widely recognized. Cells in the 
mammalian body are residing in highly complex microenvironments and 
encounter many signals that vary in time and space. Tissues are in direct 
contact with moving body fluids, which encompass the haemolymphatic 
system, the digestive system and cerebrospinal fluid. These fluids play a 
significant role in the body cells such as the provision and delivery of nutrients, 
oxygen, cell signalling components and the removal of waste. The flow of 
blood and other bodily fluids within the body exerts mechanical stress on cells 
(324). Different rates of body fluid flow have been recorded, from fast plasma 
flow of 9.8 ml/min in the portal vein of the rat (325) to slow rates of 0.19 μl/min 
of interstitial fluid drainage from rat brains (326). 20% of the human body’s 
mass is estimated to be made up of interstitial fluid which is in all tissues, 
including skin; derived from the normal leakage of plasma from blood vessels 
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and has a similar structure to that of blood plasma (327). Leishmania 
amastigotes reside and survive in the phagolysosome of mammalian 
macrophages and in CL, these infected macrophages are exposed to 
interstitial fluid in the skin. The flow of interstitial fluid in uninfected human skin 
has been recorded to be in the order of 0.1–2 μm/s but this flow in CL infected 
skin has not been determined  (327, 328, 329). 
Most in vitro studies, in the Leishmania field (on drug discovery, host cell 
transport and immunology), have been conducted on macrophages in static 
culture, typically using 4-, 12-, 16-, 24-, 48-, and 96-well plates with a culture 
medium overlay. This static system does not provide the mechanical stress, 
and O2 tension, amongst other things, to that of cells within a mammalian body 
(98). Consequently, a static system has a major limitation when evaluating 
cellular parameters in vitro, such as infection rate, drug activity, and 
macrophage functions such as phagocytosis and pinocytosis, offering a poor 
mechanistic understanding and predictive value (98, 324). Increasing the 
complexity of a culture system could produce, potentially, a more biologically 
relevant system. Additionally, the issues surrounding the use of animal models 
in terms of welfare, time and cost constraints, and the limits of non-human 
models in predicting outcomes in humans, make developing a more predictive 
in vitro culture system a high priority (324).  
A first step is transforming static cultures systems to flow systems where the 
culture medium constantly flows, to imitate the flow conditions in the 
mammalian body (330). Microfluidic (Fig 5.1.) and macrofluidic systems (Fig 
5.2.) are the main two types of media perfusion systems to conduct in vitro 
assays.  
Many “microbioreactor” systems have been described for cell culture which 
range from laminar flow, membrane systems to rotating vessel systems.  Most 
of these bioreactors require the use of particular seeding methods with narrow 
dimensional specifications (331, 332, 333). Microfluidic systems can be 
adjusted to mimic physiological conditions and deliver nutrients, dissolved 
gases and remove waste products. The advantage of a microfluidic system is, 
that less reagents are used overall helping to lower experimental costs. 
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However, microfluidic systems do have a number of disadvantages – they are 
typically very small and require significant technical ability and care when 
setting up (98). In microfluidic systems, just a few thousand cells can be 
seeded on the tiny culture surface (0.5–0.8 mm2) and this low number of 
seeded cells cannot predict precisely the in vivo pathophysiology. Another 
drawback of these systems includes the “edge effect” in which a high 
proportion of cultured cells will be located on the outer circumference of the 
chamber. These cells will be organised differently as medium evaporates at a 
higher rate at the edges compared to the central area of the chamber, affecting 
cell seeding. An uneven cell layer can skew the results (334). Another 
disadvantage, when using micro systems, is that small hydrophobic molecules 
can be adsorbed by the material that either the chamber system or the 
connecting tubes are composed of (335, 336).  A micro system will also have 
a high surface area to volume ratio and surface adsorption which will cause 
an increase in metabolic consumption rates and depletion of nutrition for the 
cells (335, 336, 337). Air bubble formation can pose problems within these 
systems, disrupting flow and affecting sheer stress (338).  
Macrofluidic systems (for example, Quasi Vivo, Kirkstall Ltd, Fig 5.2) offer 
many advantages over microfluidic systems - a higher volume of liquid is used 
which eases the preparation of low concentration compounds without wasting 
compounds through dilution. These systems can keep the shear stress 
consistently similar to the shear stress in most physiological environments 
(324). Moreover, macrofluidic systems can run for a longer time than micro 
system cultures and have a lower surface area to volume ratio, overcoming 
the major disadvantage of high metabolic consumption seen in micro systems 
(324). 
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Figure  5.1. Microfluidic system (A) The integrated perfusion culture micro-
chamber array chip. (B) Enlarged view of a micro-chamber array unit (339). 
 
 
  
 
Figure  5.2. Kirkstall LTD. Quasi Vivo 900 media perfusion system in use circulating 
RPMI 1640 media(340). 
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Our study used QV900, as described by O'Keeffe A et al (2018) with two flow 
rates, in which one rate mimics the interstitial tissue flow rate in the skin. 
Modelling of the flow rate at the cell surface and O2 tension was made by a 
collaboration between The London School of Hygiene & Tropical Medicine 
(Alec O'Keeffe and Simon L Croft) and University of Glasgow (Lauren 
Hyndman and Sean McGinty) (100).  
Here, this Chapter describes the impact of flow on host cell phagocytosis and 
macropinocytosis and how increasing the complexity of in vitro model 
influences the anti-leishmanial activity of chitosan formulations (chitosan 
solution, blank chitosan-TPP -nanoparticles and AmB loaded chitosan-TPP 
nanoparticles) against intracellular L. major amastigotes, these formulations 
showed a high in vitro activity against L. major amastigotes using static culture 
system (Chapter 4) 
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5.2. Material and methods 
Kirkstall Ltd (Rotherham, UK), established in 2006 by Dr J Malcolm Wilkinson 
in 2006, has developed cell culture technology into a commercially available 
inter-connected cell culture system, known as Quasi Vivo®, by introducing 
flow into the cell cultures to increase physiological relevance and create more 
confidence in the data produced. The Quasi Vivo system includes QV500 (an 
individual chamber system) and QV900 and their specifications are 
summarised in Table 5.1.  
 
Table 5.1. Specifications of QV500 and QV900 media perfusion system(340, 341, 
342) 
 
Features 
QV500 QV900 
Chamber width 15 mm internal 15 mm internal 
Chamber depth 
10 mm from culture surface 
to top of chamber base 
22 mm 
Materials 
Chamber: PDMS 
Tubing: Tygon 
Luers and reservoir bottle: 
Polypropylene 
Chamber: 
Base: Altuglas SG7 – Acrylic 
Resin 
Lids: Melifex  M8706 – 
Styrene TEP 
Tubing: Tygon/PTFE & FEP 
Luers and reservoir bottle: 
Polypropylene 
Overall dimensions 
23 mm height x 37 mm 
diameter 
23 mm height x 37 mm 
diameter 
Diameter of tubing 
Inlet: 1/16” ID 
Outlet: 3/32” ID 
Inlet: 1/16” ID 
Outlet: 3/32” ID 
Volume of 
chamber 
2 ml 4 ml 
 
5.2.1. Preparation of chitosan solution and blank and AmB loaded 
chitosan nanoparticles 
 All nanoparticles in this study were prepared and characterised as described 
in chapter 3 in sections 3-2-1- and 3-2-2-. After freeze drying the nanoparticle 
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suspension, the white (blank nanoparticles) or yellow (AmB loaded 
nanoparticles) product was reconstituted in double distilled water (ddH2O). 
The nanoparticles were then characterised by size, charge and AmB loading 
(see Chapter 3). A solution of HMW chitosan was prepared by dissolving 1 g 
in 100 ml of 1% (v/v) acetic acid solution at room temperature with continuous 
stirring for 24 hours until a clear solution was obtained. The pH of the solution 
was adjusted to ~ pH 6 by adding sodium hydroxide 2N (NaOH, Sigma, UK) 
solution using a pH meter (Orion Model 420A). The chitosan solutions were 
autoclaved (121 °C; 15 mins). 
5.2.2. QV900 and media perfusion system  
QV900 is a 6-chamber optical tray which can be connected together in any 
combination, providing a high degree of flexibility and the potential to culture 
cells in a defined set of conditions. QV900 is more suited to high-throughput 
testing than QV500. A 3D printed block (9mm) composed of Nylon 12 (Kirkstall 
Ltd) can be added to the chamber which will alter the depth of the chambers 
and can be used to adjust the level of oxygen and flow rates, the cells are 
subjected to. A peristaltic pump (Parker Hannifin,UK), external to the CO2 
incubator, continuously circulated culture media through the system is used.  
A constant flow rate of 360 μl/min of culture media was used. The cells 
(infected or uninfected macrophages) were cultured either at the base of a 
perfusion chamber or raised on 9 mm high inserts. This resulted in a cell 
surface flow rate of 1.33 x 10−9 at the base of the chamber or 1.17 x 10−7 (m/s) 
on an insert which is in line within the reported range for interstitial flow in the 
human skin (100). 
5.2.3. Macrophages 
Macrophages were plated on 12mm round glass coverslips (Bellco, US) 
placed in 24 well plates (Corning, UK) at a density of 4 x 105 cells per well in 
RPMI-1640 media (PEMs and THP-1) or DMEM (BMMs) supplemented with 
10% (v/v) HiFCS. 
- THP-1 cells were incubated in RPMI 1640 plus 10% (v/v) HiFCS and 
20 ng/ml phorbol 12-myristate 13-acetate (PMA; Sigma, UK) at 37°C 
203 
 
and 5% CO2 for 72 h to induce maturation transformation of these 
monocytes into adherent macrophages. 
5.2.4. Infection of macrophages by L. major promastigotes 
Macrophages 4 x 105/ml in RPMI-1640 media (PEMs and THP-1) or DMEM 
(BMMs) medium supplemented with 10% (v/v) HiFCS were plated in 24 well 
plates (Corning, UK) (1 ml per well) on 12mm round glass coverslips (Bellco, 
US) placed in 24 well and incubated for 24 hours at 37 °C in 5 % CO2. After 
24 hours, wells were washed by fresh culture medium to remove non-adherent 
cells. After washing, stationary phase L. major (MHOM/SA/85/JISH118 )  
promastigotes were added into the wells at a ratio of 5:1 (5 parasites: 1 host). 
Plates were incubated for another 24 hours at 34 °C in 5 % CO2. 
Subsequently, free parasites were removed by washing with the medium. One 
infected coverslip slide was fixed with 100 % methanol for 5 minutes and 
stained with 10 % Giemsa for 5 minutes. The number of infected macrophages 
per 100 macrophages was microscopically counted. If the initial infection was 
higher than 80 %, the assay was suitable for the experiments. Subsequently, 
two thirds of the glass coverslips were transferred to the media perfusion 
system (at the base of chamber or on the 9 mm insert) and maintained under 
flow conditions at a flow speed of 360 μl/min for 72 hours. The remaining 
coverslips were used for the static control. 
5.2.5. Measurement of macrophage functions.  
5.2.5.1. Phagocytosis  
Phagocytosis by macrophages (PEMs, BMMs and THP-1 ) was initially 
evaluated using 0.5,1 and 2 μm diameter fluorescent red labelled latex beads 
(carboxylate-modified polystyrene) (Sigma-Aldrich, UK) (343, 344). 2 μm 
beads were eventually selected as they showed maximal signal. Macrophages 
were infected with L. major promastigotes, then transferred to the three flow 
conditions as described above. To each well, 2μm beads (9.12 x 107 latex 
beads/ml) were added and the cells were incubated for 0.5, 1, 2, 4 and 24 
hours at 34 ˚C under the three different flow conditions. The experiment was 
terminated by washing the cells 4 times with ice-cold PBS pH 7.4 to remove 
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non-internalized latex beads, followed by the addition of 1 ml of 0.5% Triton 
X100 in 0.2 M NaOH to lyse the cells. Phagocytosis was quantified by the 
analysis of the cell lysate using a fluorescence plate reader (Spectramax M3, 
at excitation and emission wavelengths set at 575 and 610 nm), calibrated with 
standard solutions containing different number of latex beads in a cell lysate 
mixture. Uptake was expressed as the number of latex beads associated per 
mg of cellular protein, the protein content of the cell lysate being measured 
using a Micro BCA protein kit (Thermo Fisher, UK) assay as per supplier’s 
instructions. For control studies, 1 μg/ml cytochalasin D was used as a 
phagocytosis inhibitor (Sigma-Aldrich, UK) by incubation with macrophages 
for 2 hours prior to addition of the latex beads. Phagocytosis was completely 
inhibited after 0.5, 1, 2 and 4 hours of incubation with cytochalasin D and 90% 
after 24 hours.  
5.2.5.2. Macropinocytosis  
Macropinocytosis was measured using a fluorescence-labeled dextran dye 
(pHrodo Red dextran, average molecular weight of dextran 10,000 MW, 
Thermo Fisher, UK) (345). This dye has a pH-sensitive fluorescence emission 
that increases in intensity with increasing acidity while exhibiting a minimal 
fluorescence at neutral pH. Macrophages (PEMs, BMMs and THP-1 ) were 
infected with L. major promastigotes and then transferred to the three flow 
conditions as described above. Macrophages were washed 3 x by Live Cell 
Imaging Solution (Thermofisher, UK) and the cells were returned to RPMI 
1640 + 10% hiFCS containing 40 μg/ml pHrodo Red dextran (1 ml for each 
well) and incubated at 34 ˚C / 5% CO2 for 0.5, 1, 2, 4 and 24 hours under the 
three different flow conditions. At each time point, the cells were washed with 
Live Cell Imaging Solution and macropinocytosis was analysed by a 
Spectramax M3 at excitation and emission wavelengths set at 560 and 585 
nm respectively. Chlorpromazine hydrochloride 10 μg/ml, a known inhibitor 
(Sigma-Aldrich, UK), was used as a control and was incubated with 
macrophages for 2 hours prior to addition of fluorescence-labeled dextran dye. 
Macropinocytosis was completely inhibited after 0.5, 1, 2 and 4 hours of 
incubation with chlorpromazine hydrochloride and by 90% after 24 hours. 
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5.2.6. Evaluation of the anti-leishmanial activity of chitosan solutions, 
blank and AmB loaded chitosan TPP nanoparticles in the media 
perfusion system at pH 6.5 
PEMs were infected with L. major promastigotes, then transferred to the three 
flow conditions as described above. This experiment was conducted at pH 6.5. 
After 72 hours, the coverslips were fixed using methanol and stained with 
Giemsa and drug activity was evaluated by microscopically counting the 
number of infected and uninfected cells per 100 macrophages comparing with 
the control (Fig 5.3.) (324). The anti-leishmanial activity of compounds was 
expressed as percentage reduction in infected macrophages compared to 
untreated control wells. 
 
Figure  5.3. Schematic overview of evaluation of the anti-leishmanial activity in 
static and flow culture systems.  
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5.3. Results 
As previously mentioned, O'Keeffe A et al (2018) have described the Quasi 
Vivo QV900 macro-perfusion system and briefly, found that a 85±3% infection 
rate of macrophages at 72 hours in static cultures decreased to 62±5% for 
cultures under slow medium flow and 55±3% under fast medium flow and 
media perfusion also decreased amastigote replication and both macrophage 
phagocytosis (by 44±4% under slow flow and 57±5% under fast flow compared 
with the static condition) and macropinocytosis (by 40±4% under slow flow and 
62±5% under fast flow compared with the static condition). Mathematical and 
computational modelling were used to estimate the effect of speed of medium 
flow on infection rate, shear stress and oxygen concentration. For further 
details see publication Annex 1. 
 
5.3.1.  Macrophage functions  
5.3.1.1.  Phagocytosis.  
Phagocytosis of latex beads by uninfected and infected macrophages (PEMs, 
BMMs or THP-1) showed a clear time dependent response (Fig 5.4.), with 
phagocytosis increasing with duration of incubation. Phagocytosis was 
significantly higher in infected cells (infection rate of > 80%) compared to 
uninfected ones after 24 hours under static conditions (p<0.05 by t-test) (Table 
5.2 and Fig 5.4). PEMs and BMMs showed significantly higher phagocytosis 
of latex beads than THP-1 (p<0.05 by one- way ANOVA ). 
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Table 5.2. Phagocytosis of fluorescent latex beads (2 μm) by uninfected and infected PEMs, BMMs and THP-1 in static culture 
system. 
 Number of latex beads ± SD *105/mg protein 
 Uninfected cells - static system infected cells - static system 
Time/Hour PEMs BMMs THP-1 PEMs BMMs THP-1 
0.5 2.42 ± 0.2 2.3 ± 0.2 1 ± 0.2 3.45 ± 0.04 3 ± 0.04 1.8 ± 0.04 
1 6.93 ± 0.8 6.2 ± 0.8 5.2 ± 0.8 11.56 ± 0.02 10.9 ± 0.02 8 ± 0.02 
2 61.18 ± 1.5 60 ± 1 41 ± 1 76.58 ± 0.4 74 ± 0.2 59 ± 0.2 
4 106.74 ± 7.7 95 ± 5 66 ± 5 142.96 ± 3.9 139 ± 2 90 ± 2 
24 421.27 ± 30 396 ± 27 265 ± 27 530 ± 30 519 ± 25 398 ± 22 
Experiments were conducted in triplicate cultures, data expressed as mean +/- SD (experiment was reproduced further two times 
with confirmed similar data not shown). Phagocytosis was significantly higher (p<0.05 by t-test) in infected macrophages compared 
to uninfected ones. Phagocytosis was significantly higher (p<0.05 by t-test) in infected macrophages compared to uninfected ones.  
Initial macrophage infection rate was >80% after 24 h. 
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Figure  5.4. Phagocytosis of fluorescent latex beads (2 μm) by uninfected and 
infected PEMs (A), BMMs (B) and THP-1 (C) in static culture system. There is a 
significant increase in phagocytosis by infected macrophages compared to 
uninfected ones (p<0.05 by t-test). The data show means ± standard deviations 
(SD), N = 3. Infection rate was > 80%. 
After which, the effects of media perfusion systems on phagocytosis function 
of L. major- infected macrophages were evaluated. Flow conditions caused a 
significant reduction in phagocytosis by infected macrophages as shown in Fig 
5.5 - after 24 h of incubation, phagocytosis had significantly decreased from 
530± 30 x 105, 519± 30 x 105 and 398± 22 x 105 beads/mg protein by PEMs, 
BMMs and THP-1, respectively in static cultures to 304± 32 x 105 , 299.9± 24 
x 105  and 200± 30 x 105 beads/mg protein by PEMs, BMMs and THP-
1,respectively at slow flow speed (1.45 x 10-9 m/s ) and this phagocytosis 
decreased more at faster flow speed (1.23 x 10-7 m/s) to 231± 28 x 105 , 227.6± 
25 x 105  and 144± 18 x 105 beads/mg protein by PEMs, BMMs and THP-
1,respectively (p<0.05 by one-way ANOVA) (Table 5.3). 
(A) (B) 
(C) 
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Table 5.3. Phagocytosis of fluorescent latex beads (2 μm) by infected PEMs, BMMs and THP-1 in the three culture systems (static, slow flow 
rate 1.45 x 10⁻⁹ m/s and fast flow rate 1.23 x 10-7 m/s ).  
 
Number of latex beads ± SD *105/mg protein 
 
infected cells - static system Infected cells - 1.45 x 10-9 m/s Infected cells - 1.23 x 10-7 m/s 
Time/Hour PEMs BMMs THP-1 PEMs BMMs THP-1 PEMs BMMs THP-1 
0.5 3.45 ± 0.04 3 ± 0.04 1.8 ± 0.04 1.06 ± 0.02 1 ± 0.02 1 ± 0.02 0.54 ± 0.1 0.45 ± 0.1 0.3 ± 0.1 
1 
11.56 ± 
0.02 
10.9 ± 0.02 8 ± 0.02 6.59 ± 0.1 5.9 ± 0.1 3 ± 0.1 3.92 ± 0.06 3.89 ± 0.06 1.5 ± 0.06 
2 76.58 ± 0.4 74 ± 0.3 59 ± 0.2 40.24 ± 0.4 39 ± 0.25 22 ± 0.25 28.18 ± 0.2 27 ± 0.2 15 ± 0.2 
4 
142.96 ± 
3.9 
139 ± 3 90 ± 2 75.92 ± 5.5 73.9 ± 5 49 ± 1 53.55 ± 4.9 50 ± 4 33 ± 3 
24 
530.05 ± 
32.9 
519 ± 30 398 ± 22 
303.88 ± 
27.5 
299.9 ± 24 200 ± 30 231.11 ± 30 227.6 ± 25 144 ± 18 
Experiments were conducted in triplicate cultures, data expressed as mean +/- SD (experiment was reproduced further two times with confirmed 
similar data not shown). Flow conditions caused a significant reduction in phagocytosis by infected macrophages (p>0.05 by one-way ANOVA).  
Initial macrophage infection rate was >80% after 24 h. 
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Figure  5.5. Phagocytosis of fluorescent latex beads (2 μm) by infected PEMs (A), 
BMMs (B) and THP-1 (C) in the three culture systems (static, slow flow rate 1.45 x 
10−9 m/s and fast flow rate 1.23 x 10−7 m/s). Phagocytosis is significantly higher in 
static than in flow system (p<0.05 by one-way ANOVA). The data are means ± 
standard deviations (SD), N = 3. Infection rate > 80%. 
 
5.3.1.2. Macropinocytosis 
Macropinocytosis of pHrodo Red dextran by uninfected and infected 
macrophages (PEMs, BMMs or THP-1) showed a clear time dependent 
response with macropinocytosis increasing with duration of incubation (Fig 
5.6.). Macropinocytosis was significantly increased in infected macrophages, 
(A) (B) 
(C
) 
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from 19.02 ± 1.1, 16.5± 1.1 and 8±1.1 μg/mg protein of pHrodo Red dextran 
by uninfected PEMs, BMMs and THP-1, respectively to 25.3 ± 0.9, 23±0.8 
and 13.5±0.8 μg/mg protein of pHrodo Red dextran in infected PEMs, BMMs 
and THP-1, respectively after 24h in static conditions (p<0.05 by t-test) (Table 
5.4).  
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Table 5.4. Macropinocytosis of pHrodo™ Red dextran by uninfected and infected PEMs, BMMs and THP-1 in static culture system. 
 Concentration of dextran ± SD µg/mg protein 
 Uninfected cells - static system infected cells - static system 
Time/Hour PEMs BMMs THP-1 PEMs BMMs THP-1 
0.5 0.43 ± 0.01 0.3 ± 0.01 0.15 ± 0.01 0.92 ± 0.1 0.6 ± 0.1 0.3 ± 0.1 
1 1.28 ± 0.3 1.1 ± 0.3 0.55 ± 0.3 2.8 ± 0.2 2.2 ± 0.1 1.6 ± 0.1 
2 2.77 ± 0.5 2.5 ± 0.5 0.99 ± 0.5 3.78 ± 0.5 3.4 ± 0.3 1.8 ± 0.3 
4 4.83 ± 0.9 4.1 ± 0.9 2.5 ± 0.9 7.1 ± 0.8 5.9 ± 0.7 3.9 ± 0.7 
24 19.02 ± 1.1 16.5 ± 1.1 8 ± 1.1 25.3 ± 0.9 23 ± 0.8 13.5 ± 0.8 
Experiments were conducted in triplicate cultures, data expressed as mean +/- SD (experiment was reproduced further two times with 
confirmed similar data not shown). Macropinocytosis was significantly higher (p<0.05 by t-test) in infected macrophages compared to 
uninfected ones. Macropinocytosis was significantly higher (p<0.05 by t-test) in infected macrophages compared to uninfected ones.  Initial 
macrophage infection rate was >80% after 24 h. 
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Figure  5.6. Macropinocytosis of pHrodo Red dextran by uninfected and infected 
PEMs (A), BMMs (B) and THP-1 (C) in static culture system. There is a significant 
increase in macropinocytosis by infected PEMs compared to uninfected ones 
(p<0.05 by t- test). The data are means ± standard deviations (SD), N = 3. Infection 
rate was > 80%. 
After which, the effects of media perfusion systems on macropinocytosis 
function of L. major- infected macrophages were evaluated. Macropinocytosis 
was significantly reduced under flow conditions (Fig 5.7.), with higher speed 
of culture medium flow causing the greatest reduction, as after 24 hours of 
incubation with pHrodo Red dextran, macropinocytosis was reduced from 25.3 
± 0.9, 23± 0.8 and 13.5± 0.8 μg of pHrodo Red dextran /mg protein by PEMs, 
BMMs and THP-1, respectively under static to 15.1 ± 1, 14.99± 0.3 and 9± 0.3 
μg/mg protein by PEMs, BMMs and THP-1, respectively under low flow (1.45 
x 10-9 m/s) and more reduction occurred by higher flow (1.23 x 10-7 m/s ) to  
(A) (B) 
(C) 
214 
 
9.54 ± 1.2, 9± 1 and 5.5± 1 by PEMs, BMMs and THP-1 μg/mg protein, 
respectively (p<0.05 by one-way ANOVA) (Table 5.5).
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Table 5.5. Macropinocytosis of pHrodo™ Red dextran by infected PEMs, BMMs and THP-1 at the three culture systems (static, slow flow 
rate 1.45 x 10⁻⁹ m/s and fast flow rate 1.23 x 10⁻7 m/s ). 
 Concentration of dextran ± SD µg/mg protein 
 infected cells - static system Infected cells -1.45 x 10-9 m/s Infected cells - 1.23 x 10-7 m/s 
Time/Hour PEMs BMMs THP-1 PEMs BMMs THP-1 PEMs BMMs THP-1 
0.5 0.92 ± 0.1 0.6 ± 0.1 0.3 ± 0.1 
0.29 ± 
0.01 
0.2 ± 0.01 0 ± 0.01 0 ± 0.0 0 ± 0.02 0 ± 0.02 
1 2.8 ± 0.2 2.2 ± 0.1 1.6 ± 0.1 0.68 ± 0.5 0.55 ± 0.5 0.25 ± 0.5 
0.13 ± 
0.06 
0.1 ± 0.05 0 ± 0.05 
2 3.78 ± 0.5 3.4 ± 0.3 1.8 ± 0.3 1.75 ± 0.5 1.5 ± 0.5 0.7 ± 0.5 1.32 ± 0.2 1.1 ± 0.1 0.35 ± 0.1 
4 7.1 ± 0.8 5.9 ± 0.7 3.9 ± 0.7 3.17 ± 0.9 3 ± 0.7 1.5 ± 0.7 2.29 ± 0.7 2 ± 0.55 0.9 ± 0.5 
24 25.3 ± 0.9 23 ± 0.8 13.5 ± 0.8 15.1 ± 1 14.9 ± 0.3 9 ± 0.3 9.54 ± 1.2 9 ± 1 5.5 ± 1 
Experiments were conducted in triplicate cultures, data expressed as mean +/- SD (experiment was reproduced further two times with confirmed 
similar data not shown). Flow conditions caused a significant reduction in macropinocytosis by infected macrophages (p>0.05 by one-way 
ANOVA).  Initial macrophage infection rate was >80% after 24 h. 
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Figure  5.7. Macropinocytosis of pHrodo Red dextran by infected PEMs (A), BMMs 
(B) and THP-1 (C) at the three culture systems (static, slow flow rate 1.45 x 10−9 m/s 
and fast flow rate 1.23 x 10−7 m/s). Macropinocytosis is significantly higher in static 
than in flow systems (p<0.05 by one-way ANOVA). The data are means ± standard 
deviations (SD), N = 3. Infection rate was > 80.  
5.3.2. Effects of media perfusion system on the anti-leishmanial activity 
of chitosan formulations 
Dose-dependent anti-leishmanial activity (Fig 5.8.) was observed for all 
formulations (chitosan solution, blank chitosan-TPP nanoparticles and AmB 
loaded chitosan-TPP nanoparticles) across two media velocities and static 
culture. In the 72 h assays, the data showed that the addition of media 
perfusion reduced the anti-leishmanial activity of these three chitosan 
formulations. Chitosan solution, blank chitosan-TPP nanoparticles and AmB 
loaded chitosan-TPP nanoparticles showed a significantly higher activity in 
static culture (flow of 0 m/s) than in the QV900 system both at the base of the 
chamber (flow of 1.45 x 10−9 m/s) and on an insert (flow of 1.23 x 10−7 m/s) 
(A) (B) 
(C
) 
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(p<0.05 by an extra sum-of-squares F test). The three formulations, chitosan 
solution, blank chitosan-TPP nanoparticles and AmB loaded chitosan-TPP 
nanoparticles, were 2.08 times, 2 times and 4 times respectively, more active 
against intracellular L. major amastigotes in static culture in comparison with 
the flow of 1.45 x 10−9 m/s. Similarly, increasing the velocity of culture media 
from flow of 1.45 x 10−9 m/s to flow of 1.23 x 10−7 m/s by using the insert 
reduced the activity of chitosan solution, blank chitosan-TPP nanoparticles 
and AmB loaded chitosan-TPP nanoparticles against L. major amastigotes by 
2.4 times, 1.8 times and 2.75 times respectively (Table 5.6). Regarding pure 
AmB, we did not find a significant difference in EC50 values between the three 
culture systems (p>0.05 by an extra sum-of-squares F test). In contrast, a 
significant difference was observed in EC90 values of pure AmB as increasing 
the media perfusion decreased the effectivity of AmB against 90% of 
amastigotes (p<0.05 by an extra sum-of-squares F test) (Table 5.6). 
Table 5.6. In vitro activity of chitosan solution and nanoparticles against L. major 
amastigotes in RPMI medium (pH=6.5) at different flow rates 
Compound 
Static- 0 m/s 
Flow - 1.45 x 10−9 
m/s 
Flow - 1.23 x 10−7 
m/s 
EC50 EC90 EC50 EC90 EC50 EC90 
µg/ml 
Chitosan 
solution 
10.9 ± 1 165 ± 5 22.7 ± 1 230 ± 15 55.3 ± 2 455 ± 9 
Blank 
chitosan-TPP 
nanoparticles  
14.6 ± 4 241 ± 26 29.3 ± 3 299 ± 35 53.7 ± 4 459 ± 69 
AmB loaded 
chitosan-TPP 
nanoparticles 
0.1± 
0.01 
1 ± 0.1 
0.4 ± 
0.01 
2.5 ± 0.1 
1.1 ± 
0.02 
3.5 ± 0.3 
AmB solution 
(Pure) 
0.09 ± 
0.01 
0.5 ± 
0.02 
0.1 ± 
0.01 
0.9 ±  
0.1 
0.1 ± 
0.02 
1.5 ± 0.1 
Experiments were conducted in triplicate cultures, data expressed as mean +/- SD 
(experiment was reproduced further two times with confirmed similar data not 
shown). *Statistically significant differences were found for the EC50 values of 
chitosan solution, blank chitosan-TPP nanoparticles and AmB loaded chitosan-
TPP nanoparticles at static culture (flow of 0 m/s), flow of 1.45 x 10−9 m/s and flow 
of 1.23 x 10−7 m/s (p<0.05 by an extra sum-of-squares F test). Initial macrophage 
infection rate was >80% after 24 h. 
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Figure  5.8. Dose-response curve of the activity of chitosan solution (A), blank 
chitosan-TPP nanoparticles (B), AmB loaded chitosan-TPP nanoparticles (C) and 
AmB solution (pure) (D) against L. major amastigotes infecting PEMs in pH=6.5 
under different flow conditions. Quasi Vivo QV900 system has been used as a flow 
culture system. Values are expressed as % amastigotes inhibition relative to 
untreated controls. Data are representative of one experiment in in triplicate 
cultures, data is expressed as mean +/- SD (experiment was reproduced further 
two times with confirmed similar data and data not shown).  
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5.4. Discussion 
 
The QV900 culture flow system was used to overcome some fundamental 
limitations of in vitro static culture system when investigating cellular 
responses and anti-leishmanial activity of compounds and formulations. Static 
culture systems are unable to provide dynamic chemical or physical stimuli to 
cells, such as concentration gradients, flow, pressure, or mechanical stress 
caused by movement of fluids around them, which are physiologically relevant 
(100). 
This study found a significant increase in cell functions (phagocytosis and 
macropinocytosis) in L. major-infected macrophages (PEMs, BMMs and THP-
1) compared to uninfected cells - consistent with results described elsewhere, 
for example macrophages infected with either L. donovani or L. mexicana had 
greater pinocytic rates than uninfected macrophages, as measured by a 
fluorescent probe (fluorescein isothiocyanate dextran) (204). Similar 
observations have been reported with RAW 264.7 macrophages infected with 
L. major showing increased uptake of fluorescently labelled liposomes (204). 
This might be due to morphological changes of the infected cells or the 
parasitic infection may alter both the metabolic activity of the macrophages 
and their ability to ingest particulate material (346).  
This study found that PEMs and BMMs showed significantly higher 
phagocytosis and macropinocytosis than THP-1, and this could be explained 
as BMMs and PEMs are more homogenous than THP-1, and they are 
characterised with their homogeneity and long lifespan (230).  
We evaluated the effects of media perfusion rates on host cell phagocytosis 
and macropinocytosis. We found that phagocytosis and macropinocytosis 
were significantly decreased by media flow and increasing the media flow 
speed caused a further reduction in the uptake. This is consistent with previous 
reports of decreased uptake of fluorescein isothiocyanate (FITC)-poly 
(ethylene glycol) diacrylate particles (200 nm diameter) by human umbilical 
vein endothelial cells in a dynamic cell culture system exposed to shear stress 
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of 10 dynes/cm2 compared to the uptake in static cultures (347). Similar 
findings were also seen with a lower cellular uptake of solid silica particles 
(350 nm) by RAW 264.7 macrophages under dynamic condition compared to 
the uptake in static cultures (348). One explanation given was that the static 
system conditions might cause a sedimentation of the latex beads on the cell 
surface or exposure to higher concentrations of pHrodo Red dextran resulting 
in a local increase in their concentrations (349). In contrast, medium flow 
prevents such localization of materials with subsequently reduced uptake 
(350). 
We also showed that the media perfusion system had a significant influence 
on the anti-leishmanial activity of chitosan solution, blank chitosan-TPP 
nanoparticles and AmB loaded chitosan-TPP nanoparticles- increasing the 
flow rates caused a significant decrease in their activity. Similarly, O’Keeffe 
reported that the anti-leishmanial activity of miltefosine and paromomycin 
against L. major amastigotes was reduced under these two flow rates (high 
and slow) (324). 
This decrease in the anti-leishmanial activity of chitosan formulations under 
flow system could be attributed to a number of factors: (i) in a static system, 
waste products (because of catabolic and xenobiotic metabolism) accumulate 
in the culture medium and can cause an oxidative stress and lead to the loss 
of cellular function and viability during the culture time in vitro. On the other 
hand, culture under dynamic conditions can overcome these issues by the 
distribution of nutrients, waste products, and tested substances within the cell 
culture (351, 352, 353). (ii) It has been reported that static system conditions 
can cause a sedimentation of the drug on the cell surface resulting in a local 
increase in the drug concentrations (Fig 5.9). However, a flow method for the 
exposure of cells to the drugs can overcome this problem and leads to 
homogenous dispersion of the drugs and prevention of sedimentation (351, 
352, 353).  
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Figure  5.9. Sedimentation under a) static conditions, b) homogeneous distribution 
of drugs under flow conditions(353) 
 
(iii) The effects of the two media perfusion conditions used in our study on the 
accumulation of anti-leishmanial drugs (amphotericin B and miltefosine) have 
been previously reported by O’Keeffe et al (2017) - the accumulation of both 
drugs was significantly higher in the static system compared to the media 
perfusion system (Fig 5.10) , after 24 hours and this could be due to a 
reduction in the rate of drug uptake (324). 
The study described here also showed that cell uptake (phagocytosis and 
micropinocytosis) is reduced significantly by the application of flow compared 
with static culture conditions. Therefore, this reduction in drug accumulation 
and macrophage functions (phagocytosis and micropinocytosis) are 
contributing factor to the reduced anti-leishmanial activity seen (Fig 5.5, 5.7 
and 5.8)
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Figure  5.10. Accumulation of amphotericin B (left) and miltefosine (right) in peritoneal 
macrophages at three culture systems using the QV900 over time. Static and  two flow 
rates (1.33 x 10−9  at the base of the chamber or 1.17 x 10−7 (m/s) on an insert) (324) 
Broussou et al (2019) reported in vitro time-kill studies for a combination of 
amikacin and vancomycin against Staphylococcus aureus in static conditions 
and dynamic conditions ( fluctuating antibiotic concentrations, by using A 
Hollow-Fibre model (Fig 5.11)) and reported a significant difference in the 
efficacy of the combination between static and dynamic conditions (354).  
 
Figure  5.11. A Hollow-Fibre model (355)  
  
Both EC50 and EC90 values of AmB loaded chitosan-TPP nanoparticles against 
intracellular amastigotes significantly increased as the speed of media 
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perfusion increases and this pattern was not obvious when comparing EC50 
values of pure AmB however, the EC90 values diminished with increasing flow 
rate. Similar finding was reported by O’Keeffe et al (2017) in terms of EC50 and 
EC90 values of AmB solution at these three culture systems, could be due to 
the high activity of AmB against Leishmania amastigotes (324).  
The difference between AmB nanoparticles and AmB solution (EC90 values, at 
three culture systems) could be due to that nanoparticles are uptaked at higher 
rates compared with solution and therefore a significant less amount of AmB 
nanoparticles entered the macrophages under flow system compared with 
AmB solution (353).   
 
In conclusion, in the media perfusion culture system, flow speed was observed 
to influence the anti-leishmanial activities of the tested formulations. This could 
influence the development of new drugs for cutaneous leishmaniasis 
particularly by considering the possible higher flow rates in inflammatory sites. 
The collateral effects of flow on pathogen replication rate and on host cell 
metabolism, as indicated by reduction in phagocytosis and macropinocytosis, 
introduces new avenues of research and how these models could be used in 
studies on immune response and drug and vaccine discovery. This combined 
experimental and modelling approach permits future hypothesis testing and 
development of more complex/advanced/predictive models for drug discovery 
and development. 
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6. General discussion  
6.1. Discussion and conclusion 
Although cutaneous leishmaniasis (CL) is not fatal, it does have a significant 
impact on the health and well-being impact of those infected. The large 
numbers involved, in at least 149 tropical and sub-tropical countries, have a 
detrimental impact on the economy of low- and middle-income countries where 
this disease is found (356, 357).  
The available therapies for CL have acknowledged limitations which include 
adverse side effects/toxicity, are poorly tolerated, variable effectiveness 
against Leishmania species and are expensive in terms of both cost of drugs 
and care and other associated costs. Despite the clear need, new treatments 
for CL have not been forthcoming (51, 52).  Drug discovery is a long and costly 
process which can take 10 to 20 years from a molecule to a usable drug, with 
an associated investment of a possible 2.6 billion USD$ before a new active 
compound is identified, developed for clinical applications and brought to the 
market (358, 359). CL could be regarded as one of the more neglected of the 
NTDs, typified by a general lack of interest in pursuing and funding drug 
development, both by Pharma and other actors, for this disease. Some anti-
leishmanial drugs developed for VL that are in the current pipeline may be 
considered for the treatment of CL in the future (360).  
 
One of the strategies to address the barriers of high cost and long 
developmental time-lines is the employment of drug delivery systems with an 
already known effective drug with established clinical activity. Drug delivery 
systems give an opportunity to manage the solubility and other 
pharmacokinetic parameters of a drug, such as bioavailability, half-life and 
biodistribution, and can serve to protect a drug from degradation. All this can 
result in both reducing toxicity and enhancing efficacy.  
Amphotericin B (AmB), a polyene antibiotic, is considered the second most 
common treatment for leishmaniasis and is very effective against different 
Leishmania species experimentally, but its clinical use is limited due to its 
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inherent acute toxicity. AmB is one of the most-studied drugs for the 
development of new drug delivery strategies in the field of leishmaniasis (118, 
361). 
One of these promising drug delivery systems is AmBisome® (a liposomal 
formulation of AmB) which is effective against VL and CL. AmBisome® is less 
toxic than free AmB and the clinically used amphotericin B deoxycholate 
formulations (Fungizone©) and is recommended by the World Health 
Organization for the treatment of  VL (60).  AmBisome® has some limitations 
which include (i) the high cost (200 $ per vial of 50 mg, and is donated free for 
VL in endemic countries, not for CL), (ii) is the need for a cold chain (unstable 
over 25oC) and (iii) some renal toxicity and infusion-related reactions. In a 
recent study of CL and MCL in travellers coming back from both Old- and New-
World countries AmBisome® treatment showed only 63% positive outcome 
and 53% of them experienced renal toxicity and infusion-related reactions (59) 
and (iv) higher rates of relapse have been observed in immunocompetent 
patients with VL treated with AmBisome® (60, 61). 
There is an urgent need for new treatments which can eliminate the parasites, 
improve the healing process, are safe, reliable and also field-adaptable for use 
in diverse healthcare systems. 
Chitosan has shown promising features in effective therapeutic delivery 
systems due to its cationic structure, biocompatibility, biodegradability, 
controlled drug release, mucoadhesive, wound healing and antimicrobial 
properties. Both chitosan in solution and nanoparticles showed interesting 
antimicrobial and antileishmanial activity with variable effective values across 
different published studies.  These properties make chitosan an appropriate 
candidate for further studies to evaluate its suitability for the treatment of CL. 
In Chapter 2, pH was demonstrated to play a critical role in the anti-leishmanial 
activity of chitosan and its derivatives (except carboxymethyl chitosan which 
showed no activity at both pH values), as all showed a higher anti-leishmanial 
effectivity at a lower pH. To date, there is no literature available on the anti-
leishmanial activity of all of these derivatives or on the role of pH on the anti-
leishmanial activity of chitosan. In this chapter, HMW chitosan demonstrated 
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a higher anti-leishmanial activity against L. major and L. mexicana 
promastigotes and amastigotes than other types and derivatives of chitosan. 
Accordingly, HMW chitosan was chosen for further studies. After which, the 
aim was to investigate whether the anti-leishmanial efficacy of HMW chitosan 
is related to indirect activity (through the activation of macrophages M1 pro-
inflammatory phenotype) or via a direct way (through direct uptake of chitosan 
into the parasitophorous vacuole (PV) where the Leishmania amastigotes 
reside). Interestingly, it was shown that HMW chitosan acted by direct effect 
on the intracellular amastigotes; this has not been reported previously in any 
other literatures. 
The results pointed towards the possibility of using HMW chitosan as a drug 
delivery component for CL treatment, harnessing the benefits of both anti-
leishmanial activity of chitosan itself and to improve the therapeutic window of 
AmB (enhancing AmB anti-leishmanial activity and reducing its toxicity). AmB 
encapsulated in different types of chitosan nanoparticles has shown a 
promising in vitro and in vivo anti-leishmanial activity, see Table 4.3. Most of 
these studies used positively charged nanoparticles with a size greater than 
100 nm. Therefore, in Chapter 3, we endeavoured to prepare two types of 
AmB-loaded chitosan nanoparticles; a positively charged type with TPP and a 
negatively charged type with dextran sulphate with the smallest possible sizes. 
The goal was to obtain the smallest sizes in an attempt to improve the topical 
delivery of AmB into the dermal layer of the skin. On the other hand, smaller 
nanoparticles when administrated intravenously, show a higher permeation 
through body membranes compared to larger nanoparticles, and smaller size 
of nanoparticles facilitates a passive transport from blood vessels to tissues 
(255).  
The nanoparticle preparation parameters were optimised and two types of 
spherical blank and AmB loaded nanoparticles using the inotropic gelation 
method were successfully produced. One type of chitosan nanoparticles with 
a positive charge by using TPP as a crosslinker and this resulted in blank 
chitosan-TPP nanoparticles (size= 67 ± 7 nm, zeta potential= 28.5 ±1.9 mv) 
and AmB loaded chitosan-TPP nanoparticles ( size= 69 ± 8 nm, zeta potential= 
25.5 ± 1 mv). The other type with a negative charge by using dextran sulphate 
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as a crosslinker and this resulted in blank chitosan-dextran sulphate 
nanoparticles (size= 170 ± 9 nm, zeta potential= -12.9 ± 3 mv) and AmB loaded 
chitosan-dextran sulphate nanoparticles (size= 174 ± 8 nm, zeta potential= -
11 ± 1mv). Also, the importance of using cryoprotectants and the advantage 
of sucrose over D-mannitol in protecting the nanoparticles were identified 
during the freeze drying process. Then, the encapsulation efficacy and AmB 
loading were approximately 90% and 25%, respectively of both types of 
nanoparticles. In addition, these nanoparticles showed a high stability in terms 
of size and charge, in different conditions (different media (water, PBS, RPMI 
and mouse plasma) and at different temperatures (4, 34 or 37 ° C)). Both types 
of nanoparticles displayed a slow release of AmB in PBS or mouse plasma. 
All previous promising properties of our nanoparticles made them suitable 
candidates for further studies in terms of evaluating the anti-leishmanial 
efficacy of blank chitosan nanoparticles or AmB loaded chitosan nanoparticles 
(as delivery vehicles) and the possibility of using them in CL mouse model 
either topically or intravenously.  
The fourth chapter investigated the anti-leishmanial activity of chitosan 
formulations in vitro and in vivo. Firstly, both types of blank nanoparticles 
showed neither a significant haemolytic activity against human RBCs nor 
cytotoxicity against KB-cells. With regard to AmB loaded chitosan 
nanoparticles, both produced around 18-fold less haemolytic activity and 6-
fold less toxicity against KB cells than pure AmB.  Blank, positively surfaced 
charged, nanoparticles showed an in vitro activity against L. major and L. 
mexicana promastigotes and amastigotes at two pH’s of 7.5 and 6.5, with a 
higher activity at the lower pH. Encouragingly, AmB loaded chitosan-TPP 
nanoparticles and AmB loaded chitosan-dextran sulphate nanoparticles 
presented a similar anti-leishmanial activity to pure AmB against L. major and 
L. mexicana promastigotes and amastigotes, and a higher activity than 
AmBisome®. The little in vitro cytotoxicity and high effectivity against in vitro 
Leishmania parasites led to the evaluation of the anti-leishmanial activity of 
chitosan formulations in vivo L. major model of CL via the intravenous route of 
administration. A safe dosing regimen was established in BALB/c mice of AmB 
loaded chitosan-TPP nanoparticles and AmB loaded chitosan-dextran 
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sulphate nanoparticles via i.v. route -  5 mg/kg (AmB equivalent) and 10 mg/kg 
(AmB equivalent), respectively. Promisingly, AmB loaded chitosan-TPP 
nanoparticles (5 mg of AmB/kg/QAD for 10 days, i.v.) showed a higher in vivo 
anti-leishmanial effectivity than AmBisome® (10 mg of AmB/kg/QAD for 10 
days, i.v) and was similar to the activity of paromomycin used as the positive 
control (50 mg/kg/QD for 10 consecutive days; i.p.) in terms of reducing lesion 
size and bioluminescence signal (parasite load). This anti-leishmanial activity 
of AmB loaded chitosan-TPP nanoparticles was in a dose-response manner. 
Levels of AmB within the infected lesion (rump skin) and control skin 
(uninfected skin, back skin) were assessed at the end of the experiment and 
a good correlation between the doses of AmB loaded chitosan-TPP 
nanoparticles and the intralesional AmB and the relative reduction in parasite 
load and lesion size was found. Additionally, AmB loaded chitosan-TPP 
nanoparticles resulted in higher drug accumulation in the lesions in 
comparison with a higher dose of AmBisome®. Parasite load was determined 
via in vivo imaging (by using bioluminescent L. major strain) and compared 
with untreated controls. Previous studies have strongly correlated parasite 
load determined by both quantitative PCR and bioluminescent signal (199). 
qPCR determination of parasite load will be determined on the harvested and 
stored tissues from this study – this work fell beyond the time line of this 
project. To conclude, AmB loaded chitosan-TPP nanoparticles were more 
stable than AmBisome® and had a more sustainable drug release than 
AmBsiome (The release of AmB was 5%  from AmB loaded chitosan-TPP 
nanoparticles and 75% from AmBisome® (362) in 24 h). Moreover, AmB loaded 
chitosan-TPP nanoparticles were significantly more active than AmBisome® against 
L. major in mice even though with lower doses of these nanoparticles than 
AmBisome®.  
The possibility of using these nanoparticles as topical formulations was 
evaluated. The permeability of the nanoparticles (blank and AmB loaded 
nanoparticles) through uninfected and L. major infected mouse skin 
performing in vitro Franz cell diffusion studies was determined. Both types of 
nanoparticles acted as a drug delivery vehicle and released the AmB rather 
than permeating alongside the AmB molecules. For both types of 
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nanoparticles, AmB permeation was limited and slow, but interestingly higher 
in infected skin than uninfected, albeit in low concentrations (Kat ref). These 
outcomes in the permeation study indicate the poor suitability of these 
particular formulations as credible topical formulations to treat CL. 
The effect of media perfusion on macrophage functions and on the anti-
leishmanial activity of chitosan formulations was assessed in Chapter 5 in an 
attempt to simulate some of the more complex interactions between the 
parasite and macrophages in the mammalian host. For this purpose, a QV900 
media perfusion system was used, as described by O'Keeffe et al (2017), with 
similar flow rates to mimic the interstitial tissue flow rate in the skin. Media 
perfusion significantly decreased both phagocytosis and macropinocytosis of 
different types of macrophages (PEMs, THP-1 and BMMs). This described 
how the additional complexity of each in vitro model could improve the 
predictivity of the assay and how drug properties based on static assays can 
give rise to misleading data. The aim of this perfusion model was to develop a 
more predictive in vitro model (compared to the current static 2D one), which 
could ultimately lead to a reduction in animal use and save both time and 
expenditure evaluating poor compounds. Interestingly, the anti-leishmanial 
activity of chitosan formulations was significantly less in the media perfusion 
systems compared to the static culture system.  
6.2. Future work 
AmB loaded chitosan-TPP nanoparticles were effective in the murine model 
(female BALB/c mice) of L. major, when administrated intravenously. 
Many parts are associated with the scale-up of these nanoparticles from bench 
to the market. For instance, nature of material, procedure of nanoparticle 
development, cost,  in vivo biodegradability of nanoparticles and acceptability 
of finished product both by clinicians and patients. On account of their 
economic feasibility, AmB loaded chitosan-TPP nanoparticles are better 
because they are made of chitosan and TPP whose production scale up is 
significantly less expensive then phospholipids in liposomal AmB. 
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The evaluation of anti-leishmanial activity of AmB loaded chitosan-TPP 
nanoparticles in vivo using a New World species (for example L. mexicana) 
might be of interest for future work. Assessment of the activity of these 
nanoparticles in other models of Leishmania infection, such as self-curing 
model would be interesting (363) . Further extensive toxicity studies in animals 
would also be required.  
The therapeutic index of these nanoparticles could be improved by either 
loading two active drugs into the nanoparticles, e.g. miltefosine (or other 
known active anti-leishmanials ) and AmB, or by using a combination of 
therapy, e.g. using these nanoparticles via the i.v. route and other topical 
treatment (including thermotherapy or cryotherapy or paromomycin ointment) 
or other commercially available drugs. Both of these ways could develop more 
effective, lower-dose, and shorter treatments. It would be interesting to 
evaluate the in vitro and in vivo efficacy of AmB loaded chitosan-TPP 
nanoparticles in the treatment of VL. Another important experiment would be 
evaluating the distribution of the nanoparticles among different organs and 
study their uptake by lymphocytes, APCs and neutrophils. 
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8. Appendix 
8.1. Appendix 1: Validation of HPLC methods  
Table 8.1. HPLC validation parameters 
Parameter Value 
Accuracy 100.15 ± 0.22 
Slope 108.11 
Intercept 0.31 
Linearity range 0.5-300 µg/ml 
SE of intercept 0.2 
SD of intercept 0.52 
LOD (limit of detection) =3.3*(SD of 
intercept/Slope) 
0.015 µg/ml 
LOQ (limit of quantification) =10*(SD 
of intercept/Slope) 
0.048 µg/ml 
 
- Precision 
Accuracy can be defined as the degree to which a measured value conforms 
to the true value. In pharmaceutical analysis, an assay is said to be accurate 
if the mean result is the same as the true value. On the other hand, precision 
is described as the variability of a set of measurements. Unlike accuracy, this 
does not provide any indication of the closeness of the obtained results from 
the true value. High precision is indicative of low variability in measurements 
usually demonstrated by low standard deviation values. This is usually 
reported as a percentage relative standard deviation. 
 
 
 (%RSD): SD/Drug*100  
 
The precision of the method was determined by repeatability (intra-day) and 
intermediate precision (inter-day). Repeatability was determined by 
performing three repeated analysis of the same standard solution on the same 
day, under the same experimental conditions. The intermediate precision of 
the HPLC methods was assessed by carrying out the analysis on three 
different days (inter-day). For each drug, the percentage relative standard 
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deviation (%RSD) and the percentage recovery of the standard solutions are 
reported for each drug. 
Table 8.2. The precision of AmB HPLC assay 
Standard 
concentration 
µg/ml 
Intra-day 
calculated 
concentration 
(μg/ml) 
Inter-day 
Calculated 
concentration 
(μg/ml) 
Intra-day 
% RSD 
Inter-day 
% RSD 
300 300.03± 0.21 300.33± 0.15 0.05 0.07 
100 99.91± 0.16 100.10± 0.17 0.17 0.16 
33.3 33.26± 0.05 33.29± 0.04 0.11 0.14 
11.1 11.10± 0.09 11.27± 0.14 1.26 0.81 
3.7 3.71± 0.02 3.70± 0.05 1.28 0.41 
1.23 1.24± 0.02 1.23± 0.02 1.24 1.24 
0.4 0.39± 0.02 0.4± 0.02 5.25 3.88 
 
 
Figure Calibration curve of amphotericin B 
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